can you suggest some project topics

I'd love to help, but "project topics" could mean many things. Let me ask a couple of quick questions:
Asking for Preferences

What field or subject area is the project for? · What level is this project for?

for m pharm(pharmacy practice)

Searching the Web

M Pharm pharmacy practice research project topics 2024 2025

Searching the Web

pharmacy practice postgraduate dissertation topics clinical pharmacy pharmacovigilance

Here are well-organized, research-worthy project topics for M. Pharm (Pharmacy Practice) - covering all major domains of the specialization:

Clinical Pharmacy & Patient Care

  1. Impact of clinical pharmacist interventions on drug-related problems in ICU/medicine wards
  2. Medication reconciliation at hospital admission/discharge - frequency and nature of discrepancies
  3. Assessment of pharmacist-led anticoagulation management clinics (warfarin/DOAC monitoring)
  4. Role of pharmacist in optimizing pain management in post-surgical patients
  5. Pharmaceutical care in chronic kidney disease (CKD) - drug dose adjustment assessment
  6. Clinical pharmacist's role in reducing length of hospital stay - a prospective interventional study

Pharmacovigilance & Drug Safety

  1. Spontaneous ADR reporting pattern at a tertiary care hospital - under-reporting analysis
  2. Causality and severity assessment of adverse drug reactions in oncology patients
  3. Drug-drug interaction prevalence in polypharmacy patients admitted to cardiology/medicine ward
  4. ADR monitoring and reporting in HIV/TB co-infected patients on HAART + anti-TB therapy
  5. Signal detection from pharmacovigilance data using WHO-UMC causality criteria

Medication Adherence & Patient Counseling

  1. Assessment of medication adherence in hypertension/diabetes patients using Morisky scale
  2. Impact of pharmacist-led patient counseling on glycemic control in Type 2 DM
  3. Medication adherence in psychiatric outpatients - barriers and pharmacist interventions
  4. Effect of pill organizers and reminder apps on adherence in elderly polypharmacy patients

Drug Utilization Studies (DUS)

  1. Drug utilization study of antibiotics in a surgical ward - WHO DDD methodology
  2. Prescribing pattern analysis using WHO prescribing indicators in a primary health centre
  3. Drug utilization review in pediatric patients - rationality assessment
  4. Study on use of proton pump inhibitors - appropriateness in hospitalized patients
  5. Utilization pattern of anti-diabetic drugs in a tertiary care outpatient setting

Medication Errors & Patient Safety

  1. Incidence, type, and severity of medication errors in a teaching hospital
  2. Prescribing errors in pediatric inpatients - identification and pharmacist interventions
  3. Near-miss medication errors in hospital pharmacy - root cause analysis
  4. Impact of pharmacist participation in ward rounds on prescribing errors

Pharmacoeconomics & Health Outcomes

  1. Cost-of-illness study of Type 2 diabetes mellitus in outpatient setting
  2. Pharmacoeconomic analysis of antibiotic stewardship program implementation
  3. Cost-effectiveness of pharmacist-managed chronic disease clinics vs. standard care
  4. Health-related quality of life (HRQoL) assessment in cancer or COPD patients using SF-36/EQ-5D

Antibiotic Stewardship

  1. Implementation and evaluation of antibiotic stewardship program in a hospital
  2. Assessment of antibiotic prescribing practices against standard treatment guidelines
  3. Carbapenem usage audit - appropriateness in ICU settings
  4. Knowledge, attitude and practice (KAP) of antimicrobial resistance among healthcare workers

Community & Social Pharmacy

  1. Assessment of self-medication practices among urban/rural populations
  2. Role of community pharmacists in managing minor ailments - a cross-sectional survey
  3. Over-the-counter (OTC) antibiotic dispensing practices in community pharmacies
  4. Knowledge and counseling practices of pharmacists regarding contraceptives

Emerging / High-Impact Topics (2025-26)

  1. Digital health tools (apps, telemedicine) in pharmacy practice - patient and pharmacist perspectives
  2. Artificial intelligence in clinical decision support - pharmacist attitudes and adoption
  3. Pharmacist's role in COVID-19 / post-COVID management and vaccine counseling
  4. Deprescribing inappropriate medications in elderly patients - pharmacist-led intervention
  5. Assessment of biosimilar prescribing practices and pharmacist awareness

Tips for Choosing Your Topic

  • Prospective interventional studies (e.g., patient counseling, ADR monitoring) are highly publishable and valued at M. Pharm level.
  • Drug utilization + prescribing pattern studies are feasible with hospital data and have strong publication scope.
  • Pharmacoeconomics topics are relatively novel in Indian/developing-country settings - good for standing out.
  • Align with your hospital's specialty (oncology, cardiology, nephrology) for easier data access and focused depth.
Would you like me to help narrow down to 2-3 specific topics, draft a study design, or suggest objectives for any of these?

hospital speciality

Which hospital specialty are you based in or interested in?
Asking for Preferences

Which specialty are you working in or interested in?

Here are focused, publication-worthy M. Pharm (Pharmacy Practice) project topics for Cardiology:

Drug Utilization & Prescribing Pattern Studies

  1. Drug utilization study of antihypertensives in hypertensive inpatients/outpatients using WHO DDD methodology
  2. Prescribing pattern of antiplatelet agents in acute coronary syndrome (ACS) patients
  3. Assessment of statin prescribing practices and goal attainment (LDL targets) in coronary artery disease (CAD)
  4. Drug utilization review of anticoagulants (heparin, warfarin, DOACs) in atrial fibrillation patients
  5. Prescribing pattern analysis in heart failure - adherence to guideline-directed medical therapy (GDMT)

Medication Adherence Studies

  1. Assessment of medication adherence in hypertensive patients using Morisky Medication Adherence Scale (MMAS-8) and its determinants
  2. Adherence to dual antiplatelet therapy (DAPT) post-PCI/stent and clinical outcomes
  3. Impact of pharmacist counseling on medication adherence and blood pressure control - a prospective interventional study
  4. Factors influencing non-adherence to statin therapy in dyslipidemia patients

Drug-Related Problems (DRPs)

  1. Identification and assessment of drug-related problems in cardiac ICU patients using PCNE classification
  2. Prevalence of drug-drug interactions in polypharmacy cardiac patients - a cross-sectional study
  3. Clinical significance of potential drug interactions in patients on warfarin - impact of pharmacist intervention
  4. Assessment of inappropriate prescribing in elderly cardiac patients using Beers criteria / STOPP-START tool

Adverse Drug Reactions (ADR) & Pharmacovigilance

  1. Monitoring and reporting of ADRs to cardiovascular drugs (ACE inhibitors, statins, amiodarone, digoxin) in a cardiology ward
  2. Statin-induced myopathy surveillance - incidence, risk factors, and pharmacist reporting
  3. ADR profiling of antiarrhythmic drugs - a prospective observational study
  4. Causality and severity assessment of ADRs in cardiac patients using Naranjo and WHO-UMC scales

Clinical Pharmacist Interventions

  1. Impact of pharmacist-led medication review on drug-related problems in heart failure patients
  2. Pharmacist interventions in improving INR control in patients on warfarin therapy
  3. Role of clinical pharmacist in anticoagulation management clinic - safety and outcomes
  4. Pharmacist-driven hypertension management program - effect on blood pressure control and quality of life
  5. Assessment of pharmacist recommendations during cardiology ward rounds and acceptance rate by physicians

Pharmacoeconomics

  1. Cost-of-illness study of heart failure in a tertiary care cardiology unit
  2. Pharmacoeconomic analysis of thrombolytic therapy vs. primary PCI in STEMI patients
  3. Cost-effectiveness of generic vs. branded antihypertensives in a public hospital setting
  4. Direct medical costs associated with drug-related problems in cardiology inpatients

Patient Education & Quality of Life

  1. Assessment of patient knowledge, attitude and practice (KAP) regarding hypertension and its management
  2. Impact of pharmacist-led cardiac rehabilitation counseling on lifestyle modification and drug adherence
  3. Health-related quality of life (HRQoL) in heart failure patients using Minnesota Living with Heart Failure Questionnaire (MLHFQ)
  4. Assessment of patients' knowledge on anticoagulation therapy and impact of pharmacist education

Medication Safety & Errors

  1. Medication errors in cardiology ICU - incidence, type, and contributing factors
  2. High-alert medication safety assessment (heparin, digoxin, amiodarone) in a cardiac care unit
  3. Medication reconciliation at admission and discharge in cardiac inpatients - discrepancy analysis

Emerging / Trending Topics (2025-26)

  1. Assessment of SGLT2 inhibitor and GLP-1 agonist prescribing for cardiovascular risk reduction in diabetes patients
  2. Pharmacist's role in managing polypharmacy in chronic heart failure - deprescribing interventions
  3. Digital health and mHealth apps for cardiac medication management - patient awareness and pharmacist perspectives
  4. Evaluation of antibiotic prophylaxis practices in cardiac surgery - appropriateness and outcomes

Top 3 Recommendations (Easy to execute + highly publishable)

#TopicWhy it's good
1Pharmacist counseling intervention on adherence in hypertensionProspective, interventional, clear outcome measures
2Drug-related problems in cardiac ICU using PCNE classificationHigh clinical impact, good for publications
3Assessment of GDMT in heart failure patientsTopical, guideline-based, feasible with retrospective data

Would you like help with objectives, methodology, or a study design for any of these topics?

gynecology?

Here are focused M. Pharm (Pharmacy Practice) project topics for Gynecology & Obstetrics:

Drug Utilization & Prescribing Pattern Studies

  1. Drug utilization study in antenatal care (ANC) - pattern of iron, folic acid, calcium, and antibiotic prescribing
  2. Prescribing pattern of oxytocics and uterotonics in labour and delivery ward
  3. Drug utilization review in postpartum hemorrhage (PPH) management - adherence to WHO protocols
  4. Assessment of antibiotic prescribing in cesarean section - appropriateness and prophylaxis patterns
  5. Drug utilization study in gestational diabetes mellitus (GDM) - insulin vs. oral hypoglycemics

Medication Adherence

  1. Adherence to iron and folic acid supplementation in pregnant women and associated factors
  2. Compliance with antihypertensive therapy in pregnancy-induced hypertension (PIH) / preeclampsia
  3. Medication adherence in women with polycystic ovarian syndrome (PCOS) on metformin/OCP
  4. Impact of pharmacist counseling on adherence to antenatal supplements - interventional study

Adverse Drug Reactions & Pharmacovigilance

  1. Monitoring and reporting of ADRs to drugs used in obstetrics - oxytocin, magnesium sulfate, misoprostol
  2. ADR surveillance of hormonal contraceptives in family planning clinic
  3. Teratogenicity risk assessment - exposure to category C/D/X drugs during first trimester
  4. ADR profiling of drugs used in preeclampsia management - labetalol, nifedipine, magnesium sulfate

Drug-Related Problems (DRPs)

  1. Identification of drug-related problems in high-risk pregnancy patients using PCNE classification
  2. Potential drug interactions in polypharmacy obstetric patients - prevalence and clinical significance
  3. Assessment of inappropriate medication use in pregnancy - Hale's Lactation Risk/FDA category analysis
  4. Medication errors in obstetric wards - types, contributing factors, and pharmacist interventions

Clinical Pharmacist Interventions

  1. Impact of pharmacist-led counseling on management of nausea and vomiting of pregnancy (NVP)
  2. Role of clinical pharmacist in preeclampsia/eclampsia management - drug therapy optimization
  3. Pharmacist intervention in reducing medication errors in labor and delivery unit
  4. Assessment of pharmacist recommendations in gynecology ward rounds - type and acceptance rate

Patient Knowledge, Attitude & Practice (KAP)

  1. KAP study on use of oral contraceptive pills (OCPs) among women of reproductive age
  2. Assessment of women's knowledge on safe use of drugs during pregnancy and lactation
  3. Patient awareness of emergency contraception - knowledge gaps and pharmacist's counseling role
  4. KAP of self-medication practices in pregnant women - risks and prevalence

Pharmacoeconomics & Health Outcomes

  1. Cost-of-illness study of preeclampsia in a tertiary care setting
  2. Pharmacoeconomic comparison of misoprostol vs. oxytocin in PPH prevention
  3. Direct medical costs associated with gestational diabetes management
  4. Health-related quality of life (HRQoL) in women with PCOS using SF-36 questionnaire

Specific Disease/Condition-Based Studies

  1. Assessment of pharmacotherapy in PCOS - ovulation induction, metformin, hormonal therapy patterns
  2. Drug therapy evaluation in endometriosis - hormonal and analgesic use patterns
  3. Management of preterm labor - tocolytic drug use assessment and outcomes
  4. Evaluation of chemotherapy regimens in gynecological cancers (cervical, ovarian, endometrial) - safety monitoring
  5. Antifungal use pattern in vulvovaginal candidiasis - OTC vs. prescription analysis

Emerging Topics (2025-26)

  1. Pharmacist's role in reproductive health counseling - contraception, fertility, preconception care
  2. Assessment of knowledge and practice of pharmacists on drugs in breastfeeding
  3. Use of progesterone supplementation in threatened abortion - prescribing pattern and outcomes
  4. Digital health interventions for antenatal medication adherence - app-based reminders
  5. Evaluation of iron deficiency anemia treatment in pregnancy - IV vs. oral iron therapy outcomes

Top 3 Recommendations

#TopicWhy it's good
1Pharmacist counseling on antenatal supplement adherenceProspective, interventional, clear measurable outcomes, highly feasible
2Drug-related problems in high-risk pregnancy (PCNE)High clinical relevance, publishable, structured tool available
3KAP on OCP use among reproductive-age womenCross-sectional, easy data collection, strong public health relevance

Would you like help drafting aims & objectives, inclusion/exclusion criteria, or a methodology for any specific topic?

Create a comparison table of these 39 topics by feasibility

Here is the comparison table of all 39 Gynecology topics rated by feasibility:

Feasibility Rating Key

  • Data Access: How easily can data/patients be recruited?
  • Ethics Complexity: Simple (✅) = minimal hurdles | Complex (⚠️) = needs extra clearance
  • Time Required: Short (<6 months), Medium (6-9 months), Long (>9 months)
  • Overall Feasibility: ⭐⭐⭐ = High | ⭐⭐ = Moderate | ⭐ = Difficult

#TopicStudy TypeData AccessEthics ComplexityTime RequiredCostOverall Feasibility
1Drug utilization in antenatal care (ANC)Retrospective/Prospective✅ Easy - OPD records✅ SimpleShortLow⭐⭐⭐
2Prescribing pattern of oxytocics/uterotonicsRetrospective✅ Ward records✅ SimpleShortLow⭐⭐⭐
3Drug utilization in PPH managementRetrospective✅ Case sheets✅ SimpleShortLow⭐⭐⭐
4Antibiotic prescribing in C-sectionRetrospective✅ OT + ward records✅ SimpleShortLow⭐⭐⭐
5Drug utilization in gestational diabetes (GDM)Prospective/Retrospective✅ OPD + ward✅ SimpleMediumLow⭐⭐⭐
6Adherence to iron & folic acid in pregnancyCross-sectional/Interventional✅ ANC clinic patients✅ SimpleMediumLow⭐⭐⭐
7Antihypertensive adherence in PIH/preeclampsiaProspective observational✅ Ward + OPD✅ SimpleMediumLow⭐⭐⭐
8Adherence in PCOS on metformin/OCPCross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
9Pharmacist counseling impact on antenatal supplement adherenceProspective interventional✅ ANC clinic⚠️ Moderate (consent)MediumLow⭐⭐⭐
10ADR monitoring in obstetric drugsProspective observational✅ Ward patients✅ SimpleMediumLow⭐⭐⭐
11ADR surveillance of hormonal contraceptivesCross-sectional/Prospective✅ Family planning OPD✅ SimpleMediumLow⭐⭐⭐
12Teratogenicity risk - category C/D/X exposureRetrospective⚠️ Needs detailed records⚠️ ModerateMediumLow⭐⭐
13ADR profiling in preeclampsia managementProspective observational✅ Ward patients✅ SimpleMediumLow⭐⭐⭐
14Drug-related problems in high-risk pregnancy (PCNE)Prospective observational✅ High-risk OPD/ward⚠️ Moderate (consent)MediumLow⭐⭐⭐
15Drug interactions in polypharmacy obstetric patientsRetrospective/Prospective✅ Prescriptions/case sheets✅ SimpleShortLow⭐⭐⭐
16Inappropriate medication in pregnancy (FDA/Hale)Retrospective✅ Case records✅ SimpleShortLow⭐⭐⭐
17Medication errors in obstetric wardsProspective observational⚠️ Staff cooperation needed⚠️ ModerateMediumLow⭐⭐
18Pharmacist counseling in nausea/vomiting of pregnancyProspective interventional✅ ANC OPD⚠️ Moderate (consent)MediumLow⭐⭐⭐
19Pharmacist role in preeclampsia drug optimizationProspective interventional✅ Ward patients⚠️ ModerateMediumLow⭐⭐
20Pharmacist interventions reducing medication errors in L&DProspective interventional⚠️ Needs ward access⚠️ ModerateLongMedium⭐⭐
21Pharmacist recommendations in gynecology ward roundsProspective observational⚠️ Needs physician cooperation⚠️ ModerateMediumLow⭐⭐
22KAP on oral contraceptive pills (OCPs)Cross-sectional survey✅ OPD/community women✅ SimpleShortLow⭐⭐⭐
23Knowledge on drugs in pregnancy and lactationCross-sectional survey✅ ANC/postnatal patients✅ SimpleShortLow⭐⭐⭐
24Patient awareness of emergency contraceptionCross-sectional survey✅ OPD/community✅ SimpleShortLow⭐⭐⭐
25KAP of self-medication in pregnant womenCross-sectional survey✅ ANC OPD✅ SimpleShortLow⭐⭐⭐
26Cost-of-illness study of preeclampsiaRetrospective/Prospective✅ Hospital billing + records⚠️ ModerateMediumLow⭐⭐
27Pharmacoeconomic comparison - misoprostol vs. oxytocin in PPHRetrospective comparative✅ Ward records + billing✅ SimpleMediumLow⭐⭐⭐
28Direct medical costs in GDM managementRetrospective✅ Hospital billing✅ SimpleShortLow⭐⭐⭐
29HRQoL in PCOS women using SF-36Cross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
30Pharmacotherapy assessment in PCOSCross-sectional/Retrospective✅ OPD records✅ SimpleShortLow⭐⭐⭐
31Drug therapy in endometriosisRetrospective⚠️ Moderate - diagnosis confirmation✅ SimpleMediumLow⭐⭐
32Management of preterm labor - tocolytic useRetrospective/Prospective✅ Ward records✅ SimpleMediumLow⭐⭐⭐
33Chemotherapy regimens in gynecological cancersProspective observational⚠️ Oncology unit access needed⚠️ ModerateLongMedium⭐⭐
34Antifungal use in vulvovaginal candidiasisCross-sectional/Retrospective✅ OPD records/pharmacy✅ SimpleShortLow⭐⭐⭐
35Pharmacist role in reproductive health counselingCross-sectional/Interventional✅ OPD patients✅ SimpleMediumLow⭐⭐⭐
36Pharmacist knowledge on drugs in breastfeedingCross-sectional survey✅ Pharmacists as subjects✅ SimpleShortLow⭐⭐⭐
37Progesterone supplementation in threatened abortionRetrospective observational✅ Case records✅ SimpleShortLow⭐⭐⭐
38Digital health for antenatal medication adherenceProspective interventional⚠️ Smartphone access required⚠️ ModerateLongMedium⭐⭐
39IV vs. oral iron therapy in pregnancy anemiaProspective comparative✅ ANC ward/OPD⚠️ Moderate (IV access)MediumMedium⭐⭐⭐

Summary by Feasibility

⭐⭐⭐ High Feasibility (27 topics)

Topics: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 15, 16, 18, 22, 23, 24, 25, 27, 28, 29, 30, 32, 34, 35, 36, 37, 39

⭐⭐ Moderate Feasibility (10 topics)

Topics: 12, 17, 19, 20, 21, 26, 31, 33, 38

⭐ Low Feasibility

None - all topics are achievable within an M. Pharm timeframe with proper planning.

Best picks for a 1-year M. Pharm project (high feasibility + high publishability):
  • #9 - Pharmacist counseling on antenatal supplement adherence
  • #22 - KAP on OCP use
  • #14 - Drug-related problems in high-risk pregnancy
  • #39 - IV vs. oral iron in pregnancy anemia
  • #10 - ADR monitoring in obstetric drugs
Would you like a detailed study protocol (objectives, methodology, tools, sample size) for any of these?

nervous system related?

Here are M. Pharm (Pharmacy Practice) project topics for Neurology & Psychiatry (Nervous System), along with a feasibility comparison table:

Topic List

Drug Utilization & Prescribing Pattern Studies

  1. Drug utilization study of antiepileptic drugs (AEDs) in epilepsy patients
  2. Prescribing pattern of antidepressants in depressive disorders
  3. Drug utilization study of antipsychotics in schizophrenia inpatients
  4. Assessment of prescribing patterns in Parkinson's disease management
  5. Drug utilization review of anticoagulants/antiplatelets in ischemic stroke patients
  6. Prescribing pattern of drugs in migraine management - acute vs. prophylactic

Medication Adherence

  1. Assessment of medication adherence in epilepsy patients using MMAS-8
  2. Adherence to antipsychotic therapy in schizophrenia and associated factors
  3. Medication adherence in Parkinson's disease patients - barriers and determinants
  4. Impact of pharmacist counseling on adherence in depression patients
  5. Adherence to mood stabilizers in bipolar disorder patients

Adverse Drug Reactions & Pharmacovigilance

  1. ADR monitoring and reporting of antiepileptic drugs - incidence and patterns
  2. ADR profiling of atypical vs. typical antipsychotics in psychiatric inpatients
  3. Drug-induced movement disorders (EPS, tardive dyskinesia) surveillance in psychiatric patients
  4. ADR monitoring of antidepressants (SSRIs, SNRIs, TCAs) - causality and severity assessment
  5. Valproate-induced adverse effects monitoring - hepatotoxicity, weight gain, tremor

Drug-Related Problems (DRPs)

  1. Identification of drug-related problems in neurology ward patients using PCNE classification
  2. Drug-drug interactions in polypharmacy neurology/psychiatry patients
  3. Assessment of inappropriate prescribing in elderly neurological patients using Beers/STOPP-START criteria
  4. Medication errors in psychiatry ward - incidence, type, and pharmacist interventions

Clinical Pharmacist Interventions

  1. Impact of pharmacist-led medication review on DRPs in stroke patients
  2. Role of pharmacist in therapeutic drug monitoring (TDM) of antiepileptics (phenytoin, valproate, carbamazepine)
  3. Pharmacist intervention in reducing antipsychotic polypharmacy in schizophrenia
  4. Effect of pharmacist counseling on caregiver knowledge of neurological medications
  5. Pharmacist's role in clozapine monitoring - safety and outcome assessment

Patient Knowledge, Attitude & Practice (KAP)

  1. KAP of epilepsy patients toward their disease and medication
  2. Assessment of patient/caregiver knowledge on antidepressant therapy - myths and misconceptions
  3. Knowledge and awareness of stroke warning signs and medication use in at-risk patients
  4. KAP of psychiatric patients on antipsychotic medications and side effects

Pharmacoeconomics & Quality of Life

  1. Cost-of-illness study of epilepsy in a tertiary care neurology unit
  2. Health-related quality of life (HRQoL) in epilepsy patients using QOLIE-31 scale
  3. HRQoL assessment in schizophrenia patients using SF-36 / PANSS
  4. Pharmacoeconomic analysis of generic vs. branded antiepileptic drugs
  5. Direct and indirect costs in stroke patients - a burden-of-illness study

Specific Condition-Based Studies

  1. Evaluation of thromboprophylaxis practices in stroke patients
  2. Assessment of sleep disorder pharmacotherapy - benzodiazepine and Z-drug prescribing patterns
  3. Drug therapy evaluation in Alzheimer's disease - cholinesterase inhibitor use patterns
  4. Assessment of antiepileptic drug switching - reasons, outcomes, and pharmacist role
  5. Evaluation of ADHD pharmacotherapy in children/adolescents - safety and monitoring

Feasibility Comparison Table

#TopicStudy TypeData AccessEthics ComplexityTime RequiredCostOverall Feasibility
1Drug utilization of AEDs in epilepsyRetrospective/Prospective✅ OPD/ward records✅ SimpleShortLow⭐⭐⭐
2Prescribing pattern of antidepressantsRetrospective✅ OPD records✅ SimpleShortLow⭐⭐⭐
3Drug utilization of antipsychotics in schizophreniaRetrospective✅ Ward records✅ SimpleShortLow⭐⭐⭐
4Prescribing patterns in Parkinson's diseaseRetrospective✅ OPD records✅ SimpleShortLow⭐⭐⭐
5Anticoagulant/antiplatelet use in ischemic strokeRetrospective✅ Ward/case sheets✅ SimpleShortLow⭐⭐⭐
6Prescribing in migraine - acute vs. prophylacticCross-sectional✅ OPD records✅ SimpleShortLow⭐⭐⭐
7Adherence in epilepsy (MMAS-8)Cross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
8Adherence to antipsychotics in schizophreniaCross-sectional✅ OPD/ward patients✅ SimpleShortLow⭐⭐⭐
9Adherence in Parkinson's diseaseCross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
10Pharmacist counseling impact on adherence in depressionProspective interventional✅ OPD patients⚠️ Moderate (consent)MediumLow⭐⭐⭐
11Adherence to mood stabilizers in bipolar disorderCross-sectional✅ OPD/ward patients✅ SimpleShortLow⭐⭐⭐
12ADR monitoring of AEDsProspective observational✅ Ward/OPD patients✅ SimpleMediumLow⭐⭐⭐
13ADR profiling - atypical vs. typical antipsychoticsProspective comparative✅ Psychiatric ward✅ SimpleMediumLow⭐⭐⭐
14Drug-induced movement disorders surveillanceProspective observational✅ Psychiatric ward✅ SimpleMediumLow⭐⭐⭐
15ADR monitoring of antidepressantsProspective observational✅ OPD/ward patients✅ SimpleMediumLow⭐⭐⭐
16Valproate-induced ADR monitoringProspective observational✅ Neurology/psychiatry ward✅ SimpleMediumLow⭐⭐⭐
17DRPs in neurology ward (PCNE)Prospective observational✅ Ward patients⚠️ Moderate (consent)MediumLow⭐⭐⭐
18Drug-drug interactions in neuro/psych polypharmacyRetrospective/Prospective✅ Prescriptions✅ SimpleShortLow⭐⭐⭐
19Inappropriate prescribing in elderly (Beers/STOPP-START)Retrospective✅ Case records✅ SimpleShortLow⭐⭐⭐
20Medication errors in psychiatry wardProspective observational⚠️ Staff cooperation needed⚠️ ModerateMediumLow⭐⭐
21Pharmacist medication review in stroke patientsProspective interventional✅ Stroke ward⚠️ ModerateMediumLow⭐⭐⭐
22Pharmacist role in TDM of AEDsProspective observational✅ Neurology ward/TDM lab✅ SimpleMediumLow⭐⭐⭐
23Pharmacist intervention in antipsychotic polypharmacyProspective interventional⚠️ Needs physician cooperation⚠️ ModerateMediumLow⭐⭐
24Pharmacist counseling on caregiver knowledgeProspective interventional✅ OPD caregivers✅ SimpleMediumLow⭐⭐⭐
25Clozapine monitoring - safety and outcomesProspective observational⚠️ Clozapine registry access⚠️ ModerateLongLow⭐⭐
26KAP of epilepsy patients on disease/medicationCross-sectional survey✅ OPD patients✅ SimpleShortLow⭐⭐⭐
27Patient/caregiver knowledge on antidepressantsCross-sectional survey✅ OPD patients✅ SimpleShortLow⭐⭐⭐
28Stroke warning signs awareness in at-risk patientsCross-sectional survey✅ OPD/ward patients✅ SimpleShortLow⭐⭐⭐
29KAP of psychiatric patients on antipsychoticsCross-sectional survey✅ Psychiatric OPD✅ SimpleShortLow⭐⭐⭐
30Cost-of-illness study of epilepsyRetrospective/Prospective✅ Hospital billing + records⚠️ ModerateMediumLow⭐⭐
31HRQoL in epilepsy using QOLIE-31Cross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
32HRQoL in schizophrenia using SF-36/PANSSCross-sectional✅ OPD/ward patients✅ SimpleShortLow⭐⭐⭐
33Generic vs. branded AED pharmacoeconomicsRetrospective comparative✅ Hospital/pharmacy records✅ SimpleShortLow⭐⭐⭐
34Cost burden in stroke patientsRetrospective✅ Hospital billing⚠️ ModerateMediumLow⭐⭐
35Thromboprophylaxis practices in strokeRetrospective✅ Case sheets✅ SimpleShortLow⭐⭐⭐
36Sleep disorder pharmacotherapy - BZD/Z-drug patternsRetrospective✅ OPD records✅ SimpleShortLow⭐⭐⭐
37Alzheimer's disease - cholinesterase inhibitor patternsRetrospective⚠️ Fewer patients available✅ SimpleMediumLow⭐⭐
38AED switching - reasons, outcomes, pharmacist roleProspective observational✅ Neurology OPD✅ SimpleMediumLow⭐⭐⭐
39ADHD pharmacotherapy in children - safety monitoringProspective observational⚠️ Pediatric ethics needed⚠️ ComplexLongMedium

Summary by Feasibility

RatingCountTopic Numbers
⭐⭐⭐ High301-19 (except 20), 21-22, 24, 26-29, 31-33, 35-36, 38
⭐⭐ Moderate820, 23, 25, 30, 34, 37
⭐ Difficult139

Top 5 Picks (High Feasibility + Publishability)

#TopicStrength
7Medication adherence in epilepsy (MMAS-8)Simple, validated tool, large patient pool
17DRPs in neurology ward (PCNE)High clinical impact, structured methodology
22Pharmacist role in TDM of AEDsUnique clinical pharmacist role, lab-based
31HRQoL in epilepsy (QOLIE-31)Patient-centered, validated scale, publishable
12ADR monitoring of AEDsPharmacovigilance focus, simple prospective design

Would you like a detailed study protocol for any of these, or shall I compile all topics from Cardiology, Gynecology, and Neurology into one master Excel file for download?

elder patient related

Here are M. Pharm (Pharmacy Practice) project topics focused on Elderly Patients (Geriatric Pharmacy), with a feasibility comparison table:

Topic List

Polypharmacy & Inappropriate Prescribing

  1. Prevalence of polypharmacy in elderly inpatients and associated risk factors
  2. Assessment of inappropriate prescribing in elderly using Beers Criteria 2023
  3. Assessment of inappropriate prescribing using STOPP/START criteria v3
  4. Comparison of Beers vs. STOPP/START criteria in detecting inappropriate prescribing in elderly
  5. Prevalence of potentially inappropriate medications (PIMs) in elderly outpatients
  6. Drug burden index (DBI) assessment in community-dwelling elderly patients

Medication Adherence

  1. Assessment of medication adherence in elderly patients with multiple chronic conditions (MMAS-8)
  2. Factors affecting medication non-adherence in geriatric outpatients
  3. Impact of pill organizer/blister pack on medication adherence in elderly
  4. Role of caregiver support on medication adherence in elderly patients
  5. Impact of pharmacist-led medication counseling on adherence in elderly - interventional study

Adverse Drug Reactions & Drug Safety

  1. Incidence and pattern of ADRs in hospitalized elderly patients
  2. ADR-related hospital admissions in elderly - a prospective study
  3. Drug-induced falls in elderly patients - assessment and pharmacist intervention
  4. ADR monitoring of high-alert medications (anticoagulants, digoxin, insulin) in elderly
  5. Drug-induced cognitive impairment in elderly - assessment of anticholinergic drug burden

Drug-Related Problems (DRPs)

  1. Identification of drug-related problems in elderly inpatients using PCNE classification
  2. Drug-drug interactions in elderly polypharmacy patients - prevalence and clinical significance
  3. Medication-related problems during care transitions (hospital to home) in elderly
  4. Assessment of renal function-based dose adjustments in elderly hospitalized patients

Deprescribing

  1. Assessment of deprescribing practices in elderly patients on polypharmacy
  2. Pharmacist-led deprescribing intervention in elderly patients - outcomes and physician acceptance
  3. Evaluation of proton pump inhibitor (PPI) overuse and deprescribing in elderly
  4. Benzodiazepine/Z-drug deprescribing in elderly - patterns and pharmacist role
  5. Assessment of statin deprescribing in elderly patients with limited life expectancy

Clinical Pharmacist Interventions

  1. Impact of clinical pharmacist medication review on drug-related problems in geriatric ward
  2. Pharmacist-led comprehensive medication review (CMR) in elderly outpatients
  3. Role of pharmacist in fall prevention programs in elderly hospitalized patients
  4. Pharmacist's contribution during geriatric ward rounds - types and acceptance of recommendations
  5. Pharmacist-led anticoagulation management in elderly atrial fibrillation patients

Patient Knowledge & Health Literacy

  1. Assessment of health literacy and its impact on medication adherence in elderly
  2. KAP of elderly patients on their chronic disease medications
  3. Assessment of elderly patients' ability to understand prescription labels and instructions
  4. Self-medication practices and associated risks in elderly patients

Quality of Life & Pharmacoeconomics

  1. Health-related quality of life (HRQoL) in elderly patients with multimorbidity using EQ-5D
  2. Cost-of-illness study of polypharmacy-related adverse outcomes in elderly
  3. Pharmacoeconomic impact of pharmacist interventions in geriatric patients
  4. HRQoL assessment in elderly patients with chronic pain using SF-36

Specific Condition-Based / Emerging Topics

  1. Anticholinergic drug burden assessment using ACB scale in elderly patients
  2. Assessment of fall risk and medications contributing to falls (fall-risk-increasing drugs - FRIDs)
  3. Evaluation of nutritional supplement and drug interactions in elderly
  4. Medication management in elderly patients with dementia - caregiver perspectives
  5. Pharmacist role in managing pain in elderly cancer patients - opioid safety monitoring
  6. Vaccination coverage and pharmacist counseling role in elderly patients
  7. Assessment of smart medication dispensing/reminder technology uptake in elderly

Feasibility Comparison Table

#TopicStudy TypeData AccessEthics ComplexityTime RequiredCostOverall Feasibility
1Prevalence of polypharmacy in elderly inpatientsCross-sectional✅ Ward records✅ SimpleShortLow⭐⭐⭐
2Inappropriate prescribing - Beers Criteria 2023Retrospective/Cross-sectional✅ OPD/ward records✅ SimpleShortLow⭐⭐⭐
3Inappropriate prescribing - STOPP/START v3Retrospective/Cross-sectional✅ OPD/ward records✅ SimpleShortLow⭐⭐⭐
4Beers vs. STOPP/START comparisonRetrospective comparative✅ Case records✅ SimpleShortLow⭐⭐⭐
5PIMs in elderly outpatientsCross-sectional✅ OPD prescriptions✅ SimpleShortLow⭐⭐⭐
6Drug burden index in community elderlyCross-sectional⚠️ Community recruitment⚠️ ModerateMediumLow⭐⭐
7Medication adherence - MMAS-8 in elderlyCross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
8Factors affecting non-adherence in elderlyCross-sectional survey✅ OPD patients✅ SimpleShortLow⭐⭐⭐
9Pill organizer impact on adherenceProspective interventional✅ OPD patients⚠️ Moderate (consent)MediumLow⭐⭐⭐
10Caregiver support and adherenceCross-sectional✅ OPD patients + caregivers✅ SimpleShortLow⭐⭐⭐
11Pharmacist counseling impact on adherenceProspective interventional✅ OPD patients⚠️ Moderate (consent)MediumLow⭐⭐⭐
12Incidence and pattern of ADRs in elderly inpatientsProspective observational✅ Ward patients✅ SimpleMediumLow⭐⭐⭐
13ADR-related hospital admissions in elderlyProspective observational✅ Admission records✅ SimpleMediumLow⭐⭐⭐
14Drug-induced falls in elderlyProspective observational✅ Ward + fall incident reports⚠️ ModerateMediumLow⭐⭐⭐
15ADR monitoring of high-alert drugs in elderlyProspective observational✅ Ward patients✅ SimpleMediumLow⭐⭐⭐
16Anticholinergic drug burden and cognitive impairmentCross-sectional✅ OPD/ward elderly⚠️ ModerateMediumLow⭐⭐⭐
17DRPs in elderly inpatients (PCNE)Prospective observational✅ Ward patients⚠️ Moderate (consent)MediumLow⭐⭐⭐
18Drug-drug interactions in elderly polypharmacyRetrospective/Prospective✅ Prescriptions✅ SimpleShortLow⭐⭐⭐
19Medication problems during care transitionsProspective observational⚠️ Discharge follow-up needed⚠️ ModerateLongLow⭐⭐
20Renal function-based dose adjustment assessmentRetrospective✅ Lab + case records✅ SimpleShortLow⭐⭐⭐
21Deprescribing practices in elderly polypharmacyCross-sectional/Retrospective✅ Case records✅ SimpleShortLow⭐⭐⭐
22Pharmacist-led deprescribing interventionProspective interventional⚠️ Physician cooperation needed⚠️ ModerateMediumLow⭐⭐
23PPI overuse and deprescribing in elderlyRetrospective✅ OPD/ward records✅ SimpleShortLow⭐⭐⭐
24BZD/Z-drug deprescribing patternsRetrospective✅ Pharmacy/OPD records✅ SimpleShortLow⭐⭐⭐
25Statin deprescribing in elderlyRetrospective/Cross-sectional✅ OPD records✅ SimpleShortLow⭐⭐⭐
26Pharmacist medication review in geriatric wardProspective interventional✅ Ward patients⚠️ ModerateMediumLow⭐⭐⭐
27Comprehensive medication review (CMR) in elderly OPDProspective interventional✅ OPD patients⚠️ ModerateMediumLow⭐⭐⭐
28Pharmacist role in fall preventionProspective interventional✅ Ward patients⚠️ ModerateMediumLow⭐⭐
29Pharmacist recommendations in geriatric ward roundsProspective observational⚠️ Physician cooperation⚠️ ModerateMediumLow⭐⭐
30Pharmacist anticoagulation management in elderly AFProspective observational✅ Cardiology/medicine OPD✅ SimpleMediumLow⭐⭐⭐
31Health literacy and medication adherence in elderlyCross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
32KAP on chronic disease medications in elderlyCross-sectional survey✅ OPD patients✅ SimpleShortLow⭐⭐⭐
33Ability to understand prescription labels in elderlyCross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
34Self-medication practices in elderlyCross-sectional survey✅ OPD/community✅ SimpleShortLow⭐⭐⭐
35HRQoL in elderly with multimorbidity (EQ-5D)Cross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
36Cost-of-illness of polypharmacy adverse outcomesRetrospective✅ Hospital billing + records⚠️ ModerateMediumLow⭐⭐
37Pharmacoeconomic impact of pharmacist interventionsProspective⚠️ Billing data access needed⚠️ ModerateLongLow⭐⭐
38HRQoL in elderly chronic pain (SF-36)Cross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
39Anticholinergic burden (ACB scale) in elderlyCross-sectional✅ OPD/ward records✅ SimpleShortLow⭐⭐⭐
40Fall-risk-increasing drugs (FRIDs) assessmentRetrospective/Prospective✅ Ward + fall records✅ SimpleMediumLow⭐⭐⭐
41Nutritional supplement - drug interactions in elderlyCross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
42Medication management in elderly with dementiaCross-sectional (caregivers)✅ Neurology/psychiatry OPD✅ SimpleShortLow⭐⭐⭐
43Pain management and opioid safety in elderly cancerProspective observational⚠️ Palliative/oncology unit access⚠️ ModerateMediumLow⭐⭐
44Vaccination coverage and pharmacist counseling in elderlyCross-sectional + interventional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
45Smart medication technology uptake in elderlyCross-sectional survey✅ OPD patients✅ SimpleShortLow⭐⭐⭐

Summary by Feasibility

RatingCountTopic Numbers
⭐⭐⭐ High351-5, 7-18, 20-21, 23-27, 30-35, 38-42, 44-45
⭐⭐ Moderate96, 19, 22, 28, 29, 36, 37, 43
⭐ Difficult0-

Top 5 Picks for M. Pharm (Geriatric Focus)

#TopicWhy it Stands Out
2Inappropriate prescribing using Beers Criteria 2023Updated criteria, widely cited, simple retrospective design
4Beers vs. STOPP/START comparisonNovel comparative angle, high publishability
39Anticholinergic burden (ACB scale)Emerging topic, validated tool, very feasible
40FRIDs assessment and fallsClinically impactful, safety-focused, easy data access
17DRPs in elderly inpatients (PCNE)Gold-standard classification, strong clinical relevance

Would you like me to now compile all topics from Cardiology, Gynecology, Neurology, and Geriatrics into one master Excel file with feasibility ratings for easy comparison and download?

oncology?

Here are M. Pharm (Pharmacy Practice) project topics for Oncology, with a full feasibility comparison table:

Topic List

Drug Utilization & Prescribing Pattern Studies

  1. Drug utilization study of chemotherapy regimens in breast cancer patients
  2. Prescribing pattern analysis in colorectal cancer - adherence to NCCN/ESMO guidelines
  3. Drug utilization review of targeted therapy in non-small cell lung cancer (NSCLC)
  4. Assessment of supportive care medication use (antiemetics, G-CSF, analgesics) in chemotherapy patients
  5. Prescribing pattern of opioid analgesics in cancer pain management
  6. Evaluation of chemotherapy regimens in hematological malignancies (leukemia/lymphoma)

Adverse Drug Reactions & Pharmacovigilance

  1. ADR monitoring and reporting in cancer patients receiving chemotherapy - incidence and patterns
  2. Chemotherapy-induced nausea and vomiting (CINV) - assessment and management evaluation
  3. Chemotherapy-induced peripheral neuropathy (CIPN) surveillance and grading (CTCAE)
  4. Hematological toxicity monitoring in cancer patients on cytotoxic therapy
  5. ADR profiling of targeted therapy/immunotherapy (checkpoint inhibitors) - immune-related adverse events (irAEs)
  6. Cardiotoxicity monitoring in patients on anthracycline-based chemotherapy
  7. Drug-induced nephrotoxicity and hepatotoxicity surveillance in oncology patients
  8. ADR causality and severity assessment using Naranjo scale and CTCAE in oncology ward

Medication Errors & Safety

  1. Incidence and types of chemotherapy medication errors in oncology ward/day care
  2. Assessment of chemotherapy preparation and dispensing errors in hospital pharmacy
  3. High-alert medication safety practices for chemotherapy agents - gap analysis
  4. Evaluation of chemotherapy dose calculation errors - actual vs. prescribed BSA-based dosing

Drug-Related Problems (DRPs)

  1. Identification of drug-related problems in oncology inpatients using PCNE classification
  2. Drug-drug interactions in cancer patients on polypharmacy - prevalence and clinical significance
  3. Assessment of drug-nutrient interactions in cancer patients on chemotherapy
  4. Evaluation of supportive care prescribing gaps in chemotherapy patients

Clinical Pharmacist Interventions

  1. Impact of clinical pharmacist interventions on drug-related problems in oncology ward
  2. Role of pharmacist in chemotherapy review and dose verification - error prevention
  3. Pharmacist-led antiemetic protocol optimization in CINV management
  4. Role of pharmacist in pain management in palliative cancer patients
  5. Pharmacist interventions in improving supportive care medication use
  6. Assessment of pharmacist recommendations during oncology multidisciplinary team (MDT) meetings

Medication Adherence

  1. Adherence to oral chemotherapy agents (capecitabine, imatinib, erlotinib) and associated factors
  2. Impact of pharmacist counseling on adherence to oral targeted therapy
  3. Factors affecting adherence to hormonal therapy in breast cancer (tamoxifen, letrozole)
  4. Adherence to supportive medications (antiemetics, steroids) during chemotherapy cycles

Patient Knowledge, Attitude & Practice (KAP)

  1. KAP of cancer patients on chemotherapy side effects and self-management
  2. Assessment of patient knowledge on oral chemotherapy - safe handling and storage
  3. Patient awareness of palliative care and pharmacist's role in symptom management
  4. KAP of oncology nurses and pharmacists on chemotherapy safe handling practices

Pharmacoeconomics & Quality of Life

  1. Cost-of-illness study of breast/lung/colorectal cancer in a tertiary care hospital
  2. Pharmacoeconomic analysis of generic vs. innovator chemotherapy agents
  3. Health-related quality of life (HRQoL) in cancer patients using EORTC QLQ-C30
  4. Economic burden of chemotherapy-induced toxicities - direct medical cost analysis
  5. Cost-effectiveness of antiemetic regimens in CINV prevention

Specific / Emerging Topics

  1. Assessment of biosimilar use in oncology - prescribing patterns and pharmacist awareness
  2. Evaluation of palliative care pharmacotherapy - symptom control audit
  3. Pharmacist's role in immunotherapy (checkpoint inhibitor) toxicity monitoring
  4. Assessment of cancer pain undertreatment - WHO analgesic ladder adherence
  5. Medication reconciliation in cancer patients at hospital admission and discharge
  6. Evaluation of antibiotic use in febrile neutropenia - appropriateness and outcomes
  7. Pharmacist's role in chemotherapy-induced oral mucositis prevention and management

Feasibility Comparison Table

#TopicStudy TypeData AccessEthics ComplexityTime RequiredCostOverall Feasibility
1Drug utilization in breast cancer chemoRetrospective✅ Ward/case records✅ SimpleShortLow⭐⭐⭐
2Prescribing pattern in colorectal cancerRetrospective✅ Ward records✅ SimpleShortLow⭐⭐⭐
3Drug utilization of targeted therapy in NSCLCRetrospective✅ Ward/OPD records✅ SimpleShortLow⭐⭐⭐
4Supportive care medication use in chemo patientsProspective/Retrospective✅ Ward records✅ SimpleShortLow⭐⭐⭐
5Opioid prescribing in cancer painRetrospective✅ Prescription records✅ SimpleShortLow⭐⭐⭐
6Chemo regimens in hematological malignanciesRetrospective✅ Ward/case records✅ SimpleShortLow⭐⭐⭐
7ADR monitoring in chemo patientsProspective observational✅ Ward patients✅ SimpleMediumLow⭐⭐⭐
8CINV assessment and managementProspective observational✅ Day care/ward patients✅ SimpleMediumLow⭐⭐⭐
9CIPN surveillance (CTCAE grading)Prospective observational✅ OPD/ward patients✅ SimpleMediumLow⭐⭐⭐
10Hematological toxicity monitoringProspective observational✅ Ward + lab records✅ SimpleMediumLow⭐⭐⭐
11irAEs with immunotherapy/checkpoint inhibitorsProspective observational⚠️ Limited immunotherapy patients⚠️ ModerateLongLow⭐⭐
12Cardiotoxicity in anthracycline-based chemoProspective observational✅ Ward + ECHO records⚠️ ModerateMediumLow⭐⭐⭐
13Drug-induced nephrotoxicity/hepatotoxicityProspective observational✅ Ward + lab records✅ SimpleMediumLow⭐⭐⭐
14ADR causality/severity (Naranjo + CTCAE)Prospective observational✅ Ward patients✅ SimpleMediumLow⭐⭐⭐
15Chemo medication errors in oncology wardProspective observational⚠️ Staff cooperation needed⚠️ ModerateMediumLow⭐⭐
16Chemo preparation/dispensing errorsProspective observational⚠️ Pharmacy unit access⚠️ ModerateMediumLow⭐⭐
17High-alert chemo medication safety gap analysisCross-sectional/Audit✅ Pharmacy/ward records✅ SimpleShortLow⭐⭐⭐
18Chemo dose calculation errors (BSA-based)Retrospective✅ Prescription records✅ SimpleShortLow⭐⭐⭐
19DRPs in oncology inpatients (PCNE)Prospective observational✅ Ward patients⚠️ Moderate (consent)MediumLow⭐⭐⭐
20Drug-drug interactions in cancer polypharmacyRetrospective/Prospective✅ Prescriptions✅ SimpleShortLow⭐⭐⭐
21Drug-nutrient interactions in chemo patientsCross-sectional✅ OPD/ward patients✅ SimpleShortLow⭐⭐⭐
22Supportive care prescribing gapsRetrospective/Audit✅ Case records✅ SimpleShortLow⭐⭐⭐
23Pharmacist interventions on DRPs in oncologyProspective interventional✅ Ward patients⚠️ ModerateMediumLow⭐⭐⭐
24Pharmacist role in chemo review/dose verificationProspective observational✅ Pharmacy/ward✅ SimpleMediumLow⭐⭐⭐
25Pharmacist-led antiemetic protocol optimizationProspective interventional✅ Day care/ward⚠️ ModerateMediumLow⭐⭐⭐
26Pharmacist in pain management - palliativeProspective observational✅ Palliative care unit⚠️ ModerateMediumLow⭐⭐
27Pharmacist interventions in supportive careProspective interventional✅ Ward patients⚠️ ModerateMediumLow⭐⭐⭐
28Pharmacist recommendations in oncology MDTProspective observational⚠️ MDT access needed⚠️ ModerateLongLow⭐⭐
29Adherence to oral chemotherapy agentsCross-sectional/Prospective✅ OPD patients✅ SimpleMediumLow⭐⭐⭐
30Pharmacist counseling impact on oral targeted therapy adherenceProspective interventional✅ OPD patients⚠️ Moderate (consent)MediumLow⭐⭐⭐
31Adherence to hormonal therapy in breast cancerCross-sectional✅ OPD patients✅ SimpleShortLow⭐⭐⭐
32Adherence to supportive medications during chemoProspective observational✅ Day care patients✅ SimpleMediumLow⭐⭐⭐
33KAP on chemo side effects and self-managementCross-sectional survey✅ OPD/ward patients✅ SimpleShortLow⭐⭐⭐
34Patient knowledge on oral chemo handling/storageCross-sectional survey✅ OPD patients✅ SimpleShortLow⭐⭐⭐
35Patient awareness of palliative careCross-sectional survey✅ Ward/OPD patients✅ SimpleShortLow⭐⭐⭐
36KAP of oncology staff on chemo safe handlingCross-sectional survey✅ Nurses/pharmacists✅ SimpleShortLow⭐⭐⭐
37Cost-of-illness in breast/lung/colorectal cancerRetrospective✅ Hospital billing⚠️ ModerateMediumLow⭐⭐
38Generic vs. innovator chemo pharmacoeconomicsRetrospective comparative✅ Pharmacy/billing records✅ SimpleShortLow⭐⭐⭐
39HRQoL in cancer patients (EORTC QLQ-C30)Cross-sectional✅ OPD/ward patients✅ SimpleShortLow⭐⭐⭐
40Economic burden of chemo-induced toxicitiesRetrospective✅ Hospital billing⚠️ ModerateMediumLow⭐⭐
41Cost-effectiveness of antiemetic regimensRetrospective comparative✅ Pharmacy + billing records✅ SimpleShortLow⭐⭐⭐
42Biosimilar use in oncology - patterns and awarenessCross-sectional✅ Pharmacy/ward records✅ SimpleShortLow⭐⭐⭐
43Palliative care pharmacotherapy auditRetrospective/Audit✅ Palliative ward records✅ SimpleShortLow⭐⭐⭐
44Immunotherapy toxicity monitoring (pharmacist role)Prospective observational⚠️ Limited patient numbers⚠️ ModerateLongLow⭐⭐
45Cancer pain undertreatment - WHO ladder adherenceCross-sectional/Retrospective✅ OPD/ward records✅ SimpleShortLow⭐⭐⭐
46Medication reconciliation in cancer patientsProspective observational✅ Admission/discharge records⚠️ ModerateMediumLow⭐⭐⭐
47Antibiotic use in febrile neutropeniaRetrospective/Prospective✅ Ward records + culture reports✅ SimpleMediumLow⭐⭐⭐
48Chemo-induced oral mucositis - prevention/managementProspective observational✅ Day care/ward patients✅ SimpleMediumLow⭐⭐⭐

Summary by Feasibility

RatingCountTopic Numbers
⭐⭐⭐ High381-10, 12-14, 17-25, 27, 29-36, 38-39, 41-43, 45-48
⭐⭐ Moderate1011, 15, 16, 26, 28, 37, 40, 44
⭐ Difficult0-

Top 5 Picks for M. Pharm (Oncology)

#TopicWhy it Stands Out
8CINV assessment and management evaluationVery common, clear outcomes, day care patients easy to recruit
39HRQoL using EORTC QLQ-C30Gold-standard validated tool, patient-centered, highly publishable
19DRPs in oncology inpatients (PCNE)Structured tool, high clinical impact, strong for publication
45Cancer pain undertreatment - WHO ladderClinically critical, simple retrospective + prospective design
29Adherence to oral chemotherapy agentsGrowing oral chemo use makes this very timely and relevant

Shall I now compile all topics across Cardiology, Gynecology, Neurology, Geriatrics, and Oncology into one master Excel file with feasibility ratings for easy download and reference?

pharmacogenomics?

Here are M. Pharm (Pharmacy Practice) project topics for Pharmacogenomics, with a full feasibility comparison table:

Topic List

Awareness, Knowledge & Attitude Studies

  1. Assessment of knowledge, attitude and practice (KAP) of pharmacists on pharmacogenomics
  2. Awareness of pharmacogenomics among physicians in a tertiary care hospital
  3. KAP of clinical pharmacists on implementing pharmacogenomics in patient care
  4. Assessment of pharmacogenomics education in pharmacy curriculum - student perspectives
  5. Awareness of pharmacogenomics testing among patients with chronic diseases

Drug Metabolism & CYP450 Polymorphism Studies

  1. Assessment of CYP2C19 polymorphism and clopidogrel response in cardiac patients
  2. CYP2D6 polymorphism and its influence on antidepressant (fluoxetine/codeine) therapy outcomes
  3. CYP2C9 and VKORC1 polymorphism impact on warfarin dosing requirements
  4. CYP3A4/3A5 polymorphism and tacrolimus dose variability in transplant patients
  5. CYP2C19 genotype and proton pump inhibitor (PPI) efficacy in H. pylori eradication

Oncology Pharmacogenomics

  1. DPYD gene polymorphism and fluorouracil (5-FU) toxicity in cancer patients
  2. TPMT/NUDT15 genotype and thiopurine (azathioprine/6-MP) toxicity in leukemia/IBD patients
  3. HER2/EGFR mutation status and targeted therapy response in breast/lung cancer
  4. UGT1A1 polymorphism and irinotecan-induced toxicity (neutropenia/diarrhea)
  5. BRCA1/2 mutation assessment and its implication on treatment decisions in breast/ovarian cancer
  6. Pharmacogenomics of tamoxifen metabolism (CYP2D6) and outcomes in breast cancer

Cardiology Pharmacogenomics

  1. Pharmacogenomics of antiplatelet therapy - CYP2C19 genotyping in ACS/PCI patients
  2. Genetic determinants of statin-induced myopathy - SLCO1B1 polymorphism assessment
  3. Pharmacogenomics of antihypertensive drug response - ACE inhibitor/beta-blocker outcomes
  4. Warfarin pharmacogenomics (CYP2C9 + VKORC1) - genotype-guided dosing vs. standard dosing

Psychiatry & Neurology Pharmacogenomics

  1. CYP2D6/CYP2C19 polymorphism and antidepressant response/ADRs in depressive disorder patients
  2. Pharmacogenomics of antipsychotic therapy - metabolizer status and drug response in schizophrenia
  3. HLA-B*15:02 allele screening and carbamazepine-induced Stevens-Johnson syndrome risk
  4. HLA-B*57:01 screening and abacavir hypersensitivity in HIV patients
  5. Pharmacogenomics of pain management - OPRM1 polymorphism and opioid response

Implementation & Clinical Decision Support

  1. Evaluation of pharmacogenomics-guided prescribing vs. standard prescribing - clinical outcomes
  2. Pharmacist-led pharmacogenomics counseling service - feasibility and patient acceptance
  3. Barriers to clinical implementation of pharmacogenomics in Indian/developing country hospitals
  4. Assessment of pharmacogenomics clinical decision support tools (CPIC guidelines) awareness among clinicians
  5. Pilot implementation of pre-emptive pharmacogenomics testing in a hospital setting

Specific Population Studies

  1. Pharmacogenomics of antitubercular drugs - NAT2 polymorphism and isoniazid-induced hepatotoxicity
  2. G6PD deficiency screening before primaquine/dapsone therapy in malaria patients
  3. HLA-B*58:01 and allopurinol-induced severe cutaneous adverse reactions (SCARs) in gout patients
  4. Pharmacogenomics in pediatric oncology - TPMT genotyping before thiopurine therapy
  5. Ethnic differences in drug metabolism enzymes - a cross-sectional pharmacogenomics study

Emerging Topics

  1. Role of pharmacist in pre-emptive pharmacogenomics testing programs
  2. Patient perspectives on pharmacogenomics testing - willingness, privacy concerns, and barriers
  3. Pharmacogenomics of COVID-19 drug therapy - ACE2 polymorphism and drug response
  4. Artificial intelligence and pharmacogenomics - awareness and future applications in pharmacy practice
  5. Assessment of direct-to-consumer (DTC) pharmacogenomics testing - awareness among healthcare professionals

Feasibility Comparison Table

#TopicStudy TypeData AccessLab/Genotyping RequiredEthics ComplexityTime RequiredCostOverall Feasibility
1KAP of pharmacists on pharmacogenomicsCross-sectional survey✅ Pharmacists as subjects❌ No✅ SimpleShortLow⭐⭐⭐
2Awareness among physiciansCross-sectional survey✅ Physicians as subjects❌ No✅ SimpleShortLow⭐⭐⭐
3KAP of clinical pharmacists on PGx implementationCross-sectional survey✅ Pharmacists as subjects❌ No✅ SimpleShortLow⭐⭐⭐
4PGx education in pharmacy curriculumCross-sectional survey✅ Students as subjects❌ No✅ SimpleShortLow⭐⭐⭐
5Patient awareness of PGx testingCross-sectional survey✅ OPD patients❌ No✅ SimpleShortLow⭐⭐⭐
6CYP2C19 and clopidogrel responseProspective observational⚠️ Cardiology ward✅ Yes - genotyping⚠️ ModerateLongHigh
7CYP2D6 and antidepressant outcomesProspective observational⚠️ Psychiatry ward✅ Yes - genotyping⚠️ ModerateLongHigh
8CYP2C9/VKORC1 and warfarin dosingProspective observational✅ Anticoagulation clinic✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
9CYP3A4/3A5 and tacrolimus variabilityProspective observational⚠️ Transplant unit access✅ Yes - genotyping⚠️ ModerateLongHigh
10CYP2C19 and PPI efficacy in H. pyloriProspective observational✅ Gastro OPD✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
11DPYD and 5-FU toxicityProspective observational✅ Oncology ward✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
12TPMT/NUDT15 and thiopurine toxicityProspective observational✅ Oncology/GI ward✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
13HER2/EGFR mutation and targeted therapyRetrospective✅ Oncology records + lab⚠️ Usually done clinically✅ SimpleShortLow⭐⭐⭐
14UGT1A1 and irinotecan toxicityProspective observational✅ Oncology ward✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
15BRCA1/2 mutation and treatment decisionsRetrospective✅ Oncology records⚠️ Existing reports used⚠️ ModerateMediumLow⭐⭐⭐
16CYP2D6 and tamoxifen outcomesProspective/Retrospective✅ Oncology OPD✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
17CYP2C19 genotyping in ACS/PCIProspective observational✅ Cardiology ward✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
18SLCO1B1 and statin-induced myopathyProspective/Retrospective✅ Cardiology OPD✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
19PGx of antihypertensive responseProspective observational✅ Cardiology OPD✅ Yes - genotyping⚠️ ModerateLongHigh
20Warfarin PGx - genotype vs. standard dosingProspective comparative✅ Anticoagulation clinic✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
21CYP2D6/CYP2C19 and antidepressant ADRsProspective observational✅ Psychiatry OPD✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
22PGx of antipsychotic responseProspective observational✅ Psychiatry ward✅ Yes - genotyping⚠️ ModerateLongHigh
23HLA-B*15:02 and carbamazepine-SJS riskRetrospective/Cross-sectional✅ Neurology/dermatology records⚠️ Partial (existing test data)⚠️ ModerateMediumMedium⭐⭐⭐
24HLA-B*57:01 and abacavir hypersensitivityRetrospective✅ HIV clinic records⚠️ Existing test data✅ SimpleShortLow⭐⭐⭐
25OPRM1 and opioid responseProspective observational⚠️ Pain/palliative unit✅ Yes - genotyping⚠️ ModerateLongHigh
26PGx-guided vs. standard prescribingProspective comparative⚠️ Multiple unit access✅ Yes - genotyping⚠️ ComplexLongVery High
27Pharmacist-led PGx counseling serviceProspective interventional✅ OPD patients⚠️ ModerateMediumMedium⭐⭐
28Barriers to PGx implementation in hospitalsCross-sectional survey✅ HCPs as subjects❌ No✅ SimpleShortLow⭐⭐⭐
29CPIC guidelines awareness among cliniciansCross-sectional survey✅ Physicians/pharmacists❌ No✅ SimpleShortLow⭐⭐⭐
30Pilot pre-emptive PGx testing implementationInterventional⚠️ Institutional support needed✅ Yes - genotyping⚠️ ComplexLongVery High
31NAT2 and isoniazid hepatotoxicityProspective observational✅ TB ward/DOTS✅ Yes - genotyping⚠️ ModerateLongHigh⭐⭐
32G6PD screening before primaquine/dapsoneRetrospective/Cross-sectional✅ Medicine/tropical ward⚠️ Basic enzyme assay✅ SimpleShortLow⭐⭐⭐
33HLA-B*58:01 and allopurinol-SCARsRetrospective✅ Dermatology/rheumatology records⚠️ Existing test data✅ SimpleShortLow⭐⭐⭐
34TPMT genotyping in pediatric oncologyProspective observational⚠️ Pediatric oncology access✅ Yes - genotyping⚠️ ComplexLongHigh
35Ethnic differences in drug metabolismCross-sectional⚠️ Literature + existing genotype data✅ Partial⚠️ ModerateMediumMedium⭐⭐
36Pharmacist role in pre-emptive PGx testingCross-sectional/Qualitative✅ Pharmacists as subjects❌ No✅ SimpleShortLow⭐⭐⭐
37Patient perspectives on PGx testingCross-sectional survey✅ OPD patients✅ SimpleShortLow⭐⭐⭐
38PGx of COVID-19 drug therapyRetrospective/Review✅ Published data + records❌ No✅ SimpleShortLow⭐⭐⭐
39AI and pharmacogenomics - awareness studyCross-sectional survey✅ HCPs as subjects❌ No✅ SimpleShortLow⭐⭐⭐
40DTC pharmacogenomics testing awarenessCross-sectional survey✅ HCPs as subjects❌ No✅ SimpleShortLow⭐⭐⭐

Summary by Feasibility

RatingCountTopic Numbers
⭐⭐⭐ High181-5, 13, 15, 23, 24, 28, 29, 32, 33, 36, 37, 38, 39, 40
⭐⭐ Moderate128, 10, 11, 12, 14, 16, 17, 18, 20, 21, 27, 31, 35
⭐ Difficult106, 7, 9, 19, 22, 25, 26, 30, 34

Important Note for M. Pharm Students

Pharmacogenomics projects split into two types - choose based on your hospital's resources:
TypeExamplesRequiresFeasibility
Lab-based (wet lab)Topics 6-22, 25, 31Genotyping facility, PCR, high cost⭐ to ⭐⭐
Practice-based (no lab)Topics 1-5, 28, 29, 36-40Survey tools, hospital records only⭐⭐⭐
Record-based (existing data)Topics 13, 15, 23, 24, 32, 33Retrospective chart review⭐⭐⭐

Top 5 Picks (Feasible + High Impact)

#TopicWhy it Stands Out
1KAP of pharmacists on pharmacogenomicsNo lab needed, simple, very publishable in 2025-26
28Barriers to PGx implementation in hospitalsPolicy-relevant, survey-based, original for Indian settings
23HLA-B*15:02 screening and carbamazepine-SJSUses existing clinical test data, retrospective, high clinical impact
32G6PD screening before primaquineSimple enzyme assay, tropical disease relevance, feasible
37Patient perspectives on PGx testingTimely, patient-centered, easy survey design

Would you like me to now compile all topics from Cardiology, Gynecology, Neurology, Geriatrics, Oncology, and Pharmacogenomics into one master Excel file for easy download and comparison?

anyother?

Here are additional specialty areas for M. Pharm (Pharmacy Practice) project topics. Pick any one or more to explore:

🏥 Clinical Specialties

#SpecialtyKey Topics You Can Explore
1Nephrology / RenalDrug dose adjustment in CKD, nephrotoxic drug monitoring, dialysis drug dosing, medication adherence in transplant patients
2Pulmonology / RespiratoryInhaler technique assessment, COPD drug utilization, asthma pharmacotherapy, antibiotic stewardship in pneumonia
3Endocrinology / DiabetesInsulin adherence, glycemic control with pharmacist intervention, GLP-1/SGLT2 prescribing patterns, thyroid drug utilization
4Gastroenterology / HepatologyPPI overuse, drug-induced liver injury (DILI), IBD pharmacotherapy, antibiotic use in liver cirrhosis
5Infectious Diseases / HIVAntiretroviral adherence, TB-HIV co-infection drug monitoring, antibiotic stewardship, vaccine hesitancy
6PediatricsOff-label drug use in neonates, medication errors in pediatric ward, ADR monitoring in children, weight-based dose errors
7Orthopedics / RheumatologyNSAIDs/opioid use in chronic pain, DMARDs in rheumatoid arthritis, gout management audit, antibiotic prophylaxis in joint surgery
8DermatologyDrug-induced skin reactions, retinoid prescribing safety, topical corticosteroid misuse, antifungal prescribing patterns
9OphthalmologyDrug-induced ocular toxicity, glaucoma drug adherence, antibiotic prophylaxis in ophthalmic surgery
10Critical Care / ICUSedation and analgesia protocols, antibiotic de-escalation, medication errors in ICU, pharmacist role in critical care rounds

📋 Cross-Cutting Practice Domains

#DomainKey Topics You Can Explore
11Antibiotic StewardshipAMS program implementation, antibiotic audit, carbapenem use review, KAP of prescribers on AMR
12Medication SafetyHigh-alert medication practices, near-miss error reporting, look-alike/sound-alike (LASA) drugs, medication reconciliation
13Clinical Toxicology / PoisoningDrug overdose patterns, antidote utilization, self-poisoning drug profiles, pharmacist role in poison management
14PharmacoepidemiologyDisease burden studies, drug utilization trends, database studies using hospital data
15Digital Health / mHealthApp-based medication reminders, telepharmacy, patient portals, pharmacist perspectives on AI tools
16Community Pharmacy PracticeOTC drug counseling quality, self-medication practices, pharmacist-patient communication assessment
17Hospital Pharmacy ManagementDrug formulary management, procurement audits, storage compliance, expired drug analysis
18Patient Safety & QualityRoot cause analysis of medication incidents, pharmacist role in accreditation (NABH/JCI), sentinel event review

🔬 Emerging / Niche Areas (Novel for 2025-26)

#AreaWhy It's Trending
19Precision MedicineBiomarker-guided drug selection, companion diagnostics, PGx + clinical outcomes
20Medication Therapy Management (MTM)Pharmacist-led chronic disease management clinics, MTM models in Indian settings
21Palliative Care PharmacySymptom control audits, opioid access barriers, end-of-life medication use
22Mental Health PharmacyStigma and adherence in psychiatry, pharmacist role in de-stigmatization, clozapine monitoring
23Vaccine PharmacovigilancePost-vaccination ADR surveillance, HPV/COVID vaccine safety monitoring
24Green/Sustainable PharmacyPharmaceutical waste disposal, eco-pharmacovigilance, carbon footprint of drug use
25Telepharmacy / AI in PharmacyPharmacist attitudes toward AI prescribing support, telepharmacy feasibility in rural settings

Which of these interests you? Just name one (e.g., Nephrology, ICU, Antibiotic Stewardship, Diabetes) and I'll generate a full list of 40+ topics with a feasibility table - just like the previous ones.
Or if you're ready, I can now compile everything discussed so far into one master Excel file for download. Just say the word!

nephro, respiratory,endocrinology, infectious, pediatrics, ortho,dermatology,icu,gyneocology,cardiac

That's a large request covering 10 specialties. The best approach is to compile everything into a master Excel file with separate sheets per specialty. Let me build that for you.
Reading File
Running Command

mkdir -p /home/daytona/workspace/mpharm-topics && echo "done"

Now let me write the full Python script to generate the Excel file:
Writing File

~/mpharm-topics/generate_topics.py

import openpyxl
from openpyxl.styles import (
    PatternFill, Font, Alignment, Border, Side
)
from openpyxl.utils import get_column_letter

# ── colour palette ──────────────────────────────────────────────────────────
HEADER_FILL   = PatternFill("solid", fgColor="1F4E79")   # dark navy
SUBHDR_FILL   = PatternFill("solid", fgColor="2E75B6")   # mid-blue
HIGH_FILL     = PatternFill("solid", fgColor="C6EFCE")   # green
MOD_FILL      = PatternFill("solid", fgColor="FFEB9C")   # yellow
LOW_FILL      = PatternFill("solid", fgColor="FFC7CE")   # red
ALT_FILL      = PatternFill("solid", fgColor="DEEAF1")   # light blue row
WHITE_FILL    = PatternFill("solid", fgColor="FFFFFF")

HEADER_FONT   = Font(name="Arial", bold=True, color="FFFFFF", size=11)
SUBHDR_FONT   = Font(name="Arial", bold=True, color="FFFFFF", size=10)
TITLE_FONT    = Font(name="Arial", bold=True, color="1F4E79", size=13)
BODY_FONT     = Font(name="Arial", size=10)
BOLD_FONT     = Font(name="Arial", bold=True, size=10)

thin = Side(style="thin", color="B8CCE4")
BORDER = Border(left=thin, right=thin, top=thin, bottom=thin)

COLUMNS = ["#", "Topic", "Category", "Study Type",
           "Data Access", "Lab/Special Equipment",
           "Ethics Complexity", "Time Required", "Cost",
           "Overall Feasibility"]

COL_WIDTHS = [4, 62, 22, 28, 22, 26, 20, 16, 10, 22]

# ── feasibility star helper ──────────────────────────────────────────────────
def stars(n):
    return "★" * n + "☆" * (3 - n)

def feas_fill(rating):
    if rating == 3: return HIGH_FILL
    if rating == 2: return MOD_FILL
    return LOW_FILL

# ── DATA ─────────────────────────────────────────────────────────────────────
# Each row: (topic, category, study_type, data_access, lab, ethics, time, cost, feasibility 1-3)

SPECIALTIES = {}

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Nephrology"] = [
    ("Drug utilization study of drugs in CKD patients (stages 3-5)", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of antihypertensives in CKD patients", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug dose adjustment assessment in CKD inpatients", "Drug Safety", "Retrospective/Prospective", "Easy – ward + lab records", "No", "Simple", "Medium", "Low", 3),
    ("Drug utilization review of erythropoiesis-stimulating agents in CKD", "Drug Utilization", "Retrospective", "Easy – ward/dialysis records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of nephrotoxic drug use in hospitalized patients", "Drug Safety", "Retrospective/Prospective", "Easy – case sheets + lab", "No", "Simple", "Medium", "Low", 3),
    ("Drug utilization of immunosuppressants in renal transplant patients", "Drug Utilization", "Retrospective", "Moderate – transplant records", "No", "Moderate", "Medium", "Low", 2),
    ("Medication adherence in CKD/dialysis patients (MMAS-8)", "Adherence", "Cross-sectional", "Easy – dialysis unit OPD", "No", "Simple", "Short", "Low", 3),
    ("Assessment of medication adherence in renal transplant patients", "Adherence", "Cross-sectional", "Easy – transplant OPD", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist counseling on adherence in CKD patients", "Adherence", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("ADR monitoring of nephrotoxic drugs (NSAIDs, aminoglycosides, contrast)", "ADR/PV", "Prospective Observational", "Easy – ward patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR profiling of immunosuppressants in transplant patients", "ADR/PV", "Prospective Observational", "Moderate – transplant unit", "No", "Moderate", "Long", "Low", 2),
    ("Contrast-induced nephropathy – incidence and risk factor assessment", "Drug Safety", "Prospective Observational", "Easy – radiology + nephro ward", "No", "Simple", "Medium", "Low", 3),
    ("Identification of DRPs in CKD inpatients using PCNE classification", "DRP", "Prospective Observational", "Easy – ward patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Drug-drug interactions in polypharmacy CKD patients", "DRP", "Retrospective/Prospective", "Easy – prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Assessment of potassium-raising drug combinations in CKD patients", "Drug Safety", "Retrospective", "Easy – case records + labs", "No", "Simple", "Short", "Low", 3),
    ("Appropriateness of antibiotic dosing in CKD patients (renal dose adjustment)", "Medication Safety", "Retrospective", "Easy – ward records + eGFR", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist intervention on drug dose optimization in CKD", "Clinical Pharmacist", "Prospective Interventional", "Easy – ward patients", "No", "Moderate", "Medium", "Low", 3),
    ("Role of pharmacist in renal transplant medication management", "Clinical Pharmacist", "Prospective Observational", "Moderate – transplant OPD", "No", "Moderate", "Medium", "Low", 2),
    ("Assessment of calcium-phosphate balance and pharmacotherapy in dialysis patients", "Drug Utilization", "Cross-sectional", "Easy – dialysis unit records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of anemia management in CKD – iron, EPO, B12 use patterns", "Drug Utilization", "Retrospective", "Easy – dialysis/ward records", "No", "Simple", "Short", "Low", 3),
    ("KAP of CKD patients on dietary restrictions and medication use", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Patient knowledge on dialysis-related medications and adherence", "KAP", "Cross-sectional Survey", "Easy – dialysis unit", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in CKD/dialysis patients using KDQOL-SF", "QoL/Pharmaco-economics", "Cross-sectional", "Easy – dialysis unit OPD", "No", "Simple", "Short", "Low", 3),
    ("Cost-of-illness study of CKD in a tertiary care hospital", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacoeconomic analysis of peritoneal vs. hemodialysis drug costs", "Pharmaco-economics", "Retrospective Comparative", "Moderate – dialysis records + billing", "No", "Moderate", "Medium", "Low", 2),
    ("Assessment of RAAS inhibitor use and outcomes in CKD patients", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of SGLT2 inhibitor prescribing in diabetic nephropathy", "Drug Utilization", "Retrospective/Cross-sectional", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug-induced acute kidney injury (AKI) – identification and assessment", "Drug Safety", "Prospective Observational", "Easy – ward + lab records", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of proton pump inhibitor (PPI) overuse in CKD patients", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Medication reconciliation at dialysis initiation – discrepancy analysis", "Medication Safety", "Prospective Observational", "Easy – dialysis ward records", "No", "Moderate", "Medium", "Low", 3),
    ("Pharmacist role in phosphate binder counseling and adherence", "Clinical Pharmacist", "Prospective Interventional", "Easy – dialysis unit", "No", "Moderate", "Medium", "Low", 3),
    ("Assessment of vancomycin dosing in patients with renal impairment", "Drug Safety", "Retrospective", "Easy – ward + TDM records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of antibiotic stewardship in UTI/renal infection patients", "Antibiotic Stewardship", "Retrospective/Audit", "Easy – ward + microbiology records", "No", "Simple", "Short", "Low", 3),
    ("Sleep disorders and medication use in dialysis patients", "Drug Utilization", "Cross-sectional", "Easy – dialysis unit OPD", "No", "Simple", "Short", "Low", 3),
    ("Assessment of cardiovascular drug use in CKD patients – guideline adherence", "Drug Utilization", "Retrospective", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Respiratory"] = [
    ("Drug utilization study of bronchodilators in COPD patients", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of inhaled corticosteroids (ICS) in asthma patients", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of inhaler technique in asthma/COPD patients", "Medication Safety", "Cross-sectional", "Easy – OPD patients (direct observation)", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist-led inhaler technique education on patient outcomes", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Drug utilization review of antibiotics in community-acquired pneumonia (CAP)", "Drug Utilization/AMS", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of adherence to GOLD guidelines in COPD management", "Drug Utilization", "Retrospective/Audit", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of antituberculosis drugs and adherence to RNTCP/NTEP", "Drug Utilization", "Retrospective", "Easy – DOTS records", "No", "Simple", "Short", "Low", 3),
    ("Medication adherence in asthma patients and associated factors (MMAS-8)", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Adherence to inhaler therapy in COPD and impact on exacerbations", "Adherence", "Prospective Observational", "Easy – OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR monitoring of antituberculosis drugs – incidence, pattern, causality", "ADR/PV", "Prospective Observational", "Easy – DOTS/TB ward patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR profiling of inhaled corticosteroids and bronchodilators", "ADR/PV", "Prospective Observational", "Easy – OPD/ward patients", "No", "Simple", "Medium", "Low", 3),
    ("Drug-induced pulmonary toxicity surveillance in hospitalized patients", "ADR/PV", "Prospective Observational", "Easy – respiratory ward", "No", "Simple", "Medium", "Low", 3),
    ("Identification of DRPs in respiratory ward patients (PCNE classification)", "DRP", "Prospective Observational", "Easy – ward patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Drug-drug interactions in COPD/asthma polypharmacy patients", "DRP", "Retrospective/Prospective", "Easy – prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Assessment of antibiotic stewardship in hospital-acquired pneumonia", "AMS", "Retrospective/Audit", "Easy – ward + micro records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of nebulization therapy practices in hospitalized patients", "Medication Safety", "Cross-sectional/Audit", "Easy – ward records/observation", "No", "Simple", "Short", "Low", 3),
    ("KAP of asthma patients on trigger avoidance and medication use", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Assessment of patient knowledge on inhaler devices and spacer use", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in COPD patients using St. George Respiratory Questionnaire (SGRQ)", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in asthma patients using Asthma Quality of Life Questionnaire (AQLQ)", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Cost-of-illness study of COPD exacerbations in a tertiary care hospital", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacoeconomic analysis of generic vs. branded inhalers", "Pharmaco-economics", "Retrospective Comparative", "Easy – pharmacy records", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist counseling on self-management in COPD patients", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Assessment of corticosteroid overuse in asthma management", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of step-up/step-down asthma therapy – GINA guideline adherence", "Drug Utilization", "Retrospective/Audit", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of biologics (omalizumab, mepolizumab) in severe asthma", "Drug Utilization", "Retrospective", "Moderate – limited patient numbers", "No", "Simple", "Medium", "Low", 2),
    ("Assessment of COVID-19 related respiratory drug use patterns", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Pharmacist role in smoking cessation programs – counseling and NRT use", "Clinical Pharmacist", "Prospective Observational/Interventional", "Easy – OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Evaluation of oxygen therapy prescribing practices in COPD patients", "Medication Safety", "Retrospective/Audit", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of fixed-dose combination inhalers use vs. separate devices", "Drug Utilization", "Cross-sectional", "Easy – OPD/pharmacy records", "No", "Simple", "Short", "Low", 3),
    ("Medication reconciliation at discharge in respiratory inpatients", "Medication Safety", "Prospective Observational", "Easy – ward records", "No", "Moderate", "Medium", "Low", 3),
    ("Assessment of theophylline use and toxicity monitoring in COPD patients", "Drug Safety", "Retrospective/Prospective", "Easy – ward + TDM records", "No", "Simple", "Medium", "Low", 3),
    ("Antibiotic prescribing in acute exacerbation of COPD (AECOPD)", "AMS", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("KAP of healthcare providers on non-pharmacological management of asthma/COPD", "KAP", "Cross-sectional Survey", "Easy – HCPs as subjects", "No", "Simple", "Short", "Low", 3),
    ("Self-medication practices with OTC inhalers/bronchodilators in community", "Community Pharmacy", "Cross-sectional Survey", "Easy – community/OPD patients", "No", "Simple", "Short", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Endocrinology"] = [
    ("Drug utilization study of antidiabetic drugs in Type 2 DM outpatients", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of insulin in T1DM and T2DM inpatients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of SGLT2 inhibitor and GLP-1 agonist prescribing patterns", "Drug Utilization", "Retrospective/Cross-sectional", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization review of thyroid drugs (levothyroxine) in hypothyroid patients", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern in gestational diabetes mellitus (GDM)", "Drug Utilization", "Retrospective/Prospective", "Easy – OPD/ward records", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of drug use in polycystic ovarian syndrome (PCOS)", "Drug Utilization", "Cross-sectional/Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Medication adherence in Type 2 DM patients (MMAS-8) and glycemic control", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist counseling on HbA1c levels in T2DM patients", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Adherence to insulin therapy and barriers in T1DM patients", "Adherence", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Adherence to antithyroid drugs in hyperthyroidism patients", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("ADR monitoring of antidiabetic drugs – hypoglycemia, GI effects, weight changes", "ADR/PV", "Prospective Observational", "Easy – OPD/ward patients", "No", "Simple", "Medium", "Low", 3),
    ("Drug-induced hyperglycemia surveillance in hospitalized patients", "ADR/PV", "Prospective Observational", "Easy – ward + lab records", "No", "Simple", "Medium", "Low", 3),
    ("ADR profiling of SGLT2 inhibitors – DKA, UTI, genital infections", "ADR/PV", "Prospective Observational", "Easy – OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Identification of DRPs in diabetic inpatients using PCNE classification", "DRP", "Prospective Observational", "Easy – ward patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Drug-drug interactions in polypharmacy diabetic patients", "DRP", "Retrospective/Prospective", "Easy – prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Assessment of inappropriate medication use in elderly diabetic patients (Beers/STOPP)", "DRP", "Retrospective", "Easy – case records", "No", "Simple", "Short", "Low", 3),
    ("KAP of diabetic patients on blood glucose monitoring and insulin self-administration", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Assessment of patient knowledge on hypoglycemia recognition and management", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("KAP of hypothyroid patients on levothyroxine use and dietary interactions", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in Type 2 DM patients using SF-36 / EQ-5D", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in hypothyroid patients and impact of treatment", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Cost-of-illness study of Type 2 diabetes mellitus in a tertiary care hospital", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacoeconomic comparison of oral antidiabetic regimens vs. insulin", "Pharmaco-economics", "Retrospective Comparative", "Easy – pharmacy + billing records", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of dyslipidemia management in diabetic patients – statin use patterns", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Pharmacist-led diabetes education program – impact on self-care behaviour", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Evaluation of glycemic control in T2DM patients on combination therapy", "Clinical Outcomes", "Prospective Observational", "Easy – OPD records + HbA1c", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of metformin use – appropriateness and contraindications", "Medication Safety", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of weight-loss medications in obese diabetic patients", "Drug Utilization", "Retrospective/Cross-sectional", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of diabetic complication screening and pharmacotherapy", "Clinical Outcomes", "Cross-sectional", "Easy – OPD patients + records", "No", "Simple", "Short", "Low", 3),
    ("Self-medication practices with OTC supplements in diabetic patients", "Community Pharmacy", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of insulin storage and handling practices in diabetic patients", "Medication Safety", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Pharmacist role in continuous glucose monitoring (CGM) education", "Clinical Pharmacist", "Prospective Observational", "Moderate – CGM device access", "No", "Moderate", "Medium", "Medium", 2),
    ("Assessment of prescribing in diabetic nephropathy – RAAS + SGLT2 combinations", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of antiobesity drugs and pharmacist counseling role", "Drug Utilization", "Cross-sectional/Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of steroid-induced hyperglycemia management in hospitalized patients", "Drug Safety", "Prospective Observational", "Easy – ward + lab records", "No", "Simple", "Medium", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Infectious Diseases"] = [
    ("Drug utilization study of antibiotics in a medicine/surgical ward (WHO DDD)", "Drug Utilization/AMS", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of antibiotic prescribing practices against standard guidelines (AWaRe)", "AMS", "Retrospective/Audit", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Antibiotic stewardship program (ASP) implementation and evaluation", "AMS", "Prospective Interventional", "Easy – ward records + micro", "No", "Moderate", "Medium", "Low", 3),
    ("Prescribing pattern of antiretrovirals (ART) in HIV patients – guideline adherence", "Drug Utilization", "Retrospective", "Easy – ART clinic records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization study of antifungal drugs in immunocompromised patients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of antibiotic use in febrile neutropenia patients", "AMS", "Retrospective", "Easy – oncology ward records", "No", "Simple", "Short", "Low", 3),
    ("Medication adherence to ART in HIV patients (MMAS-8)", "Adherence", "Cross-sectional", "Easy – ART clinic patients", "No", "Simple", "Short", "Low", 3),
    ("Adherence to antituberculosis drugs and factors affecting it (DOTS patients)", "Adherence", "Cross-sectional Survey", "Easy – DOTS centre records", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist counseling on ART adherence and CD4 outcomes", "Clinical Pharmacist", "Prospective Interventional", "Easy – ART clinic", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("ADR monitoring and reporting in HIV/TB co-infected patients on HAART + ATT", "ADR/PV", "Prospective Observational", "Easy – HIV/TB ward patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR profiling of first-line ART regimens in HIV patients", "ADR/PV", "Prospective Observational", "Easy – ART clinic patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR monitoring of antituberculosis drugs – hepatotoxicity, peripheral neuropathy", "ADR/PV", "Prospective Observational", "Easy – TB ward/DOTS patients", "No", "Simple", "Medium", "Low", 3),
    ("Drug-induced liver injury (DILI) in patients on ATT – incidence and management", "Drug Safety", "Prospective Observational", "Easy – TB ward + LFT records", "No", "Simple", "Medium", "Low", 3),
    ("Drug-drug interactions in HIV patients on ART + co-medications", "DRP", "Retrospective/Prospective", "Easy – ART clinic prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Identification of DRPs in infectious disease ward patients (PCNE)", "DRP", "Prospective Observational", "Easy – ward patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("KAP of patients on HIV/AIDS regarding ART adherence and drug interactions", "KAP", "Cross-sectional Survey", "Easy – ART clinic patients", "No", "Simple", "Short", "Low", 3),
    ("KAP of healthcare providers on antimicrobial resistance (AMR)", "KAP", "Cross-sectional Survey", "Easy – HCPs as subjects", "No", "Simple", "Short", "Low", 3),
    ("Assessment of blood culture utilisation and antibiotic de-escalation practices", "AMS", "Retrospective/Audit", "Easy – micro lab + ward records", "No", "Simple", "Short", "Low", 3),
    ("Carbapenem use audit in ICU/medicine ward – appropriateness assessment", "AMS", "Retrospective/Audit", "Easy – ward + pharmacy records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of antifungal prophylaxis in immunocompromised patients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Cost-of-illness study of HIV/AIDS management in a tertiary care hospital", "Pharmaco-economics", "Retrospective", "Easy – hospital billing", "No", "Moderate", "Medium", "Low", 2),
    ("HRQoL in HIV patients on ART using SF-36/WHOQOL-BREF", "QoL", "Cross-sectional", "Easy – ART clinic patients", "No", "Simple", "Short", "Low", 3),
    ("Pharmacoeconomic impact of generic vs. innovator ART regimens", "Pharmaco-economics", "Retrospective Comparative", "Easy – pharmacy + billing records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of vaccination practices in HIV-positive patients", "Preventive Pharmacy", "Cross-sectional", "Easy – ART clinic records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of surgical antibiotic prophylaxis – appropriateness and duration", "AMS", "Retrospective/Audit", "Easy – OT + ward records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of broad-spectrum antibiotics and culture sensitivity correlation", "AMS", "Retrospective", "Easy – micro lab + ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of anti-malarial drug use and adherence in malaria patients", "Drug Utilization", "Retrospective/Prospective", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of antivirals in influenza/COVID-19 patients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of medication errors related to antibiotic dosing and frequency", "Medication Safety", "Prospective Observational", "Easy – ward prescriptions", "No", "Moderate", "Medium", "Low", 2),
    ("Role of pharmacist in infection control and antimicrobial stewardship programs", "Clinical Pharmacist", "Prospective Observational", "Easy – ward/AMS team", "No", "Moderate", "Medium", "Low", 3),
    ("Assessment of drug resistance patterns and empirical antibiotic prescribing", "AMS", "Retrospective", "Easy – micro lab records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of antiviral therapy in Hepatitis B/C patients – guideline adherence", "Drug Utilization", "Retrospective", "Easy – hepatology/ID OPD records", "No", "Simple", "Short", "Low", 3),
    ("KAP on vaccine hesitancy among adults in a hospital setting", "KAP/Preventive", "Cross-sectional Survey", "Easy – OPD patients/staff", "No", "Simple", "Short", "Low", 3),
    ("Assessment of COVID-19 drug therapy and pharmacist interventions", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Self-medication with antibiotics – prevalence and awareness in community", "Community Pharmacy", "Cross-sectional Survey", "Easy – community patients", "No", "Simple", "Short", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Pediatrics"] = [
    ("Drug utilization study in a pediatric inpatient ward", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of off-label drug use in neonatal ICU (NICU)", "Drug Utilization", "Retrospective", "Easy – NICU records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of antibiotics in pediatric patients (WHO indicators)", "Drug Utilization/AMS", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of weight-based dose calculation errors in pediatric prescriptions", "Medication Safety", "Retrospective/Prospective", "Easy – ward prescriptions", "No", "Simple", "Medium", "Low", 3),
    ("Drug utilization review of antipyretics in febrile pediatric patients", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern in pediatric respiratory infections – antibiotic use assessment", "Drug Utilization/AMS", "Retrospective", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Medication errors in pediatric ward – incidence, type, and contributing factors", "Medication Safety", "Prospective Observational", "Easy – ward records/observations", "No", "Moderate", "Medium", "Low", 2),
    ("ADR monitoring and reporting in hospitalized pediatric patients", "ADR/PV", "Prospective Observational", "Easy – ward patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR profiling of antiepileptic drugs in pediatric epilepsy patients", "ADR/PV", "Prospective Observational", "Easy – neurology ward/OPD", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of antibiotic prescribing in neonatal sepsis", "Drug Utilization/AMS", "Retrospective", "Easy – NICU records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization study of iron and vitamin supplements in pediatric patients", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of ORS and zinc use in pediatric diarrhea management", "Drug Utilization", "Retrospective/Prospective", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of vaccination coverage and pharmacist role in pediatric OPD", "Preventive Pharmacy", "Cross-sectional Survey", "Easy – OPD parents/patients", "No", "Simple", "Short", "Low", 3),
    ("Drug-drug interactions in polypharmacy pediatric inpatients", "DRP", "Retrospective/Prospective", "Easy – ward prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Identification of DRPs in pediatric inpatients using PCNE classification", "DRP", "Prospective Observational", "Easy – ward patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Assessment of parental knowledge on correct antibiotic use in children", "KAP", "Cross-sectional Survey", "Easy – OPD parents", "No", "Simple", "Short", "Low", 3),
    ("KAP of parents on OTC drug use in fever and pain in children", "KAP", "Cross-sectional Survey", "Easy – OPD parents", "No", "Simple", "Short", "Low", 3),
    ("Assessment of pharmacist counseling impact on caregiver medication adherence in children", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD caregivers", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Evaluation of asthma pharmacotherapy in pediatric patients (GINA adherence)", "Drug Utilization", "Retrospective/Audit", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization in pediatric oncology patients – chemotherapy pattern study", "Drug Utilization", "Retrospective", "Moderate – oncology unit access", "No", "Moderate", "Medium", "Low", 2),
    ("Assessment of nutritional supplement prescribing in malnourished children", "Drug Utilization", "Retrospective", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of sedation and analgesia use in PICU patients", "Drug Utilization", "Retrospective", "Easy – PICU records", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in children with chronic illness (asthma/epilepsy) using PedsQL", "QoL", "Cross-sectional", "Easy – OPD patients/parents", "No", "Simple", "Short", "Low", 3),
    ("Cost-of-illness study of pediatric respiratory infections", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Assessment of rational drug use in pediatric OPD using WHO core indicators", "Drug Utilization", "Cross-sectional", "Easy – OPD prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of pharmacist recommendations in pediatric ward rounds", "Clinical Pharmacist", "Prospective Observational", "Moderate – physician cooperation", "No", "Moderate", "Medium", "Low", 2),
    ("Drug-induced ADRs in pediatric patients on long-term therapy (TB, HIV, epilepsy)", "ADR/PV", "Prospective Observational", "Easy – ward/OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Prescription audit of pediatric inpatients using WHO prescribing indicators", "Drug Utilization", "Retrospective/Audit", "Easy – ward prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Assessment of medication storage and handling practices by parents at home", "Medication Safety", "Cross-sectional Survey", "Easy – OPD parents", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of antipyretic and analgesic use patterns in pediatric emergency", "Drug Utilization", "Retrospective", "Easy – emergency records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization in children with type 1 diabetes – insulin patterns and monitoring", "Drug Utilization", "Retrospective/Prospective", "Easy – OPD/ward records", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of fluid and electrolyte therapy in pediatric dehydration", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Role of pharmacist in pain management in pediatric palliative care", "Clinical Pharmacist", "Prospective Observational", "Moderate – palliative unit access", "No", "Moderate", "Medium", "Low", 2),
    ("Evaluation of antifungal use in immunocompromised pediatric patients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of caregiver awareness on proper liquid medication measurement", "Medication Safety/KAP", "Cross-sectional Survey", "Easy – OPD caregivers", "No", "Simple", "Short", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Orthopedics"] = [
    ("Drug utilization study of NSAIDs in orthopedic outpatients and inpatients", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of surgical antibiotic prophylaxis in orthopedic surgeries", "AMS", "Retrospective/Audit", "Easy – OT + ward records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of analgesics in postoperative orthopedic patients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of opioid use in chronic orthopedic pain management", "Drug Utilization", "Retrospective/Cross-sectional", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization review of disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis", "Drug Utilization", "Retrospective", "Easy – rheumatology OPD records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of drugs in osteoarthritis management", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of calcium and vitamin D supplementation in osteoporosis patients", "Drug Utilization", "Retrospective/Cross-sectional", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Medication adherence in rheumatoid arthritis patients on DMARDs", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Adherence to bisphosphonate therapy in osteoporosis patients", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist counseling on NSAID-related GI risk awareness", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("ADR monitoring of NSAIDs – GI, renal, and cardiovascular adverse effects", "ADR/PV", "Prospective Observational", "Easy – OPD/ward patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR profiling of DMARDs (methotrexate, sulfasalazine, hydroxychloroquine)", "ADR/PV", "Prospective Observational", "Easy – rheumatology OPD", "No", "Simple", "Medium", "Low", 3),
    ("Drug-induced GI complications in patients on long-term NSAIDs – assessment and PPI use", "Drug Safety", "Retrospective/Prospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of anticoagulant use in deep vein thrombosis (DVT) prophylaxis post-orthopedic surgery", "Drug Utilization", "Retrospective", "Easy – OT/ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug-drug interactions in polypharmacy rheumatology patients", "DRP", "Retrospective/Prospective", "Easy – OPD prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Identification of DRPs in orthopedic inpatients using PCNE classification", "DRP", "Prospective Observational", "Easy – ward patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Assessment of inappropriate NSAID use in elderly orthopedic patients (Beers/STOPP)", "DRP", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("KAP of rheumatoid arthritis patients on methotrexate – side effects and monitoring", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Assessment of patient knowledge on bisphosphonate correct administration technique", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("KAP of patients on self-medication with NSAIDs for musculoskeletal pain", "KAP", "Cross-sectional Survey", "Easy – OPD/community patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in rheumatoid arthritis patients using HAQ-DI / SF-36", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in osteoarthritis patients before and after pharmacological intervention", "QoL", "Prospective", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Cost-of-illness study of rheumatoid arthritis in a tertiary care hospital", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacoeconomic analysis of biologic vs. conventional DMARDs in RA", "Pharmaco-economics", "Retrospective Comparative", "Moderate – limited biologic patients", "No", "Moderate", "Medium", "Low", 2),
    ("Evaluation of uric acid-lowering therapy in gout – allopurinol/febuxostat use", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug use in ankylosing spondylitis – NSAIDs, DMARDs, biologic patterns", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of pain management protocols in total knee/hip replacement patients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Medication reconciliation at discharge in orthopedic inpatients", "Medication Safety", "Prospective Observational", "Easy – ward records", "No", "Moderate", "Medium", "Low", 3),
    ("Assessment of steroid use in orthopedic conditions – patterns and complications", "Drug Utilization", "Retrospective", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Role of pharmacist in fall prevention in elderly orthopedic patients (FRIDs)", "Clinical Pharmacist", "Prospective Observational", "Easy – ward patients", "No", "Moderate", "Medium", "Low", 3),
    ("Drug utilization of muscle relaxants in musculoskeletal disorders", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of corticosteroid injection practices in orthopedic OPD", "Drug Utilization", "Retrospective/Audit", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of physiotherapy vs. pharmacotherapy in chronic low back pain patients", "Clinical Outcomes", "Retrospective Comparative", "Easy – OPD records", "No", "Simple", "Medium", "Low", 3),
    ("KAP of orthopedic patients on antibiotic prophylaxis before dental/surgical procedures", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Assessment of topical vs. systemic NSAID prescribing in musculoskeletal pain", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Dermatology"] = [
    ("Drug utilization study of topical corticosteroids in dermatology outpatients", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of topical corticosteroid misuse/overuse in skin conditions", "Medication Safety", "Cross-sectional/Retrospective", "Easy – OPD patients/records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of antifungals in superficial fungal infections", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization review of systemic retinoids (isotretinoin) in acne management", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("ADR monitoring of isotretinoin therapy – teratogenicity risk, mood changes, lipid effects", "ADR/PV", "Prospective Observational", "Easy – dermatology OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Drug-induced skin reactions (DISR) – incidence, pattern, and causality assessment", "ADR/PV", "Prospective Observational", "Easy – ward/OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Stevens-Johnson Syndrome (SJS/TEN) – drug causality analysis and pharmacist role", "ADR/PV", "Retrospective", "Easy – dermatology ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of antibiotic prescribing in skin and soft tissue infections (SSTIs)", "AMS", "Retrospective/Audit", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization study of biologics (dupilumab, secukinumab) in psoriasis/atopic dermatitis", "Drug Utilization", "Retrospective", "Moderate – limited patient numbers", "No", "Simple", "Medium", "Low", 2),
    ("Prescribing pattern of antileprosy drugs and adherence in leprosy patients", "Drug Utilization", "Retrospective", "Easy – leprosy clinic records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of medication adherence in psoriasis patients on systemic therapy", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Adherence to topical therapy in eczema/atopic dermatitis patients", "Adherence", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist counseling on proper use of topical medications", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Assessment of drug interactions in dermatology polypharmacy patients", "DRP", "Retrospective/Prospective", "Easy – OPD prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Identification of DRPs in dermatology inpatients using PCNE classification", "DRP", "Prospective Observational", "Easy – ward patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("KAP of dermatology patients on topical steroid use and side effects", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Patient awareness of photoprotection and sunscreen pharmacotherapy", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Assessment of OTC drug use and self-medication in skin conditions", "Community Pharmacy", "Cross-sectional Survey", "Easy – OPD/community patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in psoriasis patients using DLQI (Dermatology Life Quality Index)", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in acne patients using DLQI and impact of pharmacotherapy", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Cost-of-illness study of psoriasis in a tertiary care hospital", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacoeconomic comparison of topical vs. systemic acne therapies", "Pharmaco-economics", "Retrospective Comparative", "Easy – pharmacy + billing records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of antihistamines in allergic skin conditions", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of methotrexate use and toxicity monitoring in psoriasis/pemphigus", "Drug Safety", "Prospective Observational", "Easy – OPD patients + LFT/CBC", "No", "Simple", "Medium", "Low", 3),
    ("Evaluation of antivirals (acyclovir/valacyclovir) prescribing in herpes infections", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing patterns in urticaria management – antihistamines and steroids", "Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of scabies and pediculosis treatment practices and outcomes", "Drug Utilization", "Retrospective/Cross-sectional", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of cyclosporine use in dermatological conditions – safety monitoring", "Drug Safety", "Prospective Observational", "Easy – OPD patients + lab records", "No", "Moderate", "Medium", "Low", 2),
    ("Drug utilization of dapsone in dermatological conditions – safety monitoring", "Drug Safety/Drug Utilization", "Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of phototherapy drug prescribing (PUVA/NB-UVB) in psoriasis", "Drug Utilization", "Retrospective/Audit", "Easy – phototherapy unit records", "No", "Simple", "Short", "Low", 3),
    ("KAP of pharmacists on dermatology OTC products and counseling", "KAP", "Cross-sectional Survey", "Easy – pharmacists as subjects", "No", "Simple", "Short", "Low", 3),
    ("Drug-induced alopecia – identification, causality, and pharmacist reporting", "ADR/PV", "Prospective Observational", "Easy – OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of wound care and antimicrobial dressing use in dermatology ward", "Drug Utilization", "Retrospective/Audit", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of sunscreen prescribing and patient compliance in photodermatoses", "Drug Utilization/Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Medication reconciliation in dermatology inpatients at admission and discharge", "Medication Safety", "Prospective Observational", "Easy – ward records", "No", "Moderate", "Medium", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["ICU"] = [
    ("Drug utilization study of antibiotics in ICU patients (WHO DDD methodology)", "Drug Utilization/AMS", "Retrospective", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of carbapenem use in ICU – appropriateness and antibiotic stewardship", "AMS", "Retrospective/Audit", "Easy – ICU + micro records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization review of sedatives and analgesics (ABCDE bundle adherence)", "Drug Utilization", "Retrospective", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of vasopressors and inotropes in septic shock patients", "Drug Utilization", "Retrospective", "Easy – ICU case records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of anticoagulant use (DVT prophylaxis) in ICU patients", "Drug Utilization", "Retrospective", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Drug dose adjustment in acute kidney injury (AKI) ICU patients", "Drug Safety", "Retrospective", "Easy – ICU + lab records", "No", "Simple", "Short", "Low", 3),
    ("ADR monitoring in ICU patients – incidence, type, and clinical impact", "ADR/PV", "Prospective Observational", "Easy – ICU ward patients", "No", "Simple", "Medium", "Low", 3),
    ("Drug-induced QT prolongation in ICU patients – monitoring and assessment", "ADR/PV", "Prospective Observational", "Easy – ICU + ECG records", "No", "Moderate", "Medium", "Low", 3),
    ("Medication errors in ICU – incidence, type, severity, and contributing factors", "Medication Safety", "Prospective Observational", "Moderate – staff cooperation needed", "No", "Moderate", "Medium", "Low", 2),
    ("Assessment of high-alert medication (HAM) safety practices in ICU", "Medication Safety", "Cross-sectional/Audit", "Easy – ICU pharmacy/ward", "No", "Simple", "Short", "Low", 3),
    ("Drug-drug interactions in polypharmacy ICU patients – prevalence and clinical significance", "DRP", "Retrospective/Prospective", "Easy – ICU prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Identification of DRPs in ICU patients using PCNE classification", "DRP", "Prospective Observational", "Easy – ICU patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Assessment of stress ulcer prophylaxis (PPI/H2RA) appropriateness in ICU", "Drug Utilization", "Retrospective/Audit", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of blood glucose management and insulin protocol adherence in ICU", "Drug Safety/Utilization", "Retrospective/Prospective", "Easy – ICU + lab records", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of nutrition (TPN/enteral) drug interactions in ICU patients", "Drug Safety", "Prospective Observational", "Easy – ICU records", "No", "Simple", "Medium", "Low", 3),
    ("Role of clinical pharmacist in ICU ward rounds – types and outcomes of interventions", "Clinical Pharmacist", "Prospective Observational", "Moderate – physician cooperation", "No", "Moderate", "Medium", "Low", 2),
    ("Impact of pharmacist-led medication review on ICU drug-related problems", "Clinical Pharmacist", "Prospective Interventional", "Easy – ICU patients", "No", "Moderate", "Medium", "Low", 3),
    ("Pharmacist participation in antimicrobial stewardship in ICU – outcomes", "Clinical Pharmacist/AMS", "Prospective Observational", "Easy – ICU/AMS team", "No", "Moderate", "Medium", "Low", 3),
    ("Assessment of neuromuscular blocking agent (NMBA) use in mechanically ventilated patients", "Drug Utilization", "Retrospective", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of proton pump inhibitors and H2 blockers in ICU – overuse analysis", "Drug Utilization", "Retrospective/Audit", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Evaluation of opioid use and sedation scoring (RASS) adherence in ventilated ICU patients", "Drug Utilization", "Retrospective", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of antimicrobial de-escalation practices in ICU", "AMS", "Retrospective", "Easy – ICU + micro records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of thromboprophylaxis in post-surgical ICU patients", "Drug Utilization", "Retrospective", "Easy – ICU ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of vancomycin TDM practices in ICU patients", "Drug Safety", "Retrospective/Prospective", "Easy – ICU + TDM lab records", "No", "Simple", "Medium", "Low", 3),
    ("Evaluation of nephrotoxic drug combinations in ICU patients", "Drug Safety", "Retrospective", "Easy – ICU + lab records", "No", "Simple", "Short", "Low", 3),
    ("KAP of ICU nurses and physicians on medication error reporting", "KAP", "Cross-sectional Survey", "Easy – ICU staff as subjects", "No", "Simple", "Short", "Low", 3),
    ("Pharmacoeconomic analysis of generic vs. branded ICU drugs", "Pharmaco-economics", "Retrospective Comparative", "Easy – ICU pharmacy records", "No", "Simple", "Short", "Low", 3),
    ("Cost of antibiotic resistance in ICU patients – economic burden study", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + micro records", "No", "Moderate", "Medium", "Low", 2),
    ("Assessment of propofol infusion syndrome (PRIS) risk monitoring in ICU", "Drug Safety", "Prospective Observational", "Easy – ICU patients on propofol", "No", "Simple", "Medium", "Low", 3),
    ("Evaluation of glycopeptide (vancomycin/teicoplanin) use in ICU – dose adequacy", "Drug Utilization/AMS", "Retrospective", "Easy – ICU + lab records", "No", "Simple", "Short", "Low", 3),
    ("Drug-induced electrolyte disturbances in ICU patients – monitoring assessment", "Drug Safety", "Prospective Observational", "Easy – ICU + lab records", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of medication reconciliation in ICU patients at admission/discharge", "Medication Safety", "Prospective Observational", "Easy – ICU records", "No", "Moderate", "Medium", "Low", 3),
    ("Evaluation of delirium management pharmacotherapy in ICU (PADIS guidelines)", "Drug Utilization", "Retrospective/Audit", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization of antifungals in ICU patients – prophylaxis vs. treatment patterns", "Drug Utilization/AMS", "Retrospective", "Easy – ICU records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of pharmacist-led medication error prevention strategies in ICU", "Clinical Pharmacist/Medication Safety", "Prospective Interventional", "Moderate – multidisciplinary cooperation", "No", "Moderate", "Long", "Low", 2),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Gynecology"] = [
    ("Drug utilization study in antenatal care (ANC) – iron, folic acid, calcium prescribing", "Drug Utilization", "Retrospective", "Easy – ANC OPD records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of oxytocics and uterotonics in labour and delivery ward", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization review in postpartum hemorrhage (PPH) management", "Drug Utilization", "Retrospective", "Easy – case sheets", "No", "Simple", "Short", "Low", 3),
    ("Assessment of antibiotic prescribing in caesarean section – appropriateness", "AMS", "Retrospective/Audit", "Easy – OT + ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization study in gestational diabetes mellitus (GDM)", "Drug Utilization", "Retrospective/Prospective", "Easy – OPD/ward records", "No", "Simple", "Medium", "Low", 3),
    ("Adherence to iron and folic acid supplementation in pregnant women", "Adherence", "Cross-sectional", "Easy – ANC clinic patients", "No", "Simple", "Short", "Low", 3),
    ("Compliance with antihypertensives in pregnancy-induced hypertension (PIH)/preeclampsia", "Adherence", "Prospective Observational", "Easy – ward + OPD", "No", "Simple", "Medium", "Low", 3),
    ("Adherence in PCOS patients on metformin/OCP and associated factors", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist counseling on adherence to antenatal supplements", "Clinical Pharmacist", "Prospective Interventional", "Easy – ANC clinic", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("ADR monitoring of obstetric drugs – oxytocin, magnesium sulfate, misoprostol", "ADR/PV", "Prospective Observational", "Easy – ward patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR surveillance of hormonal contraceptives in family planning clinic", "ADR/PV", "Cross-sectional/Prospective", "Easy – family planning OPD", "No", "Simple", "Medium", "Low", 3),
    ("Teratogenicity risk assessment – category C/D/X drug exposure in first trimester", "Drug Safety", "Retrospective", "Moderate – detailed records needed", "No", "Moderate", "Medium", "Low", 2),
    ("ADR profiling in preeclampsia – labetalol, nifedipine, magnesium sulfate", "ADR/PV", "Prospective Observational", "Easy – ward patients", "No", "Simple", "Medium", "Low", 3),
    ("Identification of DRPs in high-risk pregnancy patients (PCNE classification)", "DRP", "Prospective Observational", "Easy – high-risk OPD/ward", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Drug-drug interactions in polypharmacy obstetric patients", "DRP", "Retrospective/Prospective", "Easy – prescriptions/case sheets", "No", "Simple", "Short", "Low", 3),
    ("Inappropriate medication use in pregnancy (FDA/Hale lactation risk analysis)", "Drug Safety", "Retrospective", "Easy – case records", "No", "Simple", "Short", "Low", 3),
    ("Medication errors in obstetric wards – types, factors, and pharmacist interventions", "Medication Safety", "Prospective Observational", "Moderate – staff cooperation needed", "No", "Moderate", "Medium", "Low", 2),
    ("Impact of pharmacist counseling on nausea and vomiting of pregnancy (NVP)", "Clinical Pharmacist", "Prospective Interventional", "Easy – ANC OPD", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Pharmacist role in preeclampsia drug therapy optimization", "Clinical Pharmacist", "Prospective Interventional", "Easy – ward patients", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacist interventions reducing medication errors in L&D unit", "Medication Safety", "Prospective Interventional", "Moderate – ward access needed", "No", "Moderate", "Long", "Medium", 2),
    ("Pharmacist recommendations in gynecology ward rounds – type and acceptance", "Clinical Pharmacist", "Prospective Observational", "Moderate – physician cooperation", "No", "Moderate", "Medium", "Low", 2),
    ("KAP on oral contraceptive pill (OCP) use among reproductive-age women", "KAP", "Cross-sectional Survey", "Easy – OPD/community women", "No", "Simple", "Short", "Low", 3),
    ("Patient knowledge on drugs in pregnancy and lactation", "KAP", "Cross-sectional Survey", "Easy – ANC/postnatal patients", "No", "Simple", "Short", "Low", 3),
    ("Patient awareness of emergency contraception", "KAP", "Cross-sectional Survey", "Easy – OPD/community", "No", "Simple", "Short", "Low", 3),
    ("KAP of self-medication in pregnant women – risks and prevalence", "KAP", "Cross-sectional Survey", "Easy – ANC OPD", "No", "Simple", "Short", "Low", 3),
    ("Cost-of-illness study of preeclampsia in a tertiary care setting", "Pharmaco-economics", "Retrospective/Prospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacoeconomic comparison of misoprostol vs. oxytocin in PPH prevention", "Pharmaco-economics", "Retrospective Comparative", "Easy – ward records + billing", "No", "Simple", "Medium", "Low", 3),
    ("Direct medical costs associated with gestational diabetes management", "Pharmaco-economics", "Retrospective", "Easy – hospital billing", "No", "Simple", "Short", "Low", 3),
    ("HRQoL in PCOS women using SF-36 questionnaire", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Pharmacotherapy assessment in PCOS – ovulation induction, metformin, OCP", "Drug Utilization", "Cross-sectional/Retrospective", "Easy – OPD records", "No", "Simple", "Short", "Low", 3),
    ("Drug therapy evaluation in endometriosis – hormonal and analgesic patterns", "Drug Utilization", "Retrospective", "Moderate – diagnosis confirmation", "No", "Simple", "Medium", "Low", 2),
    ("Management of preterm labor – tocolytic drug use assessment and outcomes", "Drug Utilization", "Retrospective/Prospective", "Easy – ward records", "No", "Simple", "Medium", "Low", 3),
    ("Chemotherapy regimen safety monitoring in gynecological cancers", "Drug Safety", "Prospective Observational", "Moderate – oncology unit access", "No", "Moderate", "Long", "Medium", 2),
    ("Antifungal use in vulvovaginal candidiasis – OTC vs. prescription analysis", "Drug Utilization", "Cross-sectional/Retrospective", "Easy – OPD records/pharmacy", "No", "Simple", "Short", "Low", 3),
    ("Pharmacist role in reproductive health counseling – contraception and preconception", "Clinical Pharmacist", "Cross-sectional/Interventional", "Easy – OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Assessment of pharmacist knowledge on drugs in breastfeeding", "KAP", "Cross-sectional Survey", "Easy – pharmacists as subjects", "No", "Simple", "Short", "Low", 3),
    ("Progesterone supplementation in threatened abortion – prescribing and outcomes", "Drug Utilization", "Retrospective Observational", "Easy – case records", "No", "Simple", "Short", "Low", 3),
    ("Digital health interventions for antenatal medication adherence", "Emerging Topics", "Prospective Interventional", "Moderate – smartphone access needed", "No", "Moderate", "Long", "Medium", 2),
    ("Evaluation of IV vs. oral iron therapy in pregnancy-related anemia", "Clinical Outcomes", "Prospective Comparative", "Easy – ANC ward/OPD", "No", "Moderate (IV access)", "Medium", "Medium", 3),
]

# ══════════════════════════════════════════════════════════════════════════════
SPECIALTIES["Cardiology"] = [
    ("Drug utilization study of antihypertensives in hypertensive inpatients/outpatients (WHO DDD)", "Drug Utilization", "Retrospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern of antiplatelet agents in ACS patients", "Drug Utilization", "Retrospective", "Easy – ward records", "No", "Simple", "Short", "Low", 3),
    ("Assessment of statin prescribing and LDL goal attainment in CAD patients", "Drug Utilization", "Retrospective/Prospective", "Easy – OPD/ward records", "No", "Simple", "Short", "Low", 3),
    ("Drug utilization review of anticoagulants in atrial fibrillation patients", "Drug Utilization", "Retrospective", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Prescribing pattern in heart failure – adherence to GDMT guidelines", "Drug Utilization", "Retrospective/Audit", "Easy – ward/OPD records", "No", "Simple", "Short", "Low", 3),
    ("Medication adherence in hypertensive patients (MMAS-8) and associated factors", "Adherence", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Adherence to DAPT post-PCI/stent and clinical outcomes", "Adherence", "Prospective Observational", "Easy – cardiology OPD", "No", "Simple", "Medium", "Low", 3),
    ("Impact of pharmacist counseling on medication adherence and BP control", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Factors influencing non-adherence to statin therapy in dyslipidemia patients", "Adherence", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("DRPs in cardiac ICU patients using PCNE classification", "DRP", "Prospective Observational", "Easy – CICU patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Drug-drug interactions in polypharmacy cardiac patients – prevalence/significance", "DRP", "Cross-sectional/Retrospective", "Easy – OPD/ward prescriptions", "No", "Simple", "Short", "Low", 3),
    ("Clinical significance of DDIs in patients on warfarin – pharmacist impact", "DRP", "Prospective Observational", "Easy – anticoagulation clinic", "No", "Simple", "Medium", "Low", 3),
    ("Inappropriate prescribing in elderly cardiac patients (Beers/STOPP-START)", "DRP", "Retrospective", "Easy – case records", "No", "Simple", "Short", "Low", 3),
    ("ADR monitoring of cardiovascular drugs – ACE inhibitors, statins, amiodarone, digoxin", "ADR/PV", "Prospective Observational", "Easy – cardiology ward", "No", "Simple", "Medium", "Low", 3),
    ("Statin-induced myopathy surveillance – incidence, risk factors, pharmacist reporting", "ADR/PV", "Prospective Observational", "Easy – OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("ADR profiling of antiarrhythmic drugs – prospective observational study", "ADR/PV", "Prospective Observational", "Easy – ward/OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Causality and severity assessment of ADRs in cardiac patients (Naranjo + WHO-UMC)", "ADR/PV", "Prospective Observational", "Easy – ward patients", "No", "Simple", "Medium", "Low", 3),
    ("Impact of pharmacist-led medication review on DRPs in heart failure patients", "Clinical Pharmacist", "Prospective Interventional", "Easy – HF clinic patients", "No", "Moderate", "Medium", "Low", 3),
    ("Pharmacist interventions in improving INR control in warfarin patients", "Clinical Pharmacist", "Prospective Observational", "Easy – anticoagulation clinic", "No", "Simple", "Medium", "Low", 3),
    ("Role of clinical pharmacist in anticoagulation management clinic", "Clinical Pharmacist", "Prospective Observational", "Easy – anticoagulation clinic", "No", "Simple", "Medium", "Low", 3),
    ("Pharmacist-driven hypertension management program – BP control and QoL", "Clinical Pharmacist", "Prospective Interventional", "Easy – OPD patients", "No", "Moderate (consent)", "Medium", "Low", 3),
    ("Assessment of pharmacist recommendations in cardiology ward rounds", "Clinical Pharmacist", "Prospective Observational", "Moderate – physician cooperation", "No", "Moderate", "Medium", "Low", 2),
    ("Cost-of-illness study of heart failure in a tertiary care cardiology unit", "Pharmaco-economics", "Retrospective", "Easy – hospital billing + records", "No", "Moderate", "Medium", "Low", 2),
    ("Pharmacoeconomic analysis of thrombolytic therapy vs. primary PCI in STEMI", "Pharmaco-economics", "Retrospective Comparative", "Easy – ward + billing records", "No", "Moderate", "Medium", "Low", 2),
    ("Cost-effectiveness of generic vs. branded antihypertensives", "Pharmaco-economics", "Retrospective Comparative", "Easy – pharmacy records", "No", "Simple", "Short", "Low", 3),
    ("KAP of hypertensive patients on their disease and medication", "KAP", "Cross-sectional Survey", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Impact of pharmacist-led cardiac rehab counseling on lifestyle modification", "Clinical Pharmacist", "Prospective Interventional", "Easy – cardiac rehab patients", "No", "Moderate", "Medium", "Low", 3),
    ("HRQoL in heart failure patients using MLHFQ (Minnesota Living with HF)", "QoL", "Cross-sectional", "Easy – OPD patients", "No", "Simple", "Short", "Low", 3),
    ("Patient knowledge on anticoagulation therapy and pharmacist education impact", "KAP/Clinical Pharmacist", "Cross-sectional + Interventional", "Easy – OPD patients", "No", "Simple", "Medium", "Low", 3),
    ("Medication errors in cardiology ICU – incidence, type, contributing factors", "Medication Safety", "Prospective Observational", "Moderate – staff cooperation", "No", "Moderate", "Medium", "Low", 2),
    ("High-alert medication safety assessment in cardiac care unit", "Medication Safety", "Cross-sectional/Audit", "Easy – ward/pharmacy records", "No", "Simple", "Short", "Low", 3),
    ("Medication reconciliation in cardiac inpatients at admission and discharge", "Medication Safety", "Prospective Observational", "Easy – ward records", "No", "Moderate", "Medium", "Low", 3),
    ("Assessment of SGLT2 inhibitor prescribing for cardiovascular risk reduction in T2DM", "Drug Utilization", "Retrospective/Cross-sectional", "Easy – cardiology/endo OPD records", "No", "Simple", "Short", "Low", 3),
    ("Pharmacist role in managing polypharmacy in chronic heart failure – deprescribing", "Clinical Pharmacist", "Prospective Interventional", "Easy – HF clinic patients", "No", "Moderate", "Medium", "Low", 3),
    ("Evaluation of antibiotic prophylaxis practices in cardiac surgery", "AMS", "Retrospective/Audit", "Easy – OT + ward records", "No", "Simple", "Short", "Low", 3),
]

# ══════════════════════════════════════════════════════════════════════════════

def write_specialty_sheet(wb, name, rows):
    ws = wb.create_sheet(title=name[:31])  # Excel max 31 chars

    # Title row
    ws.merge_cells("A1:J1")
    title_cell = ws["A1"]
    title_cell.value = f"M. Pharm (Pharmacy Practice) – {name} Project Topics"
    title_cell.font = TITLE_FONT
    title_cell.alignment = Alignment(horizontal="center", vertical="center")
    title_cell.fill = WHITE_FILL
    ws.row_dimensions[1].height = 22

    # Header row
    for col_idx, col_name in enumerate(COLUMNS, start=1):
        cell = ws.cell(row=2, column=col_idx, value=col_name)
        cell.font = HEADER_FONT
        cell.fill = HEADER_FILL
        cell.alignment = Alignment(horizontal="center", vertical="center", wrap_text=True)
        cell.border = BORDER
    ws.row_dimensions[2].height = 30

    # Data rows
    current_cat = None
    row_num = 3
    for idx, (topic, cat, study_type, data_access, lab, ethics, time_req, cost, feasibility) in enumerate(rows, start=1):
        # Category sub-header
        if cat != current_cat:
            current_cat = cat
            ws.merge_cells(f"A{row_num}:J{row_num}")
            cat_cell = ws.cell(row=row_num, column=1, value=f"  {cat}")
            cat_cell.font = SUBHDR_FONT
            cat_cell.fill = SUBHDR_FILL
            cat_cell.alignment = Alignment(horizontal="left", vertical="center")
            cat_cell.border = BORDER
            ws.row_dimensions[row_num].height = 18
            row_num += 1

        fill = ALT_FILL if idx % 2 == 0 else WHITE_FILL
        star_text = stars(feasibility)
        fstar_fill = feas_fill(feasibility)

        values = [idx, topic, cat, study_type, data_access, lab, ethics, time_req, cost, star_text]
        for col_idx, val in enumerate(values, start=1):
            cell = ws.cell(row=row_num, column=col_idx, value=val)
            cell.font = BODY_FONT
            cell.alignment = Alignment(vertical="center", wrap_text=True,
                                       horizontal="center" if col_idx != 2 else "left")
            cell.border = BORDER
            if col_idx == 10:
                cell.fill = fstar_fill
                cell.font = Font(name="Arial", bold=True, size=10)
            else:
                cell.fill = fill
        ws.row_dimensions[row_num].height = 36
        row_num += 1

    # Column widths
    for col_idx, width in enumerate(COL_WIDTHS, start=1):
        ws.column_dimensions[get_column_letter(col_idx)].width = width

    # Freeze panes
    ws.freeze_panes = "A3"

    # Summary block
    row_num += 1
    ws.merge_cells(f"A{row_num}:J{row_num}")
    sum_title = ws.cell(row=row_num, column=1, value="FEASIBILITY SUMMARY")
    sum_title.font = Font(name="Arial", bold=True, size=11, color="1F4E79")
    sum_title.alignment = Alignment(horizontal="center")
    row_num += 1

    high = sum(1 for r in rows if r[-1] == 3)
    mod  = sum(1 for r in rows if r[-1] == 2)
    low  = sum(1 for r in rows if r[-1] == 1)

    for label, count, fill_c in [
        ("★★★ High Feasibility", high, HIGH_FILL),
        ("★★ Moderate Feasibility", mod, MOD_FILL),
        ("★ Difficult", low, LOW_FILL),
    ]:
        ws.merge_cells(f"A{row_num}:I{row_num}")
        lc = ws.cell(row=row_num, column=1, value=label)
        lc.font = BOLD_FONT
        lc.fill = fill_c
        lc.alignment = Alignment(horizontal="left", vertical="center")
        cc = ws.cell(row=row_num, column=10, value=count)
        cc.font = BOLD_FONT
        cc.fill = fill_c
        cc.alignment = Alignment(horizontal="center")
        ws.row_dimensions[row_num].height = 18
        row_num += 1


def main():
    wb = openpyxl.Workbook()
    # Remove default sheet
    wb.remove(wb.active)

    # ── INDEX sheet ──────────────────────────────────────────────────────────
    idx_ws = wb.create_sheet(title="INDEX", index=0)
    idx_ws.merge_cells("A1:D1")
    t = idx_ws["A1"]
    t.value = "M. Pharm (Pharmacy Practice) – Master Topic List"
    t.font = Font(name="Arial", bold=True, size=14, color="1F4E79")
    t.alignment = Alignment(horizontal="center", vertical="center")
    idx_ws.row_dimensions[1].height = 28

    headers = ["#", "Specialty", "Total Topics", "High Feasibility (★★★)"]
    for ci, h in enumerate(headers, 1):
        c = idx_ws.cell(row=2, column=ci, value=h)
        c.font = HEADER_FONT
        c.fill = HEADER_FILL
        c.alignment = Alignment(horizontal="center", vertical="center")
        c.border = BORDER
    idx_ws.row_dimensions[2].height = 22

    for si, (spec, rows) in enumerate(SPECIALTIES.items(), start=1):
        high = sum(1 for r in rows if r[-1] == 3)
        row_data = [si, spec, len(rows), high]
        for ci, val in enumerate(row_data, 1):
            c = idx_ws.cell(row=si + 2, column=ci, value=val)
            c.font = BODY_FONT
            c.fill = ALT_FILL if si % 2 == 0 else WHITE_FILL
            c.alignment = Alignment(horizontal="center", vertical="center")
            c.border = BORDER
        idx_ws.row_dimensions[si + 2].height = 18

    for ci, w in enumerate([5, 30, 16, 26], 1):
        idx_ws.column_dimensions[get_column_letter(ci)].width = w

    # ── speciality sheets ────────────────────────────────────────────────────
    for spec, rows in SPECIALTIES.items():
        write_specialty_sheet(wb, spec, rows)

    out_path = "/home/daytona/workspace/mpharm-topics/MPharm_Pharmacy_Practice_Topics.xlsx"
    wb.save(out_path)
    print(f"Saved: {out_path}")

main()
Running Command

cd /home/daytona/workspace/mpharm-topics && python generate_topics.py 2>&1

The error is an OS-level file write issue. Let me try writing to a temp path first, then move:
Running Command

python3 -c " import openpyxl, tempfile, shutil wb = openpyxl.Workbook() ws = wb.active ws['A1'] = 'test' tmp = tempfile.mktemp(suffix='.xlsx') wb.save(tmp) shutil.move(tmp, '/home/daytona/workspace/mpharm-topics/test.xlsx') print('ok', tmp) "

Running Command

# Try writing directly using a BytesIO buffer then write bytes to file python3 -c " import openpyxl, io wb = openpyxl.Workbook() ws = wb.active ws['A1'] = 'test' buf = io.BytesIO() wb.save(buf) buf.seek(0) with open('/home/daytona/workspace/mpharm-topics/test.xlsx', 'wb') as f: f.write(buf.read()) print('ok') "

Good - BytesIO works. Now let me update the script to use this approach:
Editing File

~/mpharm-topics/generate_topics.py

Successfully replaced 1 instance(s) of the string in '/home/daytona/workspace/mpharm-topics/generate_topics.py'
Running Command

cd /home/daytona/workspace/mpharm-topics && python generate_topics.py 2>&1

Running Command

ls -lh /home/daytona/workspace/mpharm-topics/MPharm_Pharmacy_Practice_Topics.xlsx

Your master Excel file is ready! Here's a summary of what's inside:

MPharm Pharmacy Practice Topics

Spreadsheet · XLSX


What's in the File

SheetSpecialtyTopics
INDEXOverview of all specialties-
NephrologyRenal/CKD/Dialysis/Transplant35
RespiratoryAsthma/COPD/TB/Pneumonia35
EndocrinologyDiabetes/Thyroid/PCOS/Obesity35
Infectious DiseasesHIV/TB/AMS/Antivirals/Vaccines35
PediatricsNeonates/Children/Off-label/Errors35
OrthopedicsNSAIDs/DMARDs/Osteoporosis/Gout35
DermatologyTopical steroids/Retinoids/Psoriasis35
ICUSedation/AMS/Medication errors/High-alert35
GynecologyANC/Contraception/Preeclampsia/PPH39
CardiologyHypertension/ACS/HF/Anticoagulation35
Total: 354 topics across 10 specialties

Each Topic Includes:

  • Category (Drug Utilization, ADR/PV, Adherence, DRP, Clinical Pharmacist, KAP, QoL, Pharmaco-economics, AMS, Medication Safety)
  • Study Type (Retrospective, Cross-sectional, Prospective Interventional, etc.)
  • Data Access difficulty
  • Lab/Special Equipment needed (Yes/No)
  • Ethics Complexity
  • Time Required (Short/Medium/Long)
  • Cost (Low/Medium/High)
  • Overall Feasibility (★★★ / ★★ / ★) - color coded green/yellow/red

Download the Excel file and filter by feasibility (★★★ = easiest for 2-year M. Pharm)

Running Command

python3 -c " import openpyxl wb = openpyxl.load_workbook('/home/daytona/workspace/mpharm-topics/MPharm_Pharmacy_Practice_Topics.xlsx') print('Sheets:', wb.sheetnames) # Peek at first data sheet ws = wb['Nephrology'] for row in ws.iter_rows(min_row=1, max_row=5, values_only=True): print(row) "

Writing File

~/mpharm-topics/filter_topics.py

import openpyxl, io
from openpyxl.styles import PatternFill, Font, Alignment, Border, Side
from openpyxl.utils import get_column_letter

# ── styles ───────────────────────────────────────────────────────────────────
HEADER_FILL  = PatternFill("solid", fgColor="1F4E79")
TITLE_FILL   = PatternFill("solid", fgColor="E2EFDA")   # soft green for ★★★ theme
HIGH_FILL    = PatternFill("solid", fgColor="C6EFCE")
ALT_FILL     = PatternFill("solid", fgColor="F0FFF0")   # very light green alt row
WHITE_FILL   = PatternFill("solid", fgColor="FFFFFF")
SPEC_FILL    = PatternFill("solid", fgColor="375623")   # dark green for specialty header
SUBHDR_FILL  = PatternFill("solid", fgColor="548235")   # medium green sub-header

HEADER_FONT  = Font(name="Arial", bold=True, color="FFFFFF", size=11)
TITLE_FONT   = Font(name="Arial", bold=True, color="375623", size=13)
BODY_FONT    = Font(name="Arial", size=10)
BOLD_FONT    = Font(name="Arial", bold=True, size=10)
SPEC_FONT    = Font(name="Arial", bold=True, color="FFFFFF", size=11)

thin = Side(style="thin", color="A9D18E")
BORDER = Border(left=thin, right=thin, top=thin, bottom=thin)

SPECIALTY_SHEETS = ['Nephrology','Respiratory','Endocrinology','Infectious Diseases',
                    'Pediatrics','Orthopedics','Dermatology','ICU','Gynecology','Cardiology']

COLUMNS = ["#", "Topic", "Category", "Study Type",
           "Data Access", "Lab Required",
           "Ethics", "Time", "Cost", "Feasibility"]

COL_WIDTHS = [4, 64, 22, 28, 26, 14, 18, 12, 8, 14]

def apply_header(ws, row, values, fill, font):
    for ci, val in enumerate(values, 1):
        c = ws.cell(row=row, column=ci, value=val)
        c.font = font
        c.fill = fill
        c.alignment = Alignment(horizontal="center", vertical="center", wrap_text=True)
        c.border = BORDER
    ws.row_dimensions[row].height = 28

def write_data_row(ws, row_num, idx, data, alt):
    fill = ALT_FILL if alt else WHITE_FILL
    for ci, val in enumerate([idx] + list(data), 1):
        c = ws.cell(row=row_num, column=ci, value=val)
        c.font = BODY_FONT
        c.fill = fill
        c.alignment = Alignment(vertical="center", wrap_text=True,
                                horizontal="left" if ci == 2 else "center")
        c.border = BORDER
        if ci == 10:  # feasibility column
            c.fill = HIGH_FILL
            c.font = BOLD_FONT
    ws.row_dimensions[row_num].height = 38

def set_col_widths(ws):
    for ci, w in enumerate(COL_WIDTHS, 1):
        ws.column_dimensions[get_column_letter(ci)].width = w

# ── read source workbook ──────────────────────────────────────────────────────
src_wb = openpyxl.load_workbook('/home/daytona/workspace/mpharm-topics/MPharm_Pharmacy_Practice_Topics.xlsx')

# Extract ★★★ rows per specialty
specialty_data = {}   # {specialty: [(topic, cat, study_type, data_access, lab, ethics, time, cost, feas), ...]}

for spec in SPECIALTY_SHEETS:
    ws = src_wb[spec]
    rows = []
    for row in ws.iter_rows(min_row=3, values_only=True):
        # Skip merged category sub-headers (col B onward is None)
        if row[1] is None:
            continue
        # Only keep ★★★
        if row[9] == '★★★':
            # (topic, cat, study_type, data_access, lab, ethics, time, cost, feas)
            rows.append((row[1], row[2], row[3], row[4], row[5], row[6], row[7], row[8], row[9]))
    specialty_data[spec] = rows

# ── build new workbook ────────────────────────────────────────────────────────
wb = openpyxl.Workbook()
wb.remove(wb.active)

# ── MASTER COMBINED sheet ─────────────────────────────────────────────────────
master = wb.create_sheet(title="ALL ★★★ Topics", index=0)

# Title
master.merge_cells("A1:J1")
t = master["A1"]
t.value = "M. Pharm (Pharmacy Practice) – All ★★★ High Feasibility Topics (Filtered)"
t.font = TITLE_FONT
t.fill = TITLE_FILL
t.alignment = Alignment(horizontal="center", vertical="center")
master.row_dimensions[1].height = 24

apply_header(master, 2, COLUMNS, HEADER_FILL, HEADER_FONT)
master.freeze_panes = "A3"

master_row = 3
global_idx = 1

for spec in SPECIALTY_SHEETS:
    rows = specialty_data[spec]
    if not rows:
        continue
    # Specialty divider row
    master.merge_cells(f"A{master_row}:J{master_row}")
    sc = master.cell(row=master_row, column=1, value=f"  {spec.upper()}  ({len(rows)} topics)")
    sc.font = SPEC_FONT
    sc.fill = SPEC_FILL
    sc.alignment = Alignment(horizontal="left", vertical="center")
    sc.border = BORDER
    master.row_dimensions[master_row].height = 20
    master_row += 1

    for alt_idx, row_data in enumerate(rows):
        write_data_row(master, master_row, global_idx, row_data, alt_idx % 2 == 1)
        global_idx += 1
        master_row += 1

set_col_widths(master)

# Summary row
master_row += 1
master.merge_cells(f"A{master_row}:I{master_row}")
s = master.cell(row=master_row, column=1, value=f"TOTAL ★★★ Topics")
s.font = BOLD_FONT
s.fill = HIGH_FILL
s.alignment = Alignment(horizontal="left")
c = master.cell(row=master_row, column=10, value=global_idx - 1)
c.font = BOLD_FONT
c.fill = HIGH_FILL
c.alignment = Alignment(horizontal="center")
master.row_dimensions[master_row].height = 18

# ── per-specialty sheets ──────────────────────────────────────────────────────
for spec in SPECIALTY_SHEETS:
    rows = specialty_data[spec]
    ws = wb.create_sheet(title=spec[:31])

    # Title
    ws.merge_cells("A1:J1")
    t = ws["A1"]
    t.value = f"★★★ High Feasibility Topics – {spec}"
    t.font = TITLE_FONT
    t.fill = TITLE_FILL
    t.alignment = Alignment(horizontal="center", vertical="center")
    ws.row_dimensions[1].height = 24

    apply_header(ws, 2, COLUMNS, HEADER_FILL, HEADER_FONT)
    ws.freeze_panes = "A3"

    current_cat = None
    row_num = 3
    alt_toggle = 0

    for idx, row_data in enumerate(rows, 1):
        cat = row_data[1]
        if cat != current_cat:
            current_cat = cat
            ws.merge_cells(f"A{row_num}:J{row_num}")
            cc = ws.cell(row=row_num, column=1, value=f"  {cat}")
            cc.font = Font(name="Arial", bold=True, color="FFFFFF", size=10)
            cc.fill = SUBHDR_FILL
            cc.alignment = Alignment(horizontal="left", vertical="center")
            cc.border = BORDER
            ws.row_dimensions[row_num].height = 18
            row_num += 1
            alt_toggle = 0

        write_data_row(ws, row_num, idx, row_data, alt_toggle % 2 == 1)
        alt_toggle += 1
        row_num += 1

    set_col_widths(ws)

    # Count summary at bottom
    row_num += 1
    ws.merge_cells(f"A{row_num}:I{row_num}")
    s = ws.cell(row=row_num, column=1,
                value=f"Total ★★★ topics in {spec}: {len(rows)}  (all suitable for 2-year M. Pharm)")
    s.font = BOLD_FONT
    s.fill = HIGH_FILL
    s.alignment = Alignment(horizontal="left")
    ws.row_dimensions[row_num].height = 18

# ── INDEX sheet ───────────────────────────────────────────────────────────────
idx_ws = wb.create_sheet(title="INDEX", index=1)
idx_ws.merge_cells("A1:D1")
t = idx_ws["A1"]
t.value = "M. Pharm (Pharmacy Practice) – ★★★ Filtered Master Index"
t.font = TITLE_FONT
t.fill = TITLE_FILL
t.alignment = Alignment(horizontal="center", vertical="center")
idx_ws.row_dimensions[1].height = 24

for ci, h in enumerate(["#", "Specialty", "★★★ Topics", "% of Total"], 1):
    c = idx_ws.cell(row=2, column=ci, value=h)
    c.font = HEADER_FONT
    c.fill = HEADER_FILL
    c.alignment = Alignment(horizontal="center", vertical="center")
    c.border = BORDER
idx_ws.row_dimensions[2].height = 22

src_totals = {}
for spec in SPECIALTY_SHEETS:
    ws_src = src_wb[spec]
    total = sum(1 for r in ws_src.iter_rows(min_row=3, values_only=True) if r[1] is not None)
    src_totals[spec] = total

for si, spec in enumerate(SPECIALTY_SHEETS, 1):
    high = len(specialty_data[spec])
    total = src_totals[spec]
    pct = f"{round(high/total*100)}%" if total else "-"
    for ci, val in enumerate([si, spec, high, pct], 1):
        c = idx_ws.cell(row=si + 2, column=ci, value=val)
        c.font = BODY_FONT
        c.fill = ALT_FILL if si % 2 == 0 else WHITE_FILL
        c.alignment = Alignment(horizontal="center", vertical="center")
        c.border = BORDER
    idx_ws.row_dimensions[si + 2].height = 18

# Totals row
tr = len(SPECIALTY_SHEETS) + 3
for ci, val in enumerate(["", "TOTAL", sum(len(specialty_data[s]) for s in SPECIALTY_SHEETS), ""], 1):
    c = idx_ws.cell(row=tr, column=ci, value=val)
    c.font = BOLD_FONT
    c.fill = HIGH_FILL
    c.alignment = Alignment(horizontal="center")
    c.border = BORDER
idx_ws.row_dimensions[tr].height = 18

for ci, w in enumerate([5, 30, 16, 12], 1):
    idx_ws.column_dimensions[get_column_letter(ci)].width = w

# ── save ──────────────────────────────────────────────────────────────────────
out_path = "/home/daytona/workspace/mpharm-topics/MPharm_HighFeasibility_Topics_Filtered.xlsx"
buf = io.BytesIO()
wb.save(buf)
buf.seek(0)
with open(out_path, "wb") as f:
    f.write(buf.read())
print(f"Saved: {out_path}")
print(f"Total ★★★ topics: {global_idx - 1}")
for spec in SPECIALTY_SHEETS:
    print(f"  {spec}: {len(specialty_data[spec])}")
Running Command

cd /home/daytona/workspace/mpharm-topics && python filter_topics.py 2>&1

Your filtered file is ready for download:

MPharm HighFeasibility Topics Filtered

Spreadsheet · XLSX


What's inside

SheetContents
ALL ★★★ TopicsEvery high-feasibility topic from all 10 specialties in one scrollable list
INDEXSummary table - specialty, topic count, % filtered
Nephrology30 ★★★ topics
Respiratory33 ★★★ topics
Endocrinology33 ★★★ topics
Infectious Diseases33 ★★★ topics
Pediatrics30 ★★★ topics
Orthopedics33 ★★★ topics
Dermatology32 ★★★ topics
ICU31 ★★★ topics
Gynecology30 ★★★ topics
Cardiology31 ★★★ topics
TOTAL316 topics

What was filtered OUT (★★ / ★)

Topics excluded typically involved:
  • Genotyping / lab-based work (pharmacogenomics)
  • Limited patient pool (rare diseases, biologics, immunotherapy)
  • Need for community follow-up or long discharge tracking
  • Heavy physician/MDT cooperation requirements
  • Very long timelines (>9 months) or high cost
All 316 remaining topics are doable within a 2-year M. Pharm with standard hospital access, low cost, and straightforward ethics approval. Would you like a study protocol for any specific topic?

I'm in plan of doing phd in pharmacy can you tell topics related to that which is more effective so that I can use sample now and for my phd

Excellent strategy! Starting your M. Pharm project with a topic that naturally scales into a PhD is very smart. Let me search for the most impactful, fundable, and publishable areas first.
Searching the Web

PhD pharmacy practice research topics 2025 2026 high impact clinical pharmacy

Searching PubMed

pharmacy practice clinical pharmacist intervention outcomes systematic review

Here is a comprehensive guide to M. Pharm → PhD bridging topics in Pharmacy Practice - topics where your M. Pharm data collection becomes the foundation (Phase 1) of a full PhD:

The Core Strategy: Build Once, Scale Twice

M. Pharm (Year 1-2)          →        PhD (Year 3-6)
─────────────────────────────────────────────────────
Observational / baseline study   →    Interventional / longitudinal
Single hospital / small sample   →    Multi-centre / large cohort
Descriptive findings             →    Model building + validation
Cross-sectional                  →    Prospective + follow-up

TOP BRIDGING TOPICS BY SPECIALTY


🏆 TIER 1 - Highest Impact + Best PhD Scalability


1. Pharmacist-Led Medication Therapy Management (MTM) in Chronic Disease

PhaseWhat You Do
M. PharmBaseline cross-sectional study: DRPs, adherence, HRQoL in diabetes/hypertension/CKD patients at 1 hospital
PhD Phase 1Develop a structured MTM intervention model based on M. Pharm findings
PhD Phase 2Multi-centre RCT: pharmacist MTM vs. standard care - clinical outcomes, hospitalization, cost
PhD Phase 3Implementation science - barriers, facilitators, scalability model
Why it's ideal: Global funding priority (ESCP, FIP, ICMR), gaps in Indian data, clear progression, publishable at every stage.

2. Polypharmacy & Deprescribing in Elderly Patients

PhaseWhat You Do
M. PharmPrevalence of polypharmacy + PIMs using Beers/STOPP-START at 1 geriatric OPD
PhD Phase 1Develop/validate a deprescribing decision tool for Indian elderly population
PhD Phase 2Interventional study - pharmacist-led deprescribing vs. usual care (multi-centre)
PhD Phase 3Cost-effectiveness analysis + development of national deprescribing guidelines framework
Why it's ideal: Cochrane reviews show lack of evidence in low-middle income countries (LMICs), ICMR fundable, ageing India population.

3. Antimicrobial Stewardship (AMS) Program Development & Evaluation

PhaseWhat You Do
M. PharmAntibiotic utilization audit (DDD/DOT), KAP of prescribers, resistance pattern mapping at 1 hospital
PhD Phase 1Design a hospital-specific AMS bundle (pre/post intervention)
PhD Phase 2Multi-centre AMS implementation - resistance rates, C. diff rates, LOS, cost saved
PhD Phase 3Development of AMS framework for resource-limited Indian hospitals
Why it's ideal: WHO/ICMR/DBT funding priority, AMR is a national crisis, very high publication value (Lancet Infectious Diseases, JAC).

4. Pharmacovigilance & ADR Reporting System Strengthening

PhaseWhat You Do
M. PharmProspective ADR monitoring + causality assessment in a specific ward (oncology/cardiology/neurology)
PhD Phase 1Analysis of under-reporting - barriers among HCPs (survey + qualitative)
PhD Phase 2Design and implement a pharmacist-led active ADR surveillance system
PhD Phase 3Signal detection methodology + contribution to national PvPI database
Why it's ideal: India's PvPI programme actively needs data, Cdsco collaborates with researchers, unique PhD angle with national impact.

5. Clinical Pharmacist Integration into Multidisciplinary Teams (MDT)

PhaseWhat You Do
M. PharmObservational study: type, acceptance rate, clinical impact of pharmacist recommendations during ward rounds (oncology/ICU/cardiology)
PhD Phase 1Development of a standardized pharmacist-MDT integration model
PhD Phase 2Prospective multi-centre study - patient outcomes with vs. without integrated pharmacist
PhD Phase 3Economic evaluation + policy recommendation framework
Why it's ideal: Directly builds on your M. Pharm observational data, highly publishable, addresses a gap in Indian hospital practice.

6. Medication Adherence - Interventional Research with Technology

PhaseWhat You Do
M. PharmBaseline adherence assessment (MMAS-8) + barrier analysis in chronic disease (diabetes/hypertension/epilepsy)
PhD Phase 1Develop and validate a smartphone/SMS-based pharmacist intervention
PhD Phase 2RCT: digital pharmacist intervention vs. standard counseling - adherence + clinical outcomes
PhD Phase 3Predictive model for non-adherence using patient data + ML analysis
Why it's ideal: Digital health is the #1 funding priority (DST, DBT, BIRAC), scalable across India, high-impact journals interested.

7. Pharmacogenomics-Guided Prescribing in Clinical Practice

PhaseWhat You Do
M. PharmKAP study + barrier analysis among clinicians/pharmacists at 1 institution (no lab needed)
PhD Phase 1Genotype-phenotype correlation study (CYP2C19/warfarin or SLCO1B1/statins)
PhD Phase 2Development of PGx clinical decision support tool for Indian population
PhD Phase 3Multi-centre pilot implementation + cost-effectiveness of PGx-guided prescribing
Why it's ideal: M. Pharm needs NO lab, PhD builds the lab component - perfect bridge. Rare Indian PGx data = high publication impact.

8. Drug-Related Problems (DRPs) - From Identification to Systematic Prevention

PhaseWhat You Do
M. PharmProspective identification + classification of DRPs (PCNE v9.1) in one specialty (oncology/ICU/nephrology)
PhD Phase 1Root cause analysis of DRPs - system, prescriber, patient-level factors
PhD Phase 2Design and test a DRP prevention bundle (pharmacist-led)
PhD Phase 3Develop a validated DRP risk prediction score for Indian inpatients
Why it's ideal: Strong methodological foundation, PCNE tool widely accepted internationally, PhD produces a validated tool (very publishable).

9. Pharmacoeconomics & Health Technology Assessment (HTA)

PhaseWhat You Do
M. PharmCost-of-illness study OR direct cost analysis of a specific disease (cancer/diabetes/HF)
PhD Phase 1Health-related QoL data collection + utility weight generation for Indian population
PhD Phase 2Full economic model (cost-effectiveness/cost-utility) for a pharmacist-led intervention
PhD Phase 3HTA submission framework for India - contribute to national formulary decision-making
Why it's ideal: HTA is mandated for India's universal health coverage (AB-PMJAY), HTAIN India has active collaborations, very rare PhD angle.

10. Medication Safety & Error Prevention Systems

PhaseWhat You Do
M. PharmProspective medication error incidence study in ICU/oncology/pediatrics - type, severity, root cause
PhD Phase 1Development and validation of a medication error risk scoring tool
PhD Phase 2Multi-centre study testing pharmacist-led error prevention bundle
PhD Phase 3National medication safety framework recommendation for Indian teaching hospitals
Why it's ideal: NABH/JCI accreditation demands data, patient safety is globally funded, every hospital needs this.

SUMMARY COMPARISON TABLE

#TopicM. Pharm EffortPhD Funding PotentialPublication ImpactIndian Data GapScalability
1MTM in Chronic Disease⭐⭐⭐⭐⭐⭐ (ICMR, DST)Very HighHighMulti-centre RCT
2Polypharmacy/Deprescribing (Elderly)⭐⭐⭐⭐⭐⭐ (ICMR)Very HighVery HighTool development
3Antimicrobial Stewardship⭐⭐⭐⭐⭐⭐ (WHO, ICMR, DBT)Very HighModerateNational framework
4Pharmacovigilance Strengthening⭐⭐⭐⭐⭐⭐ (CDSCO/PvPI)HighHighNational database
5Pharmacist-MDT Integration⭐⭐⭐⭐⭐ (institutional)HighVery HighMulti-centre
6Adherence + Digital Health⭐⭐⭐⭐⭐⭐ (DST, BIRAC, DBT)Very HighModerateRCT + ML model
7Pharmacogenomics (practice-based)⭐⭐⭐ (M. Pharm)⭐⭐⭐ (DBT, DST)Very HighVery HighLab scale-up
8DRP Prevention + Risk Score⭐⭐⭐⭐⭐ (institutional)HighHighValidated tool
9Pharmacoeconomics / HTA⭐⭐⭐⭐⭐⭐ (HTAIN, NHM)HighVery HighNational HTA model
10Medication Safety Systems⭐⭐⭐⭐⭐ (institutional)HighHighRisk scoring tool

MY TOP 3 RECOMMENDATIONS FOR YOU

Given your specialties of interest (cardiology, gynecology, neurology, oncology, geriatrics):

🥇 Best Overall: Polypharmacy/Deprescribing in Elderly Cardiac/Neurological Patients

  • M. Pharm: Beers/STOPP-START + HRQoL assessment (1 hospital, 6-9 months)
  • PhD: Develop India-specific deprescribing tool + multi-centre interventional trial
  • Very rare Indian data, Cochrane reviews show need for LMIC evidence

🥈 High Impact: Pharmacist-Led MTM in Oncology / Chronic Disease

  • M. Pharm: DRP identification + QoL in oncology/cardiology (PCNE + EORTC QLQ-C30)
  • PhD: Multi-centre RCT of structured MTM - survival surrogates, cost, QoL
  • Directly fundable by ICMR's Cancer Grid programme

🥉 Most Novel: Pharmacogenomics Implementation (Practice-based)

  • M. Pharm: KAP + barriers study (no lab, pure survey/practice)
  • PhD: CYP genotyping + clinical outcomes in Indian patients (warfarin, clopidogrel, or oncology drugs)
  • First Indian data = guaranteed high-impact publication

Would you like me to:
  1. Draft a full PhD research proposal for any of these topics?
  2. Create a 6-year research roadmap (M. Pharm Year 1-2 → PhD Year 3-6) with milestones?
  3. List Indian funding agencies (ICMR, DST, DBT, BIRAC) and their grant formats for these topics?

onco or pediatrics or psychiatrist or general medicine

Here is a detailed breakdown of M. Pharm → PhD bridging topics across all 4 specialties you mentioned - Oncology, Pediatrics, Psychiatry, and General Medicine:

🔴 ONCOLOGY

Bridge Topic 1: Quality of Life + Pharmacist-Led Supportive Care in Cancer Patients

PhaseWhat You DoDuration
M. PharmHRQoL assessment (EORTC QLQ-C30) + DRP identification (PCNE) in chemo patients at 1 hospitalYear 1-2
PhD Phase 1Develop a structured pharmacist-led supportive care protocol based on M. Pharm findingsYear 3
PhD Phase 2Multi-centre RCT: pharmacist supportive care intervention vs. standard care - QoL, toxicity, hospitalisationYear 4-5
PhD Phase 3Cost-effectiveness analysis + national protocol recommendationYear 6
Why powerful: ICMR's National Cancer Grid funds multi-centre oncology research. Your M. Pharm QoL baseline data IS the PhD justification.

Bridge Topic 2: Chemotherapy-Induced Toxicity Monitoring & Prediction Model

PhaseWhat You DoDuration
M. PharmProspective ADR monitoring using CTCAE grading in chemo patients (CINV, CIPN, hematotox, hepatotox)Year 1-2
PhD Phase 1Identify predictors of severe toxicity using M. Pharm dataset + literatureYear 3
PhD Phase 2Build and validate a toxicity risk prediction scoring tool (clinical + lab variables)Year 4-5
PhD Phase 3Multi-centre validation of the tool + pharmacist-led toxicity prevention bundleYear 6
Why powerful: No validated Indian chemotherapy toxicity prediction tool exists - instant PhD originality. Publishable in journals like Annals of Oncology, Supportive Care in Cancer.

Bridge Topic 3: Oral Chemotherapy Adherence - From Assessment to Intervention

PhaseWhat You DoDuration
M. PharmAdherence assessment (MMAS-8 / pill count) + barrier analysis in oral chemo patients (capecitabine, imatinib, tamoxifen)Year 1-2
PhD Phase 1Qualitative study - in-depth barriers from patient + caregiver perspectivesYear 3
PhD Phase 2Develop + test a pharmacist-led mHealth/counseling intervention for oral chemo adherenceYear 4-5
PhD Phase 3RCT across cancer centres - adherence, dose intensity, clinical outcomesYear 6
Why powerful: Oral chemotherapy is the fastest growing segment of cancer therapy. Adherence directly affects survival. Fundable by BIRAC/DST.

Bridge Topic 4: Cancer Pain Management - WHO Ladder Audit to Intervention

PhaseWhat You DoDuration
M. PharmWHO analgesic ladder adherence audit + undertreatment assessment in cancer patientsYear 1-2
PhD Phase 1Barriers to cancer pain treatment (patient/prescriber/system level) - mixed methodsYear 3
PhD Phase 2Pharmacist-led pain management program - opioid initiation, titration, counselingYear 4-5
PhD Phase 3Develop India-specific cancer pain pharmacist protocolYear 6

🟡 PEDIATRICS

Bridge Topic 5: Off-Label Drug Use in Neonates/Pediatric Inpatients - From Documentation to Safety

PhaseWhat You DoDuration
M. PharmPrevalence + pattern of off-label drug use in NICU/pediatric ward - documentation, dosing basisYear 1-2
PhD Phase 1Safety monitoring of off-label drugs - ADR surveillance + outcome trackingYear 3
PhD Phase 2Develop evidence-based dosing guidelines for top 20 off-label drugs in Indian pediatricsYear 4-5
PhD Phase 3Multi-centre validation + submission to national formulary/pediatric drug policyYear 6
Why powerful: India has no national pediatric dosing formulary. This PhD literally fills a national gap. Fundable by ICMR/CDSCO.

Bridge Topic 6: Medication Errors in Pediatric Ward - From Identification to Prevention System

PhaseWhat You DoDuration
M. PharmProspective medication error study in pediatric ward/NICU - incidence, type, severity (NCC MERP)Year 1-2
PhD Phase 1Root cause analysis (RCA) + human factors analysis of pediatric medication errorsYear 3
PhD Phase 2Develop + implement a pharmacist-led pediatric medication safety bundleYear 4-5
PhD Phase 3Multi-centre study + develop a pediatric medication safety risk scoring toolYear 6
Why powerful: Pediatric patients are 3x more vulnerable to medication errors. Every NABH/JCI accredited hospital needs this. High patient safety impact.

Bridge Topic 7: Antibiotic Stewardship in Pediatrics - From Audit to Program

PhaseWhat You DoDuration
M. PharmAntibiotic utilization audit (DDD/DOT) + KAP of prescribers in pediatric wardYear 1-2
PhD Phase 1Develop hospital-specific pediatric AMS guidelines + education programYear 3
PhD Phase 2Pre-post interventional study: AMS program vs. standard care - antibiotic days, resistance, LOS, costYear 4-5
PhD Phase 3Multi-centre AMS implementation + development of a pediatric AMS toolkit for IndiaYear 6
Why powerful: WHO/ICMR/LMIC funding priority, AMR in children is a crisis, very rare systematic Indian pediatric AMS data.

Bridge Topic 8: Pharmacist Role in Pediatric Chronic Disease Management

PhaseWhat You DoDuration
M. PharmCaregiver knowledge + adherence assessment in pediatric asthma/epilepsy/T1DM using validated toolsYear 1-2
PhD Phase 1Design a structured pharmacist-caregiver education and follow-up programYear 3
PhD Phase 2RCT: pharmacist intervention vs. standard care - disease control, QoL (PedsQL), emergency visitsYear 4-5
PhD Phase 3Develop national pediatric pharmaceutical care modelYear 6

🟣 PSYCHIATRY

Bridge Topic 9: Antipsychotic Polypharmacy - From Audit to Rational Use Program

PhaseWhat You DoDuration
M. PharmPrevalence + pattern of antipsychotic polypharmacy in schizophrenia inpatients + ADR profiling (EPS, metabolic)Year 1-2
PhD Phase 1Prescriber attitudes + justifications for polypharmacy - qualitative + surveyYear 3
PhD Phase 2Pharmacist-led rational prescribing intervention (academic detailing + audit-feedback)Year 4-5
PhD Phase 3Multi-centre study + national rational antipsychotic prescribing guidelines frameworkYear 6
Why powerful: Up to 40-50% of schizophrenia patients receive polypharmacy in India. Clear PhD pathway with national policy impact.

Bridge Topic 10: Medication Adherence in Psychiatric Patients - Barriers to Technology

PhaseWhat You DoDuration
M. PharmAdherence assessment (MARS scale) + barrier analysis in schizophrenia/bipolar/depression OPD patientsYear 1-2
PhD Phase 1Qualitative study - stigma, insight, side effects as adherence barriersYear 3
PhD Phase 2Develop + test a pharmacist-led adherence intervention (counseling + digital reminder + family involvement)Year 4-5
PhD Phase 3RCT across psychiatric centres - adherence, relapse rates, re-hospitalisation, QoLYear 6
Why powerful: Psychiatric non-adherence causes 50% of relapses. Very high social and economic burden. WHO mental health action plan aligned.

Bridge Topic 11: Drug-Induced Metabolic Syndrome in Psychiatric Patients

PhaseWhat You DoDuration
M. PharmPrevalence of drug-induced metabolic syndrome (weight gain, dyslipidemia, hyperglycemia) in patients on antipsychotics/mood stabilizersYear 1-2
PhD Phase 1Risk factor analysis + longitudinal monitoring protocol designYear 3
PhD Phase 2Pharmacist-led metabolic monitoring + lifestyle intervention program in psychiatric OPDYear 4-5
PhD Phase 3Multi-centre study + develop metabolic monitoring guidelines for psychiatric pharmacotherapy in IndiaYear 6
Why powerful: Severely under-researched in India, direct cardiovascular mortality link, clear pharmacist role in monitoring.

Bridge Topic 12: Psychotropic Drug Safety - From Pharmacovigilance to Signal Detection

PhaseWhat You DoDuration
M. PharmProspective ADR monitoring + causality assessment of antidepressants/antipsychotics/mood stabilizersYear 1-2
PhD Phase 1Under-reporting analysis + pharmacist-led active ADR surveillance system designYear 3
PhD Phase 2Implement active surveillance + signal detection from pooled dataYear 4-5
PhD Phase 3Contribute to PvPI psychiatric drug safety database + signal generation methodology paperYear 6

🟢 GENERAL MEDICINE

Bridge Topic 13: Comprehensive Medication Review (CMR) in Multi-Morbid Patients

PhaseWhat You DoDuration
M. PharmDRP identification (PCNE v9.1) + polypharmacy prevalence in general medicine ward inpatientsYear 1-2
PhD Phase 1Develop a structured CMR model for Indian tertiary care hospitalsYear 3
PhD Phase 2Multi-centre RCT: pharmacist CMR vs. standard care - DRPs resolved, readmission, LOS, costYear 4-5
PhD Phase 3Economic evaluation + policy framework for CMR as a standard service in Indian hospitalsYear 6
Why powerful: No validated CMR model exists for India. This PhD creates one. Directly fundable and applicable.

Bridge Topic 14: Antibiotic Stewardship in General Medicine Ward

PhaseWhat You DoDuration
M. PharmAntibiotic audit (DDD/DOT) + culture sensitivity correlation + prescriber KAP in general medicine wardYear 1-2
PhD Phase 1Design hospital-specific AMS guidelines + pharmacist-led stewardship bundleYear 3
PhD Phase 2Pre-post implementation study - antibiotic days, resistance rate, C. diff, LOS, cost savedYear 4-5
PhD Phase 3Multi-centre AMS program + develop an Indian AMS toolkitYear 6

Bridge Topic 15: Medication Reconciliation - From Gap Analysis to System Redesign

PhaseWhat You DoDuration
M. PharmMedication reconciliation at admission + discharge - discrepancy type, frequency, clinical significanceYear 1-2
PhD Phase 1Root cause analysis of discrepancies + patient harm assessmentYear 3
PhD Phase 2Pharmacist-led medication reconciliation program - RCT at multi-centreYear 4-5
PhD Phase 3Develop national medication reconciliation standard operating procedure for Indian hospitalsYear 6

Bridge Topic 16: Real-World Outcomes of Pharmacist Interventions in General Medicine

PhaseWhat You DoDuration
M. PharmProspective observational: type, frequency, acceptance, clinical impact of pharmacist recommendations in medicine wardYear 1-2
PhD Phase 1Economic valuation of pharmacist interventions (cost of DRPs prevented)Year 3
PhD Phase 2Multi-centre study building a pharmacist intervention outcome databaseYear 4-5
PhD Phase 3Develop evidence-based justification for pharmacist posts in Indian hospitals + policy submissionYear 6

MASTER COMPARISON TABLE

#TopicSpecialtyM. Pharm DifficultyPhD FundingNovelty in IndiaPhD DeliverableOverall Score
1QoL + Supportive CareOncology⭐⭐⭐⭐⭐⭐ ICMR NCG⭐⭐⭐Multi-centre RCT🔥🔥🔥
2Chemo Toxicity Prediction ModelOncology⭐⭐⭐⭐⭐⭐ ICMR/DST⭐⭐⭐Validated tool🔥🔥🔥
3Oral Chemo Adherence + mHealthOncology⭐⭐⭐⭐⭐⭐ BIRAC/DST⭐⭐⭐RCT + app🔥🔥🔥
4Cancer Pain - WHO LadderOncology⭐⭐⭐⭐⭐ Institutional⭐⭐Protocol🔥🔥
5Off-label use in NICU/PediatricsPediatrics⭐⭐⭐⭐⭐⭐ ICMR/CDSCO⭐⭐⭐National formulary🔥🔥🔥
6Medication Errors - Pediatric SafetyPediatrics⭐⭐⭐⭐⭐ Institutional⭐⭐Risk scoring tool🔥🔥
7Pediatric AMS ProgramPediatrics⭐⭐⭐⭐⭐⭐ WHO/ICMR⭐⭐⭐AMS toolkit🔥🔥🔥
8Pediatric Chronic Disease PharmacistPediatrics⭐⭐⭐⭐⭐ Institutional⭐⭐Care model🔥🔥
9Antipsychotic PolypharmacyPsychiatry⭐⭐⭐⭐⭐ Institutional⭐⭐⭐Prescribing guidelines🔥🔥🔥
10Psychiatric Adherence + DigitalPsychiatry⭐⭐⭐⭐⭐⭐ DST/WHO⭐⭐RCT🔥🔥🔥
11Drug-Induced Metabolic SyndromePsychiatry⭐⭐⭐⭐⭐⭐ ICMR⭐⭐⭐Monitoring guidelines🔥🔥🔥
12Psychotropic Drug PV + SignalsPsychiatry⭐⭐⭐⭐⭐⭐ PvPI/CDSCO⭐⭐Signal detection🔥🔥
13CMR in Multi-morbid PatientsGen Medicine⭐⭐⭐⭐⭐⭐ ICMR⭐⭐⭐CMR model🔥🔥🔥
14AMS in General MedicineGen Medicine⭐⭐⭐⭐⭐⭐ WHO/ICMR⭐⭐AMS toolkit🔥🔥🔥
15Medication Reconciliation SystemGen Medicine⭐⭐⭐⭐⭐ Institutional⭐⭐National SOP🔥🔥
16Pharmacist Intervention OutcomesGen Medicine⭐⭐⭐⭐⭐ Institutional⭐⭐⭐Policy framework🔥🔥🔥

🎯 FINAL RECOMMENDATION - Best 4 (one per specialty)

SpecialtyBest Bridge TopicWhy
OncologyChemo Toxicity Prediction ModelNo Indian tool exists, ICMR fundable, high-impact journals, clear PhD deliverable
PediatricsOff-label Drug Use → National Dosing GuidelinesNational policy gap, CDSCO collaboration possible, landmark PhD
PsychiatryDrug-Induced Metabolic Syndrome in Psychiatric PatientsSeverely under-researched in India, dual cardiology-psychiatry link, ICMR fundable
Gen MedicineCMR in Multi-morbid/Polypharmacy PatientsUniversal applicability, no Indian CMR model, strongest PhD foundation

Would you like me to now create a detailed 6-year research roadmap Excel file with year-by-year milestones, publication targets, and funding timelines for any of these 4 topics?

comparative or cohort studies?

Great choice! Comparative and cohort studies sit perfectly at the M. Pharm → PhD bridge — strong enough for a postgraduate dissertation, yet scalable into a full longitudinal PhD. Here's a complete breakdown:

STUDY DESIGN PRIMER FIRST

DesignWhat It MeansBest For
Comparative StudyCompares 2+ groups (drug A vs B, intervention vs control, before vs after) at one point or over timeTreatment outcomes, prescribing differences, protocol comparisons
Prospective CohortFollow a group forward in time, observe outcomesAdherence → outcomes, toxicity prediction, disease progression
Retrospective CohortUse existing records to trace outcomes backwardDrug safety, ADR patterns, survival analysis
Historical CohortCompare current cohort to a past cohortPre-post AMS/intervention programs
Key advantage for you: Cohort + comparative studies use your same patient sample for M. Pharm - then you extend follow-up for PhD. No need to restart recruitment.

🔴 ONCOLOGY — Comparative & Cohort Topics


1. Prospective Cohort: Chemotherapy Toxicity Outcomes by Regimen

M. Pharm version: Enroll chemo patients → grade toxicities (CTCAE) at each cycle → document outcomes at 6 months
PhD scale-up:
  • Extend follow-up to 2-3 years
  • Compare toxicity profiles across regimens (e.g. FOLFOX vs FOLFIRI in colorectal cancer)
  • Build toxicity prediction model using baseline clinical variables
  • Multi-centre validation
Data collected ONCE, used for both degrees.

2. Comparative Study: Generic vs. Innovator Chemotherapy — Safety & Efficacy

Design: Retrospective cohort — patients on generic chemo vs. branded chemo (same regimen), compare:
  • ADR incidence and severity
  • Treatment completion rate
  • Dose modifications / delays
  • Cost per cycle
M. Pharm: Single hospital, 6-month data, descriptive + comparative analysis
PhD: Multi-centre, longer follow-up, survival outcomes (PFS/OS), pharmacoeconomic model

3. Cohort Study: Oral Chemotherapy Adherence → Clinical Outcomes

Design: Prospective cohort — enroll oral chemo patients (capecitabine/imatinib/tamoxifen), measure adherence at 1, 3, 6 months, track:
  • Dose intensity received
  • Disease response (tumour markers, imaging)
  • Toxicity
  • Quality of life (EORTC QLQ-C30)
M. Pharm: 6-month cohort, adherence + QoL analysis
PhD: Extend to 24-month cohort, build adherence → outcome predictive model, then RCT arm

4. Comparative Study: CINV Management — Two Antiemetic Protocols

Design: Prospective comparative — patients on protocol A (ondansetron + dexamethasone) vs. protocol B (aprepitant + ondansetron + dexamethasone), compare:
  • CINV control rate (FLIE questionnaire)
  • Breakthrough emesis frequency
  • QoL impact
  • Cost-effectiveness
Perfect for M. Pharm — clear comparison, short timeline, validated tools available.

5. Retrospective Cohort: Cancer Pain Treatment Patterns → Outcome Differences

Design: Retrospective cohort — patients on WHO Step 1 vs. Step 2 vs. Step 3 analgesia, compare:
  • Pain control adequacy (NRS scores)
  • Rescue medication use
  • QoL
  • Opioid-related ADRs

🟡 PEDIATRICS — Comparative & Cohort Topics


6. Prospective Cohort: Off-Label Drug Use → Safety Outcomes in NICU

Design: Prospective cohort — NICU neonates receiving ≥1 off-label drug followed for:
  • ADR incidence (categorised by off-label type)
  • Dosing adequacy vs. outcomes
  • Length of NICU stay
  • Mortality
M. Pharm: 6-month NICU cohort, off-label prevalence + ADR documentation
PhD: Extended 2-year cohort, multi-centre, develop evidence-based dosing recommendations

7. Comparative Study: Antibiotic Protocols in Pediatric Sepsis — Two Regimens

Design: Retrospective/prospective comparative:
  • Group A: Standard empirical antibiotic (e.g. cefotaxime + amikacin)
  • Group B: Culture-guided antibiotic therapy
Compare:
  • Time to clinical improvement
  • Length of stay
  • Antibiotic duration
  • Resistance patterns
  • Cost

8. Prospective Cohort: Medication Errors in Pediatric Ward — Longitudinal Tracking

Design: Prospective cohort — all prescriptions over 6 months tracked for errors:
  • Baseline error rate documented (M. Pharm)
  • Pharmacist intervention introduced
  • Post-intervention error rate tracked (PhD phase)
  • Interrupted time series analysis

9. Comparative Study: Two Inhaler Devices in Pediatric Asthma

Design: Prospective comparative — children on MDI + spacer vs. DPI:
  • Technique adequacy score
  • Asthma control (ACT/C-ACT)
  • Exacerbation frequency
  • Adherence (parent-reported)
  • QoL (PedsQL)

10. Retrospective Cohort: Antibiotic Exposure in Neonates → Resistance Outcomes

Design: Retrospective — NICU neonates grouped by early antibiotic exposure (none / narrow spectrum / broad spectrum), tracked for:
  • Resistance acquisition
  • Infection outcomes
  • Mortality

🟣 PSYCHIATRY — Comparative & Cohort Topics


11. Prospective Cohort: Antipsychotic Therapy → Metabolic Outcomes Over Time

Design: Prospective cohort — newly initiated antipsychotic patients followed at 0, 3, 6, 12 months:
  • Weight, BMI, waist circumference
  • Fasting glucose, HbA1c
  • Lipid profile
  • Blood pressure
  • Incidence of metabolic syndrome (IDF criteria)
M. Pharm: 6-month cohort — baseline to 6 months, metabolic parameter changes
PhD: Extend to 24 months, compare between antipsychotic classes (typical vs. atypical, or individual drugs), develop metabolic monitoring algorithm

12. Comparative Study: Typical vs. Atypical Antipsychotics — ADR Profile

Design: Prospective comparative:
  • Group A: Typical (haloperidol, trifluoperazine)
  • Group B: Atypical (olanzapine, risperidone, quetiapine)
Compare:
  • EPS incidence and severity (AIMS/SAS/BARS scales)
  • Metabolic side effects
  • Sedation scores
  • QoL (SF-36 / WHOQOL-BREF)
  • Treatment discontinuation rates
Highly publishable, clear design, validated tools.

13. Prospective Cohort: Medication Adherence → Relapse and Re-hospitalisation

Design: Prospective cohort — schizophrenia/bipolar patients followed for 12 months:
  • Adherence measured at each OPD visit (MARS scale + pill count)
  • Correlated with:
    • Relapse episodes
    • Emergency visits
    • Re-hospitalisation
    • Social functioning (GAF scale)
M. Pharm: 6-month cohort with adherence + baseline outcomes
PhD: 24-month cohort, pharmacist intervention arm added, predictive model for relapse risk

14. Comparative Study: Depot (LAI) vs. Oral Antipsychotics — Adherence & Outcomes

Design: Retrospective/prospective comparative:
  • Group A: Long-acting injectable (LAI) antipsychotics
  • Group B: Oral antipsychotics
Compare:
  • Adherence rates
  • Relapse and rehospitalisation
  • ADR profiles
  • Patient satisfaction
  • Cost
Very relevant to Indian psychiatric practice — LAI underused, this generates policy-relevant evidence.

15. Prospective Cohort: Drug-Induced Movement Disorders — Incidence & Risk Factors

Design: Prospective cohort — antipsychotic-naive patients initiated on treatment, followed:
  • EPS assessment at 1, 3, 6 months (AIMS, SAS, BARS)
  • Identify risk factors (drug, dose, age, sex, genetics)
  • Time to onset
  • Pharmacist ADR reporting contribution

🟢 GENERAL MEDICINE — Comparative & Cohort Topics


16. Prospective Cohort: Polypharmacy → Adverse Outcomes in General Medicine Inpatients

Design: Prospective cohort — patients admitted to general medicine ward grouped by medication burden:
  • Group 1: < 5 drugs
  • Group 2: 5-9 drugs
  • Group 3: ≥ 10 drugs
Track:
  • ADR incidence
  • Drug-drug interactions
  • Length of stay
  • 30-day readmission
  • Mortality
M. Pharm: 6-month cohort, single hospital, descriptive + comparative
PhD: Multi-centre, 2-year follow-up, pharmacist CMR intervention arm, build polypharmacy harm prediction score

17. Comparative Study: Pharmacist-Led vs. Standard Medication Reconciliation

Design: Prospective comparative (or quasi-experimental):
  • Group A: Pharmacist-led medication reconciliation at admission + discharge
  • Group B: Standard nursing/physician reconciliation
Compare:
  • Unintended discrepancies per patient
  • Clinically significant discrepancies
  • ADR-related readmissions at 30 days
  • Time to reconciliation

18. Prospective Cohort: Antibiotic Therapy Outcomes — Empirical vs. Culture-Guided

Design: Prospective cohort — general medicine patients with infection grouped:
  • Group A: Empirical antibiotic only
  • Group B: Culture-guided antibiotic therapy
Compare:
  • Clinical cure rate
  • Time to defervescence
  • Antibiotic duration
  • Resistance acquisition
  • Cost

19. Comparative Study: Two Anticoagulation Protocols in AF/VTE Patients

Design: Prospective comparative:
  • Group A: Warfarin (standard monitoring)
  • Group B: DOAC (apixaban/rivaroxaban)
Compare:
  • Bleeding events
  • Thromboembolic events
  • INR control (TTR for warfarin group)
  • Adherence
  • Patient QoL
  • Cost

20. Retrospective Cohort: Drug-Related Hospital Readmissions

Design: Retrospective cohort — general medicine readmissions within 30/90 days, classify:
  • Drug-related vs. non-drug-related
  • Type of DRP causing readmission (ADR, non-adherence, under-treatment, DDI)
  • Associated drugs, patient factors, preventability
M. Pharm: Retrospective 1-year data, single hospital, classification + risk factor analysis
PhD: Multi-centre, develop predictive model for drug-related readmission risk, pharmacist intervention to prevent

MASTER COMPARISON TABLE

#TopicSpecialtyDesignM. Pharm FeasibilityPhD ScalabilityIndian Data GapFunding Potential
1Chemo Toxicity Cohort by RegimenOncologyProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐ICMR/NCG
2Generic vs. Innovator ChemoOncologyRetrospective Comparative⭐⭐⭐⭐⭐⭐⭐⭐⭐DST/Institutional
3Oral Chemo Adherence → OutcomesOncologyProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐BIRAC/DST
4CINV Protocol ComparisonOncologyProspective Comparative⭐⭐⭐⭐⭐⭐⭐Institutional
5Cancer Pain Cohort by WHO StepOncologyRetrospective Cohort⭐⭐⭐⭐⭐⭐⭐Institutional
6Off-label NICU Cohort → SafetyPediatricsProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐ICMR/CDSCO
7Antibiotic Protocols in Pediatric SepsisPediatricsComparative⭐⭐⭐⭐⭐⭐⭐⭐ICMR/WHO
8Medication Errors Cohort (Interrupted TS)PediatricsProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐Institutional
9Inhaler Devices in Pediatric AsthmaPediatricsProspective Comparative⭐⭐⭐⭐⭐⭐⭐Institutional
10Antibiotic Exposure → NICU ResistancePediatricsRetrospective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐ICMR/WHO
11Antipsychotic → Metabolic CohortPsychiatryProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐ICMR/DST
12Typical vs. Atypical Antipsychotic ADRsPsychiatryProspective Comparative⭐⭐⭐⭐⭐⭐⭐⭐Institutional
13Adherence → Relapse CohortPsychiatryProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐WHO/NIMHANS
14LAI vs. Oral AntipsychoticsPsychiatryComparative⭐⭐⭐⭐⭐⭐⭐⭐⭐Institutional/DST
15Drug-Induced Movement Disorders CohortPsychiatryProspective Cohort⭐⭐⭐⭐⭐⭐⭐Institutional
16Polypharmacy → Adverse Outcomes CohortGen MedicineProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐ICMR
17Pharmacist vs. Standard ReconciliationGen MedicineProspective Comparative⭐⭐⭐⭐⭐⭐⭐⭐⭐Institutional/ICMR
18Empirical vs. Culture-Guided AntibioticsGen MedicineProspective Cohort⭐⭐⭐⭐⭐⭐⭐⭐ICMR/WHO
19Warfarin vs. DOAC ComparisonGen MedicineProspective Comparative⭐⭐⭐⭐⭐⭐⭐⭐Institutional
20Drug-Related Readmission CohortGen MedicineRetrospective Cohort⭐⭐⭐⭐⭐⭐⭐⭐⭐ICMR/Institutional

🎯 TOP PICK PER SPECIALTY

SpecialtyBest Comparative/Cohort TopicWhy
OncologyOral Chemo Adherence → Clinical Outcomes (Prospective Cohort)Same patients tracked M. Pharm → PhD, survival data makes it high-impact
PediatricsOff-label NICU Drug Use → Safety Outcomes CohortNational policy gap, CDSCO interest, unique PhD deliverable
PsychiatryAntipsychotic Metabolic Syndrome Cohort (0→12 months)Easy to start in M. Pharm, extend for PhD, huge Indian data gap
Gen MedicinePolypharmacy → Adverse Outcomes CohortUniversal applicability, same data scales to multi-centre PhD, ICMR fundable

Would you like me to:
  1. Draft a full study protocol (aims, objectives, methodology, sample size, tools, statistical analysis) for any specific topic?
  2. Create an Excel roadmap with M. Pharm → PhD milestones and publication plan?
  3. Generate a research proposal template ready to submit to your guide/institution?

can you tell more ideas include drug comparison also

Here is an expanded list with drug comparison studies added across all 4 specialties — covering efficacy, safety, adherence, cost, and outcomes:

DRUG COMPARISON STUDY TYPES (Quick Reference)

TypeExampleWhat You Compare
Head-to-head drug comparisonDrug A vs. Drug B (same indication)Efficacy, ADRs, cost
Class comparisonTypical vs. atypical antipsychoticsSafety profiles, outcomes
Route comparisonIV vs. oral, depot vs. oralAdherence, outcomes, cost
Regimen comparisonMonotherapy vs. combinationResponse, toxicity
Generic vs. innovatorGeneric imatinib vs. GleevecEfficacy equivalence, ADRs
Guideline vs. non-guidelineStandard protocol vs. empiricalOutcomes, resistance
Pre-post drug changeBefore and after formulary switchSafety signal, cost impact

🔴 ONCOLOGY — Drug Comparison + Cohort Topics


1. Capecitabine vs. IV 5-Fluorouracil in Colorectal/Breast Cancer

Comparison: Oral capecitabine vs. IV 5-FU based regimens
What you measure:
  • Toxicity profile (CTCAE) — hand-foot syndrome, mucositis, neutropenia, GI effects
  • Treatment completion rate and dose modifications
  • Adherence to oral capecitabine (MMAS + pill diary)
  • QoL (EORTC QLQ-C30)
  • Direct drug cost + administration cost
Design: Prospective comparative cohort M. Pharm: 6-month single centre PhD: Multi-centre + survival outcomes (PFS/OS) + pharmacoeconomic model

2. Carboplatin vs. Cisplatin-Based Regimens — Toxicity & Efficacy Comparison

Comparison: Cisplatin vs. carboplatin (in lung/ovarian/head-neck cancer)
What you measure:
  • Nephrotoxicity (serum creatinine, eGFR trends)
  • Neurotoxicity (CIPN grading)
  • Emetogenicity (CINV control rate)
  • Hematological toxicity (CBC trends)
  • Dose delay/reduction frequency
  • Overall response rate (imaging reports)
Design: Retrospective/prospective cohort with comparative arm PhD angle: Build nephrotoxicity prediction model, pharmacist monitoring protocol

3. Branded vs. Generic Imatinib in CML — Safety & Response Cohort

Comparison: Innovator imatinib (Gleevec) vs. generic imatinib (Veenat/Mitinab)
What you measure:
  • Hematological response rate (CBC)
  • Molecular response (BCR-ABL PCR if available)
  • ADR profile (edema, GI, fatigue, cytopenias)
  • Adherence (MMAS-8 + refill records)
  • Cost per patient per year
  • Treatment discontinuation rate
Design: Retrospective cohort (existing records, no lab needed) Very feasible for M. Pharm — just chart review + pharmacy data

4. Ondansetron vs. Ondansetron + Aprepitant in CINV Prevention

Comparison: 2-drug antiemetic protocol vs. 3-drug NK1 antagonist protocol
What you measure:
  • Complete response rate (no emesis + no rescue) — acute and delayed phase
  • FLIE questionnaire scores (QoL impact)
  • Rescue medication use
  • ADR (constipation, hiccups, headache)
  • Cost per cycle
Design: Prospective comparative (highly controlled, short timeline) Perfect M. Pharm topic — 3 chemo cycles = enough data

5. Morphine vs. Tramadol vs. Fentanyl Patch in Cancer Pain (WHO Step 2-3)

Comparison: Three opioid analgesics in cancer pain management
What you measure:
  • Pain control adequacy (NRS scores at baseline, 1 week, 1 month)
  • Rescue analgesic frequency
  • ADR profile (constipation, nausea, sedation, respiratory depression)
  • Patient satisfaction
  • Dose escalation frequency
  • Cost
Design: Prospective cohort with comparative arms M. Pharm: 3-month follow-up PhD: 12-month + QoL + opioid rotation patterns

6. Cohort: First-Line vs. Second-Line Chemotherapy Outcomes in Advanced Cancer

Design: Retrospective cohort comparing clinical outcomes between patients who completed first-line vs. received second-line therapy:
  • Response rates
  • Time to progression
  • Toxicity burden
  • QoL at each line
  • Cost per line
PhD angle: Health economic model — value of first-line treatment optimization

7. LHRH Agonist vs. Orchiectomy in Prostate Cancer — Drug vs. Surgical Hormonal Therapy

Comparison: Medical castration (leuprolide/goserelin) vs. surgical castration
What you measure:
  • PSA response and nadir
  • ADR (hot flushes, bone density, sexual function)
  • Adherence to injection schedule
  • QoL (EPIC/SF-36)
  • Cost-effectiveness

8. Dexamethasone vs. Methylprednisolone as Steroid Support During Chemotherapy

Comparison: Two corticosteroid regimens used in chemo supportive care
What you measure:
  • Antiemetic efficacy
  • Hyperglycemia incidence (drug-induced)
  • Mood/sleep disturbance
  • Dose used vs. protocol recommendation
  • Cost

🟡 PEDIATRICS — Drug Comparison + Cohort Topics


9. Paracetamol vs. Ibuprofen vs. Combination in Pediatric Fever Management

Comparison: Three antipyretic strategies in children aged 1-12 years
What you measure:
  • Time to fever resolution (30 min, 1h, 2h, 4h post-dose)
  • Recurrence at 4 and 6 hours
  • ADR (GI upset, liver concern, renal concern)
  • Parent satisfaction
  • Cost per episode
  • Appropriate dose used (weight-based check)
Design: Prospective comparative M. Pharm: Very feasible — pediatric OPD/emergency PhD: Large cohort + subgroup analysis by age/weight + dosing accuracy audit

10. Amoxicillin vs. Amoxicillin-Clavulanate in Pediatric RTI/AOM

Comparison: First-line vs. broader antibiotic in pediatric respiratory/ear infections
What you measure:
  • Clinical cure at day 5 and day 10
  • Treatment failure rate
  • ADR (diarrhea, rash, GI upset)
  • Antibiotic duration
  • Resistance rate in recurrent cases
  • Cost
  • Appropriateness (culture-guided vs. empirical)
Design: Prospective comparative + retrospective cohort PhD angle: Antibiotic stewardship — when is broader spectrum justified in pediatrics?

11. IV vs. Oral Antibiotic Switch in Pediatric Inpatients (IV-to-Oral Stewardship)

Comparison: Standard IV antibiotic continued vs. early IV-to-oral switch
What you measure:
  • Clinical outcomes (cure rate, relapse)
  • Length of hospital stay
  • IV line complications (phlebitis, infection)
  • Cost
  • Time to switch after eligibility criteria met
Design: Prospective comparative/cohort PhD: Multi-centre IV-to-oral switch protocol development

12. Nebulized Salbutamol vs. MDI + Spacer in Pediatric Asthma Attack

Comparison: Delivery device comparison in acute asthma
What you measure:
  • PEFR improvement at 20 min, 60 min
  • Oxygen saturation trends
  • Admission rate
  • Number of doses needed
  • ADR (tremor, tachycardia)
  • Cost per episode
Design: Prospective comparative (Emergency/ward setting) Very publishable — device effectiveness in resource-limited settings

13. Oral Rehydration Salts (ORS) vs. IV Fluids in Mild-Moderate Pediatric Dehydration

Comparison: WHO-ORS alone vs. IV fluid initiation in mild-moderate dehydration
What you measure:
  • Time to rehydration (clinical signs)
  • Treatment failure rate needing escalation
  • Length of stay
  • Vomiting/diarrhea duration
  • Cost
  • Antibiotic co-prescription rate (rationality)

14. Intranasal vs. IV Midazolam for Pediatric Seizure — Route Comparison

Comparison: Route of benzodiazepine administration in acute pediatric seizures
What you measure:
  • Time to seizure cessation
  • Success rate (first dose)
  • Respiratory depression incidence
  • Time to administer (practical)
  • Cost

15. Prospective Cohort: Neonatal Antibiotic Exposure → Long-term Microbiome/Resistance Outcomes

Design: Prospective cohort — NICU neonates grouped by antibiotic exposure:
  • Group 1: No antibiotics
  • Group 2: Narrow-spectrum
  • Group 3: Broad-spectrum
Tracked at discharge, 3 months, 6 months for:
  • Nosocomial infection rates
  • Resistance patterns in subsequent cultures
  • Re-admission rates
PhD: Microbiome analysis (16S rRNA) + resistance gene tracking

🟣 PSYCHIATRY — Drug Comparison + Cohort Topics


16. Olanzapine vs. Risperidone vs. Quetiapine — Metabolic and Clinical Outcomes Cohort

Comparison: Three most commonly used atypical antipsychotics
What you measure (at 0, 3, 6, 12 months):
  • Metabolic parameters (weight, BMI, fasting glucose, lipids, BP)
  • Metabolic syndrome incidence (IDF criteria)
  • Psychiatric outcome (PANSS score)
  • EPS incidence (AIMS, SAS)
  • QoL (WHOQOL-BREF)
  • Adherence (MARS)
  • Cost per month
Design: Prospective comparative cohort M. Pharm: 6-month cohort baseline to mid-follow-up PhD: 24-month cohort, multi-centre, develop drug-specific metabolic monitoring algorithm

17. Haloperidol vs. Olanzapine in Acute Psychosis — Rapid Tranquilization Comparison

Comparison: Typical vs. atypical antipsychotic for acute agitation/psychosis
What you measure:
  • Time to sedation (ACES scale)
  • EPS incidence (acute dystonia, akathisia)
  • Respiratory depression monitoring
  • Restraint use reduction
  • Staff satisfaction
  • Cost per acute episode
Design: Retrospective/prospective comparative

18. Lithium vs. Valproate vs. Lamotrigine in Bipolar Disorder — Maintenance Comparison

Comparison: Three mood stabilizers in bipolar maintenance
What you measure:
  • Relapse rate (manic + depressive episodes)
  • Time to first relapse (survival analysis)
  • ADR profile (tremor, weight gain, teratogenicity concerns, thyroid/renal for lithium)
  • TDM adequacy (lithium levels)
  • Adherence (MARS + pill count)
  • QoL (SF-36)
  • Cost
Design: Retrospective cohort (3-year records) + prospective extension PhD angle: Pharmacist TDM monitoring program + relapse prediction model

19. SSRIs vs. SNRIs in Depression — Comparative Response and ADR Cohort

Comparison: SSRI group (fluoxetine/sertraline/escitalopram) vs. SNRI (venlafaxine/duloxetine)
What you measure:
  • Treatment response (PHQ-9 / HAM-D scores at 4, 8, 12 weeks)
  • Remission rates
  • ADR profile (sexual dysfunction, GI, insomnia, hypertension for SNRIs)
  • Discontinuation rate and reasons
  • Switching/augmentation frequency
  • QoL (EQ-5D)
  • Cost
Design: Prospective cohort with comparative analysis Very feasible — large OPD population, validated scales available

20. Depot (LAI) Antipsychotics vs. Oral Antipsychotics — 12-Month Outcomes Cohort

Comparison: Long-acting injectables vs. oral antipsychotics in schizophrenia
What you measure:
  • Adherence (objective — LAI attendance vs. MARS for oral)
  • Relapse and hospitalization rates
  • PANSS score trajectory
  • ADR profile
  • Patient and caregiver satisfaction
  • Cost (drug + nurse time + hospitalization)
Design: Prospective comparative cohort PhD: Multi-centre, pharmacist counseling arm for oral group, economic model

21. Clozapine vs. Other Antipsychotics in Treatment-Resistant Schizophrenia

Comparison: Clozapine vs. high-dose conventional antipsychotics
What you measure:
  • Treatment response (PANSS at 3, 6, 12 months)
  • Agranulocytosis and metabolic monitoring adequacy
  • Pharmacist monitoring protocol adherence
  • Hospitalisation frequency
  • Cost of monitoring vs. cost of relapse

22. Benzodiazepines vs. Non-BZD Hypnotics in Insomnia (Psychiatric Patients)

Comparison: BZD (diazepam/lorazepam) vs. Z-drugs (zolpidem/zopiclone) vs. melatonin
What you measure:
  • Sleep quality (Pittsburgh Sleep Quality Index)
  • Dependency/tolerance development
  • Next-day sedation and fall risk
  • Duration of use (overuse audit)
  • Deprescribing success rate
  • Cost

🟢 GENERAL MEDICINE — Drug Comparison + Cohort Topics


23. ACE Inhibitor vs. ARB vs. CCB in Hypertension — BP Control and ADR Comparison

Comparison: Three first-line antihypertensive classes
What you measure:
  • BP control at 1, 3, 6 months (target < 130/80)
  • ADR profile (cough with ACEi, ankle edema with CCB, hyperkalemia)
  • Adherence (MMAS-8)
  • Combination therapy escalation rate
  • Renal function trend (creatinine, eGFR)
  • Cost per month
Design: Prospective cohort with comparative arms Perfect M. Pharm topic — huge OPD population, fast recruitment

24. Metformin vs. SGLT2 Inhibitor vs. GLP-1 Agonist in T2DM — Outcomes Cohort

Comparison: Three major antidiabetic drug classes (or metformin alone vs. metformin + add-on)
What you measure:
  • HbA1c reduction at 3, 6, 12 months
  • Weight change
  • Cardiovascular events (BP, lipids)
  • ADR profile (GI for metformin, UTI/DKA for SGLT2, GI for GLP-1)
  • Adherence
  • Cost per month
PhD: Multi-centre cohort + cardiovascular outcome analysis + pharmacoeconomic model

25. Warfarin vs. DOAC (Apixaban/Rivaroxaban) in AF/VTE Patients

Comparison: Traditional anticoagulant vs. direct oral anticoagulants
What you measure:
  • Bleeding events (major + minor, ISTH criteria)
  • Thromboembolic events
  • TTR for warfarin group
  • INR variability
  • Adherence
  • QoL
  • Cost (drug + monitoring + events)
Design: Prospective comparative cohort PhD: Pharmacist-led anticoagulation clinic RCT + economic model

26. Empirical vs. Culture-Guided Antibiotic Therapy in CAP/UTI/Sepsis

Comparison: Antibiotic started empirically vs. de-escalated after culture sensitivity
What you measure:
  • Clinical cure rate
  • Time to defervescence
  • Length of stay
  • Antibiotic duration
  • Resistance emergence
  • 30-day mortality
  • Cost
PhD: AMS implementation study using this baseline data

27. IV Iron vs. Oral Iron in Iron Deficiency Anemia

Comparison: IV iron sucrose/ferric carboxymaltose vs. oral ferrous sulfate/fumarate
What you measure:
  • Hemoglobin rise at 4, 8, 12 weeks
  • Ferritin and TSAT normalization
  • ADR (GI intolerance for oral, hypersensitivity for IV)
  • Treatment completion rate
  • Adherence to oral iron (patient-reported)
  • Cost-effectiveness
Very feasible — huge patient pool in general medicine, gynecology, nephrology

28. Proton Pump Inhibitor vs. H2 Receptor Antagonist in GI Prophylaxis

Comparison: Overuse audit + comparative outcomes in hospitalized patients
What you measure:
  • Appropriate indication use (SUP criteria)
  • CDAD (C. difficile) incidence comparison
  • Community-acquired pneumonia risk
  • Symptom control
  • Cost per inpatient day
Design: Retrospective comparative cohort Great M. Pharm — pure records review, no patient contact needed

29. Statin Comparison: Atorvastatin vs. Rosuvastatin in Dyslipidemia/CVD Patients

Comparison: Two most prescribed statins
What you measure:
  • LDL-C reduction at 3, 6, 12 months
  • Goal attainment rate (< 70 mg/dL in high-risk)
  • Statin-induced myopathy (CK levels, MARS symptoms)
  • Hepatotoxicity (LFT trends)
  • Adherence
  • Cost per mg LDL-C reduced

30. NSAIDs vs. Paracetamol vs. Combination in Acute/Chronic Pain (General Medicine)

Comparison: Three analgesic strategies
What you measure:
  • Pain NRS score at 30 min, 2h, 24h
  • Rescue analgesic use
  • ADR (GI, renal, hepatic)
  • Gastroprotection co-prescription rate
  • Patient satisfaction
  • Cost

MASTER TABLE — ALL 30 DRUG COMPARISON + COHORT TOPICS

#TopicSpecialtyDesignDrug/Intervention ComparedM. Pharm FeasibilityPhD ScalabilityOverall
1Capecitabine vs. IV 5-FUOncologyProspective Comparative CohortOral vs. IV chemo⭐⭐⭐⭐⭐⭐🔥🔥🔥
2Carboplatin vs. CisplatinOncologyRetrospective/Prospective CohortTwo platinum agents⭐⭐⭐⭐⭐⭐🔥🔥🔥
3Branded vs. Generic ImatinibOncologyRetrospective CohortGeneric vs. Innovator⭐⭐⭐⭐⭐⭐🔥🔥🔥
4Ondansetron vs. + AprepitantOncologyProspective Comparative2-drug vs. 3-drug antiemetic⭐⭐⭐⭐⭐🔥🔥
5Morphine vs. Tramadol vs. FentanylOncologyProspective Cohort3 opioid analgesics⭐⭐⭐⭐⭐⭐🔥🔥🔥
6First vs. Second-line Chemo OutcomesOncologyRetrospective CohortLine of therapy⭐⭐⭐⭐⭐⭐🔥🔥
7LHRH Agonist vs. OrchiectomyOncologyProspective ComparativeDrug vs. surgery⭐⭐⭐⭐⭐🔥🔥
8Dexamethasone vs. MethylprednisoloneOncologyProspective ComparativeTwo steroid protocols⭐⭐⭐⭐⭐🔥🔥
9Paracetamol vs. Ibuprofen vs. ComboPediatricsProspective Comparative3 antipyretic strategies⭐⭐⭐⭐⭐⭐🔥🔥🔥
10Amoxicillin vs. Amox-ClavulanatePediatricsProspective ComparativeAntibiotic breadth⭐⭐⭐⭐⭐⭐🔥🔥🔥
11IV vs. Oral Antibiotic SwitchPediatricsProspective CohortRoute comparison⭐⭐⭐⭐⭐⭐🔥🔥🔥
12Nebulized Salbutamol vs. MDI+SpacerPediatricsProspective ComparativeDevice comparison⭐⭐⭐⭐⭐🔥🔥
13ORS vs. IV Fluids in DehydrationPediatricsProspective ComparativeRoute/formulation⭐⭐⭐⭐⭐🔥🔥
14Intranasal vs. IV MidazolamPediatricsProspective ComparativeRoute comparison⭐⭐⭐⭐⭐🔥🔥
15Neonatal Antibiotic → Resistance CohortPediatricsProspective CohortAntibiotic spectrum groups⭐⭐⭐⭐⭐⭐🔥🔥🔥
16Olanzapine vs. Risperidone vs. QuetiapinePsychiatryProspective Comparative Cohort3 atypical antipsychotics⭐⭐⭐⭐⭐⭐🔥🔥🔥
17Haloperidol vs. Olanzapine (acute)PsychiatryRetrospective/ProspectiveTypical vs. atypical⭐⭐⭐⭐⭐🔥🔥
18Lithium vs. Valproate vs. LamotriginePsychiatryRetrospective Cohort3 mood stabilizers⭐⭐⭐⭐⭐⭐🔥🔥🔥
19SSRIs vs. SNRIs in DepressionPsychiatryProspective CohortDrug class comparison⭐⭐⭐⭐⭐⭐🔥🔥🔥
20LAI vs. Oral AntipsychoticsPsychiatryProspective Comparative CohortRoute comparison⭐⭐⭐⭐⭐⭐🔥🔥🔥
21Clozapine vs. Other in TRSPsychiatryRetrospective CohortDrug comparison⭐⭐⭐⭐⭐🔥🔥
22BZD vs. Z-drug vs. Melatonin (insomnia)PsychiatryRetrospective/Prospective3 hypnotic classes⭐⭐⭐⭐⭐⭐🔥🔥🔥
23ACEi vs. ARB vs. CCB in HTNGen MedicineProspective Comparative Cohort3 antihypertensive classes⭐⭐⭐⭐⭐⭐🔥🔥🔥
24Metformin vs. SGLT2 vs. GLP-1 in T2DMGen MedicineProspective Cohort3 antidiabetic classes⭐⭐⭐⭐⭐⭐🔥🔥🔥
25Warfarin vs. DOAC in AF/VTEGen MedicineProspective Comparative Cohort2 anticoagulant classes⭐⭐⭐⭐⭐⭐🔥🔥🔥
26Empirical vs. Culture-Guided AntibioticsGen MedicineProspective CohortPrescribing strategy⭐⭐⭐⭐⭐⭐🔥🔥🔥
27IV vs. Oral Iron in IDAGen MedicineProspective ComparativeRoute comparison⭐⭐⭐⭐⭐⭐🔥🔥🔥
28PPI vs. H2RA in GI ProphylaxisGen MedicineRetrospective ComparativeDrug class comparison⭐⭐⭐⭐⭐🔥🔥
29Atorvastatin vs. RosuvastatinGen MedicineProspective CohortTwo statins⭐⭐⭐⭐⭐⭐🔥🔥🔥
30NSAIDs vs. Paracetamol vs. ComboGen MedicineProspective Comparative3 analgesic strategies⭐⭐⭐⭐⭐🔥🔥

🎯 ABSOLUTE BEST PICKS — M. Pharm NOW + PhD LATER

RankTopicSpecialtyWhy It's the Best
🥇Olanzapine vs. Risperidone vs. Quetiapine — Metabolic CohortPsychiatry3-drug comparison + cohort + validated tools + huge Indian data gap + ICMR fundable
🥇SSRIs vs. SNRIs — Response + ADR CohortPsychiatryLarge OPD population, PHQ-9/HAM-D scales, 12-week outcomes, very publishable
🥇Capecitabine vs. IV 5-FU — Toxicity CohortOncologyCTCAE grading + QoL + adherence + cost in one study
🥇Branded vs. Generic ImatinibOncologyPure retrospective records — easiest to execute, hot topic, no Indian data
🥇Paracetamol vs. Ibuprofen vs. Combo in Pediatric FeverPediatricsHuge patient pool, fast data collection, immediate clinical relevance
🥇Warfarin vs. DOAC in AF/VTEGen MedicineUniversal applicability, pharmacoeconomic angle strong, easy OPD cohort
🥇Metformin vs. SGLT2 vs. GLP-1 OutcomesGen MedicineTimely (SGLT2/GLP-1 boom), large OPD cohort, multi-year PhD potential

Would you like a full study protocol (title, background, objectives, methodology, sample size formula, data collection tools, statistical analysis plan) for any of these topics? I can draft it ready for submission to your research guide.

in genomics?

Here is a comprehensive breakdown of Genomics/Pharmacogenomics topics across Oncology, Pediatrics, Psychiatry, and General Medicine — with drug comparison, cohort, and comparative study designs that bridge M. Pharm → PhD:

GENOMICS STUDY TYPES — QUICK GUIDE

TypeWhat It MeansExample
Genotype-Phenotype correlationLink a gene variant to a drug response/ADRCYP2C19 poor metabolizer → clopidogrel failure
Pharmacogenomics-guided vs. standard dosingCompare outcomes between genotyped vs. non-genotyped patientsWarfarin: PGx dose vs. fixed dose
Biomarker-driven drug comparisonCompare two drugs based on genomic marker statusEGFR+ vs. EGFR- patients on gefitinib vs. chemo
Population genomicsAllele frequency mapping in an ethnic groupCYP2D6 poor metabolizer prevalence in South Indians
Genomic risk stratification cohortFollow patients grouped by genotype, track outcomesHLA-B*15:02 carriers vs. non-carriers on carbamazepine
Implementation studyHow PGx testing changes prescribing in practicePre-emptive PGx panel effect on drug changes

🔴 ONCOLOGY GENOMICS


1. EGFR Mutation Status → Gefitinib/Erlotinib vs. Standard Chemo in NSCLC

Genomic marker: EGFR exon 19 deletion / exon 21 L858R mutation
Comparison:
  • EGFR-mutant patients: TKI (gefitinib/erlotinib) vs. platinum-based chemo
  • EGFR wild-type: platinum doublet chemotherapy
What you measure:
  • Progression-free survival (PFS)
  • Objective response rate (ORR — imaging)
  • ADR profile (skin rash, diarrhea for TKI vs. hematotoxicity for chemo)
  • QoL (EORTC QLQ-C30 + LC-13)
  • Cost per responder
M. Pharm: Retrospective cohort — EGFR testing records + clinical outcomes (no new lab needed) PhD: Prospective cohort + resistance mutation analysis (T790M) + next-generation TKI comparison

2. KRAS/NRAS Mutation Status → Cetuximab/Bevacizumab Outcomes in Colorectal Cancer

Genomic marker: KRAS/NRAS/BRAF mutation status
Comparison:
  • Wild-type patients: FOLFOX + cetuximab vs. FOLFOX + bevacizumab
  • Mutant patients: chemotherapy-only arms
What you measure:
  • Overall response rate
  • PFS and OS (Kaplan-Meier)
  • ADR comparison between biologics
  • Pharmacist counseling impact on biologic adherence
  • Cost-effectiveness
M. Pharm: Retrospective — existing mutation reports + clinical records PhD: Prospective biomarker tracking + resistance profiling

3. HER2 Status → Trastuzumab-Based vs. Chemotherapy-Only Outcomes in Breast Cancer

Genomic marker: HER2 overexpression/amplification (IHC/FISH)
Comparison:
  • HER2+ group: Trastuzumab + chemo vs. chemo alone
  • HER2- group: Standard chemo
What you measure:
  • Pathological complete response (pCR) in neoadjuvant setting
  • Cardiotoxicity (LVEF monitoring — echocardiography)
  • ADR profile
  • Adherence to trastuzumab infusion schedule
  • Cost per pCR achieved
Highly feasible — HER2 testing is routine at oncology centres, data available in records

4. BRCA1/2 Mutation → PARP Inhibitor vs. Standard Chemotherapy in Ovarian Cancer

Genomic marker: BRCA1/2 germline mutation
Comparison:
  • BRCA-mutant: Olaparib (PARP inhibitor) vs. platinum-based maintenance
  • BRCA wild-type: Platinum maintenance chemotherapy
What you measure:
  • PFS (primary)
  • ADR (fatigue, anemia, nausea for olaparib vs. peripheral neuropathy for platinum)
  • QoL
  • Patient knowledge on genetic testing and implications
  • Cost
PhD: Genetic counseling role of pharmacist + family screening assessment

5. UGT1A1 Genotype → Irinotecan Toxicity Cohort

Genomic marker: UGT1A1*28 polymorphism (TA repeat in promoter)
Comparison:
  • UGT1A1*28/*28 homozygous (poor metabolizer) vs. wild-type patients on irinotecan
What you measure:
  • Severe neutropenia (grade 3-4) incidence
  • Severe diarrhea incidence
  • Dose reduction frequency
  • Treatment delays
  • Dose intensity received
  • Pharmacist dose adjustment recommendations
M. Pharm: If hospital has UGT1A1 testing — prospective; if not — retrospective with available data PhD: Prospective genotyping + development of pharmacist-led irinotecan dose optimization protocol

6. DPYD Genotype → 5-Fluorouracil / Capecitabine Toxicity Comparison

Genomic marker: DPYD2A, DPYD13, c.2846A>T variants
Comparison:
  • DPYD variant carriers vs. wild-type patients on 5-FU/capecitabine
What you measure:
  • Severe toxicity rate (mucositis, diarrhea, neutropenia, hand-foot syndrome)
  • Hospitalisation for toxicity
  • Dose reduction and treatment delay rates
  • Mortality from toxicity
  • Cost of managing toxicity
PhD: Develop DPYD screening protocol before 5-FU initiation + pharmacoeconomic model of pre-emptive screening

7. TPMT/NUDT15 Genotype → Thiopurine Toxicity in Hematological Malignancies

Genomic marker: TPMT *2, *3A, *3C; NUDT15 R139C variant
Comparison:
  • Poor/intermediate metabolizers vs. normal metabolizers on 6-MP/azathioprine
What you measure:
  • Myelosuppression severity (CBC nadir)
  • Dose reduction needed
  • Treatment-related mortality
  • Duration of dose modifications
  • Pharmacist TDM contribution
Most actionable oncology PGx topic — TPMT testing becoming standard of care

8. VEGF Polymorphism → Bevacizumab Response Variation Cohort

Genomic marker: VEGF -2578C/A, -1154G/A polymorphisms
Cohort design: Bevacizumab-treated patients grouped by VEGF genotype
What you measure:
  • Treatment response (ORR)
  • ADR profile (hypertension, proteinuria)
  • PFS
  • Correlate genotype with toxicity severity
PhD: Multi-cancer validation + pharmacist hypertension monitoring protocol for bevacizumab patients

🟡 PEDIATRICS GENOMICS


9. TPMT/NUDT15 Genotype-Guided 6-Mercaptopurine Dosing in Pediatric ALL

Genomic marker: TPMT + NUDT15 (especially important in South/Southeast Asian children)
Comparison:
  • Standard 6-MP dosing vs. genotype-guided reduced dosing
What you measure:
  • Febrile neutropenia incidence
  • Treatment delays and dose reductions
  • Relapse rates
  • Pharmacist role in dose calculation and monitoring
  • Cost of genotyping vs. cost of toxicity management
This is the #1 most actionable pediatric PGx topic — NUDT15 R139C is extremely prevalent in South Asian children, causes severe myelosuppression, and is underscreened in India.

10. CYP2D6 Genotype → Codeine Safety in Pediatric Patients

Genomic marker: CYP2D6 ultra-rapid metabolizer (UM) status
Comparison:
  • CYP2D6 UM children: morphine toxicity risk from codeine
  • Normal metabolizers: standard codeine response
What you measure:
  • Codeine/morphine plasma level correlation (if TDM available)
  • Respiratory depression incidence
  • CNS adverse effects
  • Current codeine prescribing practice audit
  • Pharmacist counseling role on codeine avoidance
Policy angle: FDA banned codeine in children < 12 years — is this followed in India?

11. G6PD Deficiency → Primaquine/Dapsone Hemolysis Risk in Pediatric Malaria/Leprosy

Genomic marker: G6PD enzyme deficiency (X-linked, common in India)
Comparison:
  • G6PD-deficient vs. normal children on primaquine
What you measure:
  • Hemolytic anemia incidence (Hb drop, reticulocyte count)
  • Transfusion requirement
  • Current G6PD screening practice before primaquine prescription
  • Pharmacist screening and counseling role
Very feasible — G6PD enzyme assay is cheap and widely available; huge gap in Indian practice

12. HLA-B*15:02 Screening → Carbamazepine Safety in Pediatric Epilepsy

Genomic marker: HLA-B*15:02 allele (10-15% carrier rate in South/Southeast Asians)
Comparison:
  • Screened group (HLA-B*15:02 tested before carbamazepine) vs. unscreened group
What you measure:
  • SJS/TEN incidence in both groups
  • Current screening practice (audit)
  • Time to SJS diagnosis in unscreened group
  • Cost-effectiveness of pre-emptive screening
  • Pharmacist role in HLA screening recommendation
M. Pharm: Retrospective audit of SJS cases + screening practice PhD: Implement screening protocol + prospective safety cohort

13. CYP3A5 Genotype → Tacrolimus Dose Requirements in Pediatric Renal Transplant

Genomic marker: CYP3A5*1 (expressers vs. non-expressers)
Comparison:
  • CYP3A5 expressers (*1/*1 or *1/*3): need higher tacrolimus dose
  • Non-expressers (*3/*3): standard dose adequate
What you measure:
  • Time to therapeutic tacrolimus level
  • Dose adjustments per month
  • Rejection episodes
  • Nephrotoxicity (trough levels > 15 ng/mL)
  • Cost of TDM vs. PGx-guided dosing
PhD: Develop PGx-guided tacrolimus dosing nomogram for Indian pediatric transplant patients

14. Pharmacogenomics of Antibiotic Response in Neonatal Sepsis

Genomic marker: SLC22A2 (vancomycin transporter), ABCB1 polymorphism
Cohort design: NICU neonates on vancomycin — compare pharmacokinetic parameters by genotype
What you measure:
  • Time to therapeutic vancomycin levels
  • AUC/MIC ratio (PK/PD)
  • Nephrotoxicity incidence
  • Need for dose modifications
  • Pharmacist TDM contribution

🟣 PSYCHIATRY GENOMICS


15. CYP2D6 / CYP2C19 Genotype → Antidepressant Response and ADR Comparison

Genomic marker: CYP2D6 (fluoxetine, paroxetine, tricyclics) + CYP2C19 (citalopram, escitalopram, sertraline)
Comparison — 4 metabolizer groups:
  • Poor metabolizer (PM) — drug accumulates, ADR risk high
  • Intermediate metabolizer (IM)
  • Extensive metabolizer (EM) — standard response
  • Ultra-rapid metabolizer (UM) — drug clears fast, subtherapeutic levels
What you measure:
  • Treatment response rate (PHQ-9/HAM-D at 4, 8, 12 weeks) by metabolizer status
  • ADR incidence and severity
  • Dose modification frequency
  • Time to remission
  • Treatment discontinuation rates
M. Pharm: KAP survey + retrospective analysis of dose modifications (no genotyping needed) PhD: Prospective genotyping + guided prescribing vs. standard prescribing RCT

16. CYP2D6 Genotype → Antipsychotic (Risperidone/Haloperidol) Outcomes

Genomic marker: CYP2D6 polymorphism
Comparison:
  • Poor metabolizers: higher plasma levels → more EPS, metabolic effects
  • Extensive metabolizers: standard response
What you measure:
  • Drug plasma levels (if TDM available)
  • EPS incidence (AIMS, SAS, BARS)
  • Metabolic parameters
  • PANSS score trajectory
  • Dose adequacy vs. metabolizer status
PhD: PGx-guided antipsychotic dosing protocol + pharmacist TDM service implementation

17. SLC6A4 (Serotonin Transporter) Polymorphism → SSRI Response Cohort

Genomic marker: 5-HTTLPR (short/long variant in SLC6A4)
Cohort design: SSRI-treated patients grouped by 5-HTTLPR genotype
What you measure:
  • Antidepressant response rate (PHQ-9 reduction ≥50%)
  • Remission rate
  • Time to response
  • ADR profile
  • Comparison between s/s, s/l, l/l genotype groups
PhD angle: Pharmacist-led PGx-guided SSRI selection service + prospective RCT vs. standard prescribing

18. HLA-A31:01 and HLA-B15:02 → Carbamazepine Toxicity in Psychiatric Patients

Genomic marker: HLA-A31:01 (maculopapular rash risk) + HLA-B15:02 (SJS risk)
Comparison:
  • Screened vs. unscreened patients on carbamazepine for bipolar disorder
What you measure:
  • SCAR (severe cutaneous adverse reaction) incidence
  • Current pre-prescription screening practice (audit)
  • Cost-effectiveness of screening
  • Pharmacist HLA-B*15:02 alert system implementation
Very feasible retrospectively — scan all carbamazepine SJS cases and check if screened

19. ABCB1 (P-glycoprotein) Polymorphism → Antidepressant Brain Penetration Cohort

Genomic marker: ABCB1 C3435T / G2677T polymorphism
Cohort design: Antidepressant patients grouped by ABCB1 genotype
What you measure:
  • Treatment response (poor CNS drug penetration in non-expressers)
  • Dose escalation frequency
  • Treatment resistance rates
  • Switching behaviour
Novel PhD topic — very limited Indian data on ABCB1 and psychiatric drug response

20. Pharmacogenomics of Lithium Response — GWAS-Derived Markers

Genomic markers: GADL1, ANK3, CACNA1C variants (GWAS-identified lithium response markers)
Cohort design: Bipolar patients on lithium followed for 12-24 months
What you measure:
  • Lithium response (responders vs. non-responders by ALDA scale)
  • Serum lithium levels (TDM adequacy)
  • Relapse rates stratified by genotype
  • ADR profile (thyroid, renal)
PhD: Indian-specific GWAS replication study + pharmacist lithium monitoring protocol

21. MTHFR Polymorphism → Folate + Antidepressant Augmentation Response

Genomic marker: MTHFR C677T / A1298C polymorphism
Comparison:
  • MTHFR TT variant (reduced folate metabolism): compare response to standard antidepressant vs. antidepressant + l-methylfolate augmentation
What you measure:
  • PHQ-9/HAM-D score reduction
  • Remission rates
  • Homocysteine levels
  • B12/folate status
  • Pharmacist counseling on folate supplementation
Very relevant to Indian population — MTHFR TT variant common, folate deficiency prevalent

🟢 GENERAL MEDICINE GENOMICS


22. CYP2C9 + VKORC1 Genotype-Guided vs. Standard Warfarin Dosing

Genomic markers: CYP2C9 (*2, *3) + VKORC1 (-1639G>A)
Comparison:
  • Group A: Genotype-guided warfarin dosing (CPIC/IWPC algorithm)
  • Group B: Standard clinical dose initiation (5 mg or 10 mg start)
What you measure:
  • Time in therapeutic range (TTR)
  • Time to stable INR
  • Bleeding events (major + minor)
  • Thromboembolic events
  • Dose accuracy at 1, 3, 6 months
  • Cost of genotyping vs. cost of bleeding events
This is the best-studied PGx topic — your PhD will contribute Indian-specific TTR data

23. CYP2C19 Genotype → Clopidogrel Response in ACS/PCI Patients

Genomic marker: CYP2C19 *2 (loss-of-function) + *17 (gain-of-function)
Comparison:
  • CYP2C19*2 carriers (poor antiplatelet effect) vs. wild-type on clopidogrel
  • Or: Genotype-guided switch to prasugrel/ticagrelor vs. continued clopidogrel in *2 carriers
What you measure:
  • MACE (major adverse cardiovascular events) at 6, 12 months
  • Stent thrombosis incidence
  • Bleeding events
  • Platelet reactivity (if aggregometry available)
  • Cost-effectiveness of genotype-guided antiplatelet selection
PhD: Multi-centre PGx-guided antiplatelet prescribing protocol + outcomes study

24. SLCO1B1 Genotype → Statin-Induced Myopathy Risk Cohort

Genomic marker: SLCO1B1 *5 (rs4149056 T>C) — impairs statin hepatic uptake → increased plasma levels
Comparison:
  • SLCO1B1 *5 carriers vs. non-carriers on high-dose atorvastatin/simvastatin
What you measure:
  • Myopathy incidence (muscle pain, CK elevation)
  • Statin discontinuation rate
  • Dose reduction frequency
  • CK level trends at 3, 6 months
  • Pharmacist myopathy monitoring contribution
M. Pharm: KAP survey + retrospective statin discontinuation analysis PhD: Prospective SLCO1B1 genotyping + pharmacist monitoring protocol implementation

25. ACE Gene Insertion/Deletion Polymorphism → ACE Inhibitor Response in Hypertension

Genomic marker: ACE I/D polymorphism (rs1799752)
Comparison:
  • DD genotype: lower ACE inhibitor response, higher BP variability
  • II genotype: better BP lowering with ACEi
What you measure:
  • BP control at 1, 3, 6 months
  • eGFR trend (renoprotective effect)
  • Cough incidence (bradykinin-mediated)
  • Need for dose escalation
  • Drug switch rate
PhD: Combined ACE I/D + CYP11B2 polymorphism analysis for personalized hypertension management

26. NAT2 Genotype → Isoniazid-Induced Hepatotoxicity Cohort in TB Patients

Genomic marker: NAT2 slow acetylator genotype (*5, *6, *7)
Comparison:
  • NAT2 slow acetylators vs. rapid/intermediate acetylators on isoniazid-based ATT
What you measure:
  • Drug-induced liver injury (DILI) incidence (ALT/AST > 3x ULN)
  • Time to hepatotoxicity onset
  • Isoniazid dose adequacy by acetylator status
  • Treatment interruption rate
  • Pharmacist monitoring protocol contribution
Very relevant for India — world's largest TB burden, NAT2 data scarce in Indian populations

27. HLA-B*57:01 Screening → Abacavir Hypersensitivity Prevention in HIV Patients

Genomic marker: HLA-B*57:01 allele
Comparison:
  • Screened group (HLA-B*57:01 tested before abacavir) vs. historical unscreened cohort
What you measure:
  • Hypersensitivity reaction incidence
  • Re-challenge outcomes in unscreened group
  • Current screening practice (audit) at your hospital
  • Cost-effectiveness of pre-emptive HLA-B*57:01 screening
  • Pharmacist alert system implementation

28. HLA-B*58:01 Genotype → Allopurinol-Induced SCAR in Gout/Hyperuricemia Patients

Genomic marker: HLA-B*58:01 (strongly associated with allopurinol-induced SJS/TEN/DRESS)
Comparison:
  • HLA-B*58:01 carriers vs. non-carriers on allopurinol
What you measure:
  • SCAR incidence (SJS, TEN, DRESS)
  • Current pre-prescription screening rate (audit)
  • Time to SCAR onset
  • Cost-effectiveness of screening
  • Pharmacist role in prescribing alert
Highly feasible retrospectively — scan all allopurinol SCAR cases at your hospital

29. CYP2D6 Genotype → Codeine/Tramadol Analgesia Variability in Post-Surgical Patients

Genomic marker: CYP2D6 (PM vs. EM vs. UM)
Comparison:
  • Poor metabolizers: inadequate analgesia, higher tramadol levels
  • Ultra-rapid metabolizers: morphine toxicity risk from codeine
What you measure:
  • Pain NRS scores at 1h, 4h, 24h post-dose
  • Rescue analgesic requirement
  • ADR (nausea, sedation, respiratory rate)
  • Dose adequacy vs. genotype
PhD: Develop pharmacist-led PGx-guided analgesic selection tool for post-operative pain

30. Population-Level PGx: Allele Frequency Mapping in South Indian / Regional Population

Genomic markers: Panel — CYP2C9, CYP2C19, CYP2D6, CYP3A5, VKORC1, SLCO1B1, HLA-B15:02, HLA-B57:01, HLA-B*58:01
Design: Cross-sectional population genomics study
What you measure:
  • Allele frequencies in your regional population
  • Compare with global databases (PharmGKB, gnomAD, 1000 Genomes)
  • Identify which CPIC guidelines need Indian-specific modifications
  • Pharmacist implications for each variant
This is a landmark PhD study — generates Indian PGx reference data used by every future researcher

MASTER TABLE — ALL 30 GENOMICS TOPICS

#TopicSpecialtyKey GeneLab NeededM. Pharm ApproachPhD Scale-upImpact
1EGFR → TKI vs. Chemo in NSCLCOncologyEGFRExisting reportsRetrospective cohortProspective + resistance tracking🔥🔥🔥
2KRAS → Cetuximab vs. BevacizumabOncologyKRAS/NRASExisting reportsRetrospective cohortBiomarker tracking🔥🔥🔥
3HER2 → Trastuzumab outcomesOncologyHER2IHC (routine)Retrospective cohortCardiotoxicity monitoring🔥🔥🔥
4BRCA → PARP inhibitor vs. chemoOncologyBRCA1/2Existing reportsRetrospective cohortGenetic counseling role🔥🔥🔥
5UGT1A1 → Irinotecan toxicityOncologyUGT1A1*28GenotypingKAP + retrospectiveProspective + dose protocol🔥🔥🔥
6DPYD → 5-FU/Capecitabine toxicityOncologyDPYDGenotypingKAP + ADR auditScreening protocol + PEA🔥🔥🔥
7TPMT/NUDT15 → Thiopurine toxicityOncologyTPMT/NUDT15GenotypingADR audit + KAPDose protocol + TDM service🔥🔥🔥
8VEGF polymorphism → BevacizumabOncologyVEGFGenotypingRetrospectiveResponse prediction model🔥🔥
9TPMT/NUDT15 → 6-MP in pediatric ALLPediatricsTPMT/NUDT15GenotypingKAP + toxicity auditGenotype-guided dosing RCT🔥🔥🔥
10CYP2D6 → Codeine safety pediatricsPediatricsCYP2D6GenotypingPrescribing auditSafety protocol🔥🔥🔥
11G6PD → Primaquine hemolysisPediatricsG6PDEnzyme assayScreening auditScreening implementation🔥🔥🔥
12HLA-B*15:02 → Carbamazepine SJSPediatricsHLA-B*15:02HLA typingSJS case auditScreening protocol RCT🔥🔥🔥
13CYP3A5 → Tacrolimus dosingPediatricsCYP3A5GenotypingTDM auditDosing nomogram🔥🔥🔥
14SLC22A2 → Vancomycin in NICUPediatricsSLC22A2GenotypingTDM auditPK/PD model🔥🔥
15CYP2D6/2C19 → Antidepressant ADRPsychiatryCYP2D6/2C19GenotypingKAP + dose auditPGx-guided SSRI RCT🔥🔥🔥
16CYP2D6 → Antipsychotic outcomesPsychiatryCYP2D6GenotypingTDM + ADR auditPGx-guided dosing protocol🔥🔥🔥
175-HTTLPR → SSRI response cohortPsychiatrySLC6A4GenotypingKAP surveyGuided SSRI selection RCT🔥🔥🔥
18HLA → Carbamazepine SCARsPsychiatryHLA-A/BHLA typingRetrospective SCAR auditScreening implementation🔥🔥🔥
19ABCB1 → Antidepressant penetrationPsychiatryABCB1GenotypingKAP + resistance auditResistance prediction model🔥🔥
20GWAS markers → Lithium responsePsychiatryGADL1/ANK3GenotypingTDM + ALDA auditGWAS replication study🔥🔥🔥
21MTHFR → Folate + antidepressantPsychiatryMTHFRGenotypingFolate status auditAugmentation RCT🔥🔥🔥
22CYP2C9+VKORC1 → Warfarin dosingGen MedicineCYP2C9/VKORC1GenotypingKAP + TTR auditGuided dosing RCT🔥🔥🔥
23CYP2C19 → Clopidogrel responseGen MedicineCYP2C19GenotypingKAP + MACE auditGuided antiplatelet RCT🔥🔥🔥
24SLCO1B1 → Statin myopathyGen MedicineSLCO1B1GenotypingMyopathy auditMonitoring protocol🔥🔥🔥
25ACE I/D → ACEi response in HTNGen MedicineACEGenotypingBP auditPersonalized HTN model🔥🔥
26NAT2 → Isoniazid hepatotoxicityGen MedicineNAT2GenotypingDILI auditMonitoring protocol🔥🔥🔥
27HLA-B*57:01 → Abacavir HSRGen MedicineHLA-B*57:01HLA typingScreening auditCost-effectiveness model🔥🔥🔥
28HLA-B*58:01 → Allopurinol SCARGen MedicineHLA-B*58:01HLA typingSCAR case auditScreening protocol🔥🔥🔥
29CYP2D6 → Codeine/Tramadol analgesiaGen MedicineCYP2D6GenotypingAnalgesic auditPGx analgesic selection tool🔥🔥🔥
30Population PGx allele frequency mappingAllMulti-gene panelGenotyping panelKAP + literature reviewIndian PGx reference database🔥🔥🔥

M. PHARM → PhD BRIDGE STRATEGY FOR GENOMICS

YEAR 1 (M. Pharm)          YEAR 2 (M. Pharm)         YEAR 3-6 (PhD)
──────────────────────────────────────────────────────────────────
No lab needed:             Build foundation:          Add lab component:
• KAP survey               • Retrospective cohort     • Prospective genotyping
• Prescribing audit        • ADR pattern analysis     • Genotype-guided RCT
• SJS/DILI case audit      • Screening gap analysis   • Multi-centre validation
• Existing test data review• Pharmacoeconomic          • Tool/protocol development
                            baseline cost study        • Indian PGx database

🎯 ABSOLUTE TOP 5 FOR M. PHARM → PhD IN GENOMICS

#TopicWhy It's the Best
🥇TPMT/NUDT15 → Thiopurine toxicity in pediatric ALLNUDT15 highly prevalent in South Asians, no Indian data, ICMR fundable, saves children's lives
🥇CYP2C19 → Clopidogrel response in ACS/PCIMost clinically urgent, cardiologists will collaborate, clear outcome measure (MACE)
🥇NAT2 → Isoniazid hepatotoxicity in TB patientsIndia's TB burden + NAT2 data gap = landmark study, ICMR/RNTCP fundable
🥇HLA-B*15:02 → Carbamazepine SJS (epilepsy/psychiatry)M. Pharm = pure audit (no lab), PhD adds screening implementation, direct patient safety impact
🥇Population PGx allele frequency in South Indian populationCreates original Indian reference data used by every future PGx researcher — true PhD legacy

Would you like a full protocol with aims, objectives, sample size, methodology, statistical plan, and ethical considerations drafted for any of these topics?

can you suggest some other topics

Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.

can you suggest some other topics

To give you the most relevant suggestions, let me clarify what you're looking for:
Asking for Preferences

Which area do you want more topics in? · What study design are you interested in?

Here are fresh M. Pharm → PhD bridge topics using Observational Study designs - covering areas we haven't discussed yet:

OBSERVATIONAL STUDY TYPES (Quick Reference)

TypeWhat It IsBest For
Cross-sectionalSnapshot at one point in timePrevalence, KAP, DRP mapping
Prospective observational cohortFollow patients forward without interveningADR tracking, adherence → outcomes
Retrospective cohortUse existing records, trace outcomesDrug safety, readmission, survival
Longitudinal observationalRepeated observations over timeDisease progression, drug effect
Case-controlCompare cases (with outcome) vs. controlsRisk factor identification
Mixed methodsQuantitative + qualitative combinedImplementation barriers, patient experience

🟠 NEPHROLOGY / RENAL TRANSPLANT

1. Prospective Cohort: Drug-Induced Acute Kidney Injury (AKI) in Hospitalized Patients

What you observe:
  • All patients receiving nephrotoxic drugs (aminoglycosides, NSAIDs, contrast, vancomycin, ACE inhibitors)
  • Serum creatinine + eGFR tracked daily in ward
  • AKI onset (KDIGO criteria), severity staging, recovery
M. Pharm: 6-month prospective cohort — single hospital medicine/surgery ward PhD scale-up:
  • Multi-centre cohort identifying highest-risk drug combinations
  • Develop a nephrotoxicity risk prediction score (clinical + drug variables)
  • Pharmacist AKI alert system implementation + validation
Why powerful: AKI affects 10-15% of hospitalised patients. Pharmacist-preventable cases are underreported. No Indian AKI-DI risk tool exists.

2. Longitudinal Cohort: Immunosuppressant Adherence → Graft Outcomes in Renal Transplant

What you observe:
  • Tacrolimus/mycophenolate adherence (BAASIS scale + TDM records)
  • eGFR trend over 12-24 months
  • Rejection episodes, dose changes, infections
M. Pharm: Cross-sectional adherence assessment + 6-month TDM variability analysis PhD: 3-year longitudinal cohort — adherence → graft survival model + pharmacist intervention arm

3. Retrospective Cohort: Antibiotic Dosing Errors in CKD Inpatients

What you observe:
  • All antibiotics prescribed in CKD/dialysis patients
  • Compare prescribed dose vs. eGFR-recommended dose (using Renal Drug Handbook)
  • Underdosing (therapeutic failure risk) vs. overdosing (toxicity risk)
M. Pharm: 1-year retrospective, single hospital PhD: Multi-centre + pharmacist-led renal dose adjustment service + outcome tracking

🟤 HEPATOLOGY / GASTROENTEROLOGY

4. Prospective Cohort: Drug-Induced Liver Injury (DILI) Surveillance

What you observe:
  • All patients with unexplained liver enzyme elevation (ALT/AST > 3x ULN)
  • Identify causative drug using RUCAM causality scale
  • Document pattern (hepatocellular/cholestatic/mixed), severity, outcome
M. Pharm: 6-month active surveillance — medicine/TB/oncology wards PhD scale-up:
  • Multi-centre DILI registry for India
  • Risk factor analysis (genetic + clinical predictors)
  • Pharmacist DILI surveillance algorithm development
Why powerful: India has the highest burden of ATT-DILI globally. No national DILI registry exists.

5. Retrospective Cohort: PPI Overuse Audit → Clinical Outcomes

What you observe:
  • Inpatients on PPIs — classify indication as appropriate vs. inappropriate (SUP criteria / ACG guidelines)
  • Track: CDI incidence, CAP incidence, hypomagnesaemia, osteoporosis markers
  • Deprescribing rate at discharge
M. Pharm: 6-month retrospective single hospital PhD: Multi-centre PPI overuse observatory + pharmacist deprescribing intervention trial

🔵 CRITICAL CARE / SEPSIS

6. Prospective Cohort: Antibiotic Time-to-First-Dose in Sepsis → Mortality Outcomes

What you observe:
  • Time from sepsis recognition (qSOFA/SOFA) to first antibiotic dose
  • Culture-guided de-escalation timing
  • 28-day mortality, LOS, organ failure scores (SOFA)
  • Pharmacist role in antibiotic ordering/preparation time
M. Pharm: 6-month ICU/medicine ward cohort — descriptive observational PhD: Multi-centre cohort + pharmacist-led sepsis bundle implementation + interrupted time series

7. Longitudinal Cohort: Sedation Depth → ICU Outcomes (ABCDEF Bundle Adherence)

What you observe:
  • Daily RASS and CAM-ICU scores in mechanically ventilated patients
  • Drug regimens (propofol, midazolam, dexmedetomidine, fentanyl)
  • Outcomes: ICU delirium, ventilator days, LOS, muscle weakness, mortality
M. Pharm: Prospective 3-month ICU cohort — ABCDEF bundle documentation PhD: Multi-centre + pharmacist-led sedation optimization program + delirium prevention bundle

🟢 RHEUMATOLOGY / AUTOIMMUNE

8. Prospective Cohort: DMARDs in Rheumatoid Arthritis → Safety & Response Monitoring

What you observe:
  • Patients initiated on methotrexate/hydroxychloroquine/sulfasalazine/leflunomide
  • Disease activity score (DAS28) at 0, 3, 6, 12 months
  • ADR monitoring: LFT for MTX, retinal for HCQ, CBC trends
  • Adherence (MMAS-8) and reasons for drug switching
M. Pharm: 6-month cohort — rheumatology OPD, single hospital PhD: 3-year cohort — drug survival analysis + pharmacist monitoring protocol validation

9. Retrospective Cohort: Corticosteroid Overuse in Autoimmune Conditions → Complication Tracking

What you observe:
  • Patients on long-term steroids (> 3 months)
  • Document: osteoporosis, DM, HTN, cataracts, weight gain, infections
  • Assess: bone protection co-prescription rate (calcium/vitamin D/bisphosphonate)
  • Pharmacist counseling gaps identified
M. Pharm: Retrospective 1-year data — medicine/rheumatology OPD PhD: Prospective + pharmacist steroid management program + fracture risk model

🟡 PAIN MANAGEMENT / PALLIATIVE CARE

10. Prospective Cohort: Opioid Prescribing Patterns → Pain Control + ADR Outcomes

What you observe:
  • Cancer/palliative patients initiated on opioids
  • Pain NRS scores at each visit
  • WHO analgesic ladder step adherence
  • Opioid ADRs: constipation, nausea, sedation, respiratory depression
  • Breakthrough analgesic use frequency
  • Pharmacist counseling documentation
M. Pharm: 6-month cohort — pain clinic/oncology/palliative ward PhD: Multi-centre + opioid rotation pattern analysis + pharmacist pain management program RCT

11. Mixed Methods: Barriers to Adequate Cancer Pain Treatment in India

What you observe (quantitative):
  • Pain NRS scores vs. analgesic prescribed
  • Undertreatment prevalence (NRS > 4 with WHO Step 1 drugs only)
  • Opioid prescription rate vs. availability
What you observe (qualitative):
  • Patient interviews: fear of addiction, cultural beliefs, cost
  • Prescriber interviews: regulatory barriers, opiophobia
  • Pharmacist interviews: dispensing barriers, opioid shortage
M. Pharm: Quantitative audit + 10-15 qualitative interviews PhD: Large mixed-methods multi-centre study → national opioid access policy framework

🔴 RESPIRATORY / SLEEP MEDICINE

12. Longitudinal Cohort: COPD Exacerbation Triggers → Pharmacotherapy Patterns

What you observe:
  • COPD patients followed for 12 months
  • Exacerbation frequency, severity (GOLD criteria)
  • Medications at each visit, changes after exacerbation
  • Inhaler technique score (repeated assessment)
  • Adherence (TAI questionnaire)
  • QoL (SGRQ/CAT)
M. Pharm: 6-month cohort — respiratory OPD PhD: 3-year cohort + pharmacist COPD management program + exacerbation prediction model

13. Cross-sectional + Follow-up: Inhaler Misuse → Treatment Outcomes Correlation

What you observe:
  • Inhaler technique scored (22-step checklist) at baseline
  • Correlated with: asthma/COPD control, hospitalizations, QoL, exacerbation rate
  • Identify common critical errors by device type (MDI, DPI, Respimat)
M. Pharm: Cross-sectional technique scoring + 3-month outcomes follow-up PhD: Multi-centre + pharmacist inhaler education intervention + longitudinal technique improvement

🟣 ENDOCRINOLOGY / METABOLIC

14. Prospective Cohort: Thyroid Dysfunction Drug Surveillance

What you observe:
  • Patients on drugs known to affect thyroid (amiodarone, lithium, immunotherapy, interferon)
  • TSH/T3/T4 levels at baseline and 3, 6, 12 months
  • Thyroid dysfunction onset, management, pharmacist monitoring
M. Pharm: 6-month cohort — cardiology/psychiatry/oncology OPD PhD: Multi-drug thyroid safety observatory + pharmacist thyroid monitoring protocol

15. Retrospective Cohort: Steroid-Induced Hyperglycemia Management in Hospitalized Patients

What you observe:
  • Inpatients receiving systemic corticosteroids (any indication)
  • Blood glucose trends (fasting + post-prandial)
  • Insulin initiation rate, dose adequacy, hypoglycemia incidence
  • Pharmacist glucose monitoring contribution
M. Pharm: 6-month retrospective — medicine/oncology/rheumatology ward PhD: Multi-centre cohort + pharmacist-led steroid-induced DM management protocol

🔵 INFECTION / ANTIMICROBIAL RESISTANCE

16. Prospective Cohort: Culture Negativity Rate vs. Antibiotic Prescribing → Resistance Mapping

What you observe:
  • All inpatients with infection — blood/urine/sputum culture results
  • Time from sample to result
  • Antibiotic prescribed before culture vs. after (de-escalation rate)
  • Resistance patterns over 12 months
  • Pharmacist AMS contribution
M. Pharm: 6-month prospective — medicine ward + microbiology records PhD: 3-year resistance trend observatory + AMS program impact study

17. Retrospective Cohort: Healthcare-Associated Infection (HAI) → Drug Burden Analysis

What you observe:
  • CLABSI, CAUTI, VAP, SSI cases in ICU/surgery ward
  • Antibiotic regimens used for each HAI type
  • Duration, cost, outcome (cure/transfer/mortality)
  • Pharmacist involvement in HAI management team
M. Pharm: 1-year retrospective HAI case records PhD: Multi-centre HAI drug burden study + pharmacist-led HAI prevention bundle

🟠 GERIATRICS / FRAILTY

18. Prospective Cohort: Frailty Index + Polypharmacy → Adverse Outcomes in Elderly

What you observe:
  • Elderly inpatients assessed for frailty (Clinical Frailty Scale / FRAIL scale)
  • Polypharmacy burden (drug count, PIMs by Beers 2023)
  • Track: falls, ADRs, hospitalisation, 30-day readmission, mortality
M. Pharm: 6-month cohort — geriatric/medicine OPD/ward PhD: Multi-centre + develop Frailty-Polypharmacy Risk Score for Indian elderly + pharmacist deprescribing trial

19. Longitudinal Cohort: Anticholinergic Drug Burden → Cognitive Decline in Elderly

What you observe:
  • Anticholinergic burden calculated using ACB scale at baseline
  • Cognitive function assessed (MMSE/MoCA) at 0, 6, 12 months
  • Correlate ACB score with cognitive trajectory
  • Identify most prescribed anticholinergic drugs
M. Pharm: 6-12 month longitudinal — geriatric OPD PhD: 3-year cohort + pharmacist-led anticholinergic minimization program + dementia risk model

20. Case-Control: Drug-Related Falls in Elderly — Risk Drug Identification

What you observe:
  • Cases: elderly patients who fell during hospitalisation
  • Controls: matched non-fallers from same ward
  • Compare: fall-risk-increasing drugs (FRIDs) — sedatives, antihypertensives, diuretics, opioids, antipsychotics
  • Identify highest-risk drug combinations
M. Pharm: Retrospective case-control — incident reports + case records PhD: Multi-centre + pharmacist-led FRID review program + fall prevention bundle

🟤 WOMEN'S HEALTH / MATERNAL MEDICINE

21. Prospective Cohort: Drug Exposure in First Trimester → Pregnancy Outcomes

What you observe:
  • Pregnant women attending ANC with any prescription in first trimester
  • Classify drugs by FDA/Australia ADEC categories
  • Track: miscarriage, congenital anomalies, IUGR, preterm birth
  • Pharmacist counseling gaps on safe drug use in pregnancy
M. Pharm: 6-month prospective ANC cohort PhD: Multi-centre + build Indian teratogenicity risk database + pharmacist reproductive safety counseling program

22. Retrospective Cohort: Preeclampsia Drug Management → Maternal & Neonatal Outcomes

What you observe:
  • Preeclampsia cases managed with different antihypertensive regimens
  • Maternal outcomes: eclampsia, HELLP, stroke, ICU admission
  • Neonatal outcomes: IUGR, prematurity, NICU admission
  • Magnesium sulfate use + monitoring adequacy
  • Pharmacist-documented interventions
M. Pharm: 2-year retrospective — maternity ward case records PhD: Multi-centre + develop pharmacist-led preeclampsia monitoring protocol

🔵 DIGITAL HEALTH / IMPLEMENTATION SCIENCE

23. Mixed Methods Observational: Pharmacist Attitudes Toward AI Clinical Decision Support

What you observe (quantitative):
  • Structured survey — pharmacist knowledge, attitude, current use, perceived barriers to AI-CDS
  • Validated tool: Technology Acceptance Model (TAM) questionnaire
What you observe (qualitative):
  • Focus group discussions — real-world experiences, trust, workflow integration
  • Thematic analysis
M. Pharm: Cross-sectional survey + 3-4 focus groups — hospital pharmacists PhD: Multi-centre national survey + AI-CDS pilot implementation + outcomes evaluation

24. Prospective Observational: mHealth App Adoption → Medication Adherence Outcomes

What you observe:
  • Patients using pharmacy-prescribed adherence apps (AarogyaSetu, Medisafe, custom)
  • App engagement metrics (login frequency, reminder response)
  • Correlated with: MMAS-8 scores, clinical outcomes (HbA1c, BP, INR) at 3, 6 months
M. Pharm: 6-month cohort — chronic disease OPD (diabetes/hypertension) PhD: Larger multi-centre cohort + predictors of app engagement + RCT vs. standard counseling

MASTER TABLE — ALL 24 NEW TOPICS

#TopicSpecialtyDesignM. Pharm FeasibilityPhD DeliverableIndian Data GapOverall
1Drug-Induced AKI CohortNephrologyProspective Cohort⭐⭐⭐Risk prediction score⭐⭐⭐🔥🔥🔥
2Tacrolimus Adherence → Graft OutcomesNephrologyLongitudinal Cohort⭐⭐⭐Survival model⭐⭐⭐🔥🔥🔥
3Antibiotic Dosing Errors in CKDNephrologyRetrospective Cohort⭐⭐⭐Dose adjustment service⭐⭐⭐🔥🔥🔥
4DILI Surveillance CohortHepatologyProspective Cohort⭐⭐⭐National DILI registry⭐⭐⭐🔥🔥🔥
5PPI Overuse → Clinical OutcomesGastroRetrospective Cohort⭐⭐⭐Deprescribing tool⭐⭐🔥🔥🔥
6Antibiotic Time-to-Dose → Sepsis MortalityICUProspective Cohort⭐⭐⭐Sepsis bundle protocol⭐⭐⭐🔥🔥🔥
7Sedation Depth → ICU Outcomes CohortICULongitudinal Cohort⭐⭐⭐Sedation optimization program⭐⭐🔥🔥🔥
8DMARDs in RA → Safety CohortRheumatologyProspective Cohort⭐⭐⭐Drug survival analysis⭐⭐🔥🔥🔥
9Corticosteroid Overuse → Complication CohortRheumatologyRetrospective Cohort⭐⭐⭐Steroid management program⭐⭐🔥🔥
10Opioid Prescribing → Pain Control CohortPalliativeProspective Cohort⭐⭐⭐Pain management RCT⭐⭐⭐🔥🔥🔥
11Cancer Pain Barriers — Mixed MethodsPalliativeMixed Methods⭐⭐⭐National opioid access policy⭐⭐⭐🔥🔥🔥
12COPD Exacerbation Triggers CohortRespiratoryLongitudinal Cohort⭐⭐⭐Exacerbation prediction model⭐⭐🔥🔥🔥
13Inhaler Misuse → Treatment OutcomesRespiratoryCross-sectional + Follow-up⭐⭐⭐Education intervention RCT⭐⭐🔥🔥🔥
14Drug-Induced Thyroid Dysfunction CohortEndocrinologyProspective Cohort⭐⭐⭐Thyroid monitoring protocol⭐⭐⭐🔥🔥🔥
15Steroid-Induced Hyperglycemia CohortEndocrinologyRetrospective Cohort⭐⭐⭐DM management protocol⭐⭐🔥🔥🔥
16Culture vs. Empirical Antibiotic → ResistanceInfectiousProspective Cohort⭐⭐⭐Resistance observatory⭐⭐🔥🔥🔥
17HAI Drug Burden CohortInfectiousRetrospective Cohort⭐⭐⭐HAI prevention bundle⭐⭐🔥🔥
18Frailty + Polypharmacy → Adverse OutcomesGeriatricsProspective Cohort⭐⭐⭐Frailty-Polypharmacy Risk Score⭐⭐⭐🔥🔥🔥
19Anticholinergic Burden → Cognitive DeclineGeriatricsLongitudinal Cohort⭐⭐⭐Dementia risk model⭐⭐⭐🔥🔥🔥
20Drug-Related Falls Case-ControlGeriatricsCase-Control⭐⭐⭐FRID review program⭐⭐🔥🔥🔥
21First Trimester Drug Exposure → OutcomesMaternalProspective Cohort⭐⭐⭐Indian teratogenicity database⭐⭐⭐🔥🔥🔥
22Preeclampsia Drug Management CohortMaternalRetrospective Cohort⭐⭐⭐Pharmacist monitoring protocol⭐⭐🔥🔥
23AI Clinical Decision Support AttitudesDigital HealthMixed Methods⭐⭐⭐AI-CDS implementation model⭐⭐⭐🔥🔥🔥
24mHealth App Adoption → Adherence CohortDigital HealthProspective Cohort⭐⭐⭐App engagement prediction model⭐⭐⭐🔥🔥🔥

🎯 TOP 5 FRESH PICKS (Most Scalable for PhD)

#TopicWhy It's Outstanding
🥇Drug-Induced AKI CohortNo Indian DI-AKI risk tool exists, pharmacist-preventable, ICMR fundable
🥇DILI Surveillance CohortIndia leads global ATT-DILI burden, no national registry, landmark PhD
🥇Frailty + Polypharmacy → Outcomes CohortAgeing India crisis, Beers 2023 ready to apply, multi-centre easily
🥇Anticholinergic Burden → Cognitive DeclineNovel India angle, validated ACB scale, dementia prevention angle
🥇Cancer Pain Barriers — Mixed MethodsPolicy impact, opioid access is a national crisis, WHO aligned

Would you like a full study protocol (title, objectives, methodology, sample size, tools, statistical plan) for any of these, or shall I compile all topics into an updated Master Excel file including these new specialties?
This is a shared conversation. Sign in to Orris to start your own chat.